
<html lang="en"     class="pb-page"  data-request-id="bad81614-5c1c-4e23-9323-bd9a3c99ec58"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00485;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-14;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections" /></meta><meta name="dc.Creator" content="Zhenkun  Ma" /></meta><meta name="dc.Creator" content="Anthony Simon  Lynch" /></meta><meta name="dc.Description" content="The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes ..." /></meta><meta name="Description" content="The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 9, 2016" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00485" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00485" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00485" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00485" /></link>
        
    
    

<title>Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00485" /></meta><meta property="og:title" content="Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0010.jpeg" /></meta><meta property="og:description" content="The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can develop resistance to rifamycins rapidly and the clinical utility of the rifamycin class is typically limited to antibiotic combinations to minimize the development of resistance. To develop a better therapy against persistent bacterial infections, a series of rifamycin based bifunctional molecules were designed, synthesized, and evaluated with the goal to identify a dual-acting drug that maintains the potent activity of rifamycins against persistent pathogens and at the same time minimize the development of rifamycin resistance. TNP-2092 was identified as a drug candidate and is currently in an early stage of clinical development for the treatment of prosthetic joint infections." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00485"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00485">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00485&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00485&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00485&amp;href=/doi/10.1021/acs.jmedchem.6b00485" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6645-6657</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01874" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.5b01871" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenkun++Ma">Zhenkun Ma</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+Simon++Lynch">Anthony Simon Lynch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">TenNor Therapeutics Ltd., 218 Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Janssen Research & Development LLC., 1400 McKean Road, Spring House, Pennsylvania 18940, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +86 512-8686-1980. Fax: +86 512-8686-1986. E-mail: <a href="/cdn-cgi/l/email-protection#a2d8cac7ccc9d7cc8ccfc3e2d6c7cccccdd0da8cc1cdcf"><span class="__cf_email__" data-cfemail="9ee4f6fbf0f5ebf0b0f3ffdeeafbf0f0f1ece6b0fdf1f3">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00485&amp;href=/doi/10.1021%2Facs.jmedchem.6b00485" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6645â6657</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 23, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 April 2016</li><li><span class="item_label"><b>Published</b> online</span>9 July 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00485" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00485</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editorsâ Choice" /></img><span>ACS Editorsâ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00485"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6216</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00485" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zhenkun&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Simon Lynch&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6645-6657&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00485&quot;},&quot;abstract&quot;:&quot;The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can develop resistance to rifamycins rapidly and the clinical utility of the rifamycin class is typically limited to antibiotic combinations to minimize the development of resistance. To develop a better therapy against persistent bacterial infections, a series of rifamycin based bifunctional molecules were designed, synthesized, and evaluated with the goal to identify a dual-acting drug that maintains the potent activity of rifamycins against persistent pathogens and at the same time minimize the development of rifamycin resistance. TNP-2092 was identified as a drug candidate and is currently in an early stage of clinical development for the treatment of prosthetic joint infections.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00485&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00485" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00485&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00485" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00485&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00485" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00485&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00485&amp;href=/doi/10.1021/acs.jmedchem.6b00485" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00485" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00485" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00485%26sid%3Dliteratum%253Aachs%26pmid%3D27336583%26genre%3Darticle%26aulast%3DMa%26date%3D2016%26atitle%3DDevelopment%2Bof%2Ba%2BDual-Acting%2BAntibacterial%2BAgent%2B%2528TNP-2092%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BPersistent%2BBacterial%2BInfections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D14%26spage%3D6645%26epage%3D6657%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/jmcmar.2016.59.issue-14/20160728/jmcmar.2016.59.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can develop resistance to rifamycins rapidly and the clinical utility of the rifamycin class is typically limited to antibiotic combinations to minimize the development of resistance. To develop a better therapy against persistent bacterial infections, a series of rifamycin based bifunctional molecules were designed, synthesized, and evaluated with the goal to identify a dual-acting drug that maintains the potent activity of rifamycins against persistent pathogens and at the same time minimize the development of rifamycin resistance. TNP-2092 was identified as a drug candidate and is currently in an early stage of clinical development for the treatment of prosthetic joint infections.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Prosthetic joint infections (PJIs) are difficult to treat and are often associated with significant morbidity and substantial health care expenditures.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The incidence of prosthesis implantations and, as a consequence, the burden of PJIs are expected to continue to rise rapidly. In the United States, there were about 1 million total hip and knee replacement surgeries performed in 2010, and this number is projected to reach 4 million by 2030. However, the implementation of enhanced infection prevention measures does not appear to have resulted in a significant reduction in the PJI incident rate in the United States. In fact, the incidence rate has increased slightly from 1.99% to 2.18% for hip and from 2.05% to 2.18% for knee replacement from 2001 to 2009, respectively.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The management of PJIs is difficult, requiring surgical intervention accompanied by prolonged antibiotic therapy. For early stage infections (less than 30 days postimplantation or less than 3 weeks after the onset of infectious symptoms) with a well-fixed prosthesis without a sinus tract, a debridement and prosthesis retention strategy is advised. All other patients should proceed to one-stage or two-stage prosthesis exchange (revision) surgery. For certain patients, exchange surgery is not possible and limb amputation becomes the last resort.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p"><i>Staphylococcus aure</i>us and coagulase-negative staphylococci (CoNS) are responsible for the majority of PJIs and are associated with higher treatment failure rates than observed with other causative pathogens. The treatment strategy for staphylococcal PJIs involves a prolonged rifampin-based combination therapy, including 2â6 weeks of intravenous antibiotic therapy in combination with oral rifampin, followed by rifampin plus a companion antibiotic for a total of 3â6 months.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The formation of bacterial biofilms on the surface of prosthesis appears to play an important role in the pathogenesis of PJI and is believed to be the underlying mechanism for persistence. It is a well-known phenomenon that pathogens living in bacterial biofilms can effectively evade host immune responses and can become tolerant to antibiotic treatment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">PJIs are devastating to patients and have significant economic impact to the healthcare system. Patient suffering and treatment costs increase dramatically with more invasive surgical intervention strategies. Early diagnosis and early treatment are critical to reduce the need for exchange surgery, permanent resection, and amputation. However, the least invasive PJI treatment strategy (debridement and retention procedure) can only be applied to patients who have a well-fixed prosthesis without sinus tract involvement and within the first month of prosthesis implantation or within 3 weeks of the onset of infection symptoms. Despite the stringent inclusion criteria and prolonged antibiotic therapy, this treatment strategy can still be associated with low and unreliable treatment outcomes with the overall success rate reported as 14â100%.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Overall, there is an urgent need for better therapies against persistent bacterial infections associated with bacterial biofilm formation. A new antibacterial agent that is more efficacious in eradicating pathogens living in bacterial biofilms, particularly for those formed by <i>S. aureus</i> and CoNS, could represent a major advancement in PJI treatment. Such an agent could potentially lead to improved cure rate, shorter treatment duration, and simplified therapy under the current treatment guidelines. More importantly, such an agent could potentially change the PJI treatment paradigm, allowing more patients to utilize the debridement and prosthesis retention treatment strategy and reducing the need for more aggressive surgeries. A more efficacious therapy against bacterial biofilms accompanied by an early diagnostic biomarker for PJI could potentially make a surgery-free PJI treatment strategy a reality.</div><div class="NLM_p last">The rifamycin family of antibiotics is one of the most potent classes known against pathogens living in bacterial biofilms.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Rifampin is a member of the rifamycin family and plays an essential role in current staphylococcal PJI management.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, pathogens develop resistance to rifamycins rapidly, as single point mutations on bacterial RNA polymerase typically confer high levels of rifamycin resistance. Hence, in clinical practice, rifamycins need always to be used in combination with other antibiotics in order to minimize resistance development. To take advantage of the potent activity of the rifamycin class against pathogens living in biofilms and at the same time to minimize the emergence of resistance, a new strategy is currently in development by attaching another antibiotic functionality to the rifamycin core to form hybrid antimicrobials with a dual-mechanism of action. In this article we summarize the efforts in discovering and developing dual-action molecule <b>1</b> (TNP-2092, CBR-2092) based on rifamycins.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Rifamycins as Leads for New Agents To Treat Persistent Bacterial Infections</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rifamycin class of antibiotics was first discovered in 1957 as natural products produced by <i>Streptomyces mediterranei.</i><a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, the naturally occurring rifamycins are unsuitable as therapeutic agents due to relatively poor potency and undesirable pharmacokinetics. Synthetic modifications of the natural products have led to significant improvements in potency and pharmacokinetic properties. Currently, there are four semisynthetic compounds, rifampin, rifapentine, rifabutin, and rifaximin, in clinical use. Rifampin is the cornerstone agent in a four-drug combination regimen for the treatment of tuberculosis.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Rifapentine possesses a longer half-life than rifampin and can be used as intermittent therapy for the treatment of tuberculosis. Rifabutin exhibits a reduced cytochrome P450 induction potential and has advantage in treating tuberculosis and human immunodeficiency virus co-infected patients. Rifaximin is unique in its pharmacokinetics; it is not orally absorbable and is used for the treatment of symptoms associated with gastrointestinal tract infections, including travelersâ diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">The mechanism of action of the rifamycin class has been extensively studied. Rifamycins are DNA-dependent RNA polymerase inhibitors. They bind to the Î² subunit of the bacterial RNA polymerase in the RNA exit channel and block RNA elongation during the transcription process.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Pathogens develop resistance to rifamycins rapidly mainly due to point mutations in the rifamycin-binding region of the Î² subunit of the bacterial RNA polymerase. A single point mutation of one of the key residues in the rifamycin binding pocket can lead to high levels of rifamycin resistance.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">One of the key characteristics of the rifamycin class is its activity against persistent bacterial infections. Unlike the majority of other antibiotic classes that require active bacterial growth to exert their antibacterial activity, rifamycins are active against pathogens in slow growing, stationary, and nonreplicating metabolic states, owing to its ability to interfere with the critical bacterial gene transcription process and its ability to distribute to deep-seated infection sites. These unique attributes have important clinical applications and have made rifamycin class agents the drug-of-choice for many persistent bacterial infections. Rifampin is the most important member of the rifamycin class from a clinical perspective and is a key component of the four-drug regimen for the treatment of tuberculosis. Rifampin is mainly responsible for shortening the duration of tuberculosis therapy from 12 months to the current 6 months.<a onclick="showRef(event, 'ref8 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref12">(8, 12)</a> Rifampin is also being utilized or studied for the treatment of other persistent and difficult-to-treat bacterial infections including infective endocarditis, osteomyelitis, and PJIs.<a onclick="showRef(event, 'ref5 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref13">(5, 13)</a></div><div class="NLM_p">Rifampin has demonstrated good activity against pathogens living in bacterial biofilms in vitro and in animal models of biofilm-associated, persistent infections<a onclick="showRef(event, 'ref5 ref14'); return false;" href="javascript:void(0);" class="ref ref5 ref14">(5, 14)</a> and is recommended as a key component in the treatment of PJIs according to various clinical practice guidelines.<a onclick="showRef(event, 'ref3 ref15'); return false;" href="javascript:void(0);" class="ref ref3 ref15">(3, 15)</a> The contribution of rifampin in the management of PJIs has been demonstrated in many clinical trials.<a onclick="showRef(event, 'cit6b ref16'); return false;" href="javascript:void(0);" class="ref cit6b ref16">(6b, 16)</a> It has been well documented that rifampin should always be used in combinations with other antibiotics to minimize the development of resistance.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, the companion antibiotic can help to kill planktonic bacterial and prevent bacteremia. Various antibiotics have been explored as companion agents for rifampin in the management of the early stage of staphylococcal PJIs. The clinical practice guidelines published by the Infectious Diseases Society of America (IDSA) recommends 2â6 weeks of a pathogen-specific intravenous antimicrobial therapy in combination with rifampin 300â450 mg given orally twice daily followed by rifampin plus a companion oral drug for a total of 3 months for a total hip arthroplasty infection and 6 months for a total knee arthroplasty infection.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Recommended oral companion drugs for rifampin are two fluoroquinolones, ciprofloxacin and levofloxacin, based on in vitro and in vivo animal studies in combination with clinical evidence.<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a></div><div class="NLM_p last">Currently, the rifampin-containing drug combinations are perhaps the best option available for the treatment of staphylococcal PJIs and associated with improved cure rate. However, the current treatment strategy is clearly inadequate, as it requires parallel surgical intervention to be effective, and despite this, the success rate is still low and unreliable and the consequence of treatment failure is devastating.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Design, Synthesis, and Evaluation of Dual-Acting Rifamycins</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">One potential approach to improve PJI treatment is through the development of rifamycin based dual-action molecules. This approach takes advantage of the proven efficacy of the rifamycin combinations against PJIs and at the same time to alleviate the problems associated with the use of drug combinations.</div><div class="NLM_p">There are a number of problems associated with rifampin based drug combinations in the treatment of PJI. First, rifampin and its companion drug may have different pharmacokinetic profiles. For example, they may have different serum half-lives and tissue distributions. This can lead to unbalanced drug exposure at the infection site, leaving rifampin âunprotectedâ from a resistance-development perspective at certain points in the dosing cycle and therein allowing for the development of rifampin resistance. Second, the antibacterial spectrum of the companion antibiotic (e.g., ciprofloxacin) can be very different from rifampin and represents another cause for concern for the development of resistance by organisms not fully covered by both antibiotics. Third, there can be significant additive toxicity associated with the use of drug combinations or other undesired drugâdrug interactions that impact the pharmacokinetics of companion agents. Fourth, patients have to take multiple different antibiotics, particularly in the initial phase of the PJI treatment where rifampin is given orally and other drugs are given intravenously. Finally, another specific issue associated with the recommended PJI regimen rifampin plus a fluoroquinolone (ciprofloxacin or levofloxacin) combination is the antagonism between these two classes of agents. The antagonistic effect between rifampin and the fluoroquinolone has been observed in vitro and in vivo with different members of the fluoroquinolone class and against different pathogens.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> A dual-acting molecule that contains a rifamycin and a fluoroquinolone structural motif can theoretically address the above problems associated with rifampin and fluoroquinolone drug combinations.</div><div class="NLM_p">As a general strategy to minimize antibiotic resistance development, dual-acting antibacterial molecules that can attack bacteria with two different modes of action have been explored for many years. This area has been reviewed several times in the past few years, including a comprehensive chemistry review published in 2015.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> One of the early examples of the dual-acting approach is <b>2</b> (Ro 23-9424), a hybrid compound comprising a cephalosporin and a fluoroquinolone moiety.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Compound <b>2</b> itself behaves like a cephalosporin and does not possess the mode of action of a fluoroquinolone. However, <b>2</b> can be cleaved either chemically or metabolically to release the fleroxacin moiety and this degradation product can then exert its antibacterial activity via the mode of action of a fluoroquinolone (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Compound <b>2</b> is therefore not a true dual-acting antibacterial agent and is in effect a cephalosporin acting as a fluoroquinolone prodrug. However, <b>2</b> failed to demonstrate any advantage over a cephalosporin or a fluoroquinolone in preventing resistance development.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Proposed enzymatic activation process for cephalosporinâfluoroquinolone hybrid compound <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recent efforts have been focused on the development of noncleavable dual-action molecules. Antibiotic classes involved include fluoroquinolones, macrolides, Î²-lactams, oxazolidinones, tetracyclines, aminoglycosides, rifamycins, glycopeptides, and some less known antibiotic classes.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> One of the noncleavable antibiotic hybrids is <b>3</b> (cadazolid), formed by a fluoroquinolone and an oxazolidinone core via a stable linker (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Compound <b>3</b> is currently in phase III clinical trials for the treatment of <i>Clostridium difficile</i> infections. Mode of action studies conducted with <i>C. diffi</i>cile indicated that <b>3</b> retains the mode of action of an oxazolidinone but failed to demonstrate a substantial contribution from the fluoroquinolone function.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In effect, <b>3</b> behaves like a more potent linezolid with a low systemic exposure and a high local concentration in the gastrointestinal tract.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of oxazolidinoneâfluoroquinolone hybrid compound <b>3</b> (Cadazolid).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the key components for a successful dual-action antibacterial program is to implement a robust compound evaluation strategy. An experienced medicinal chemist with knowledge of the structureâactivity relationships for each of the parent antibiotic classes can design and synthesize certain hybrid compounds containing two antibiotic motifs. However, the resulting hybrid compounds may or may not have the desired dual modes of action. Critical data need to be generated rapidly to guide the lead optimization and candidate selection process. A robust compound evaluation strategy should include assays to progressively assess compounds in enzyme, whole-cell and animal levels. Such an evaluation scheme is shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> which includes (i) validated biochemical assays to assess the activity and potency of the hybrid compounds against target proteins/enzymes of both parent drugs, (ii) whole cell assays on isogenic bacterial panels with defined antibiotic resistance mutations on drug targets associated with both parent drugs, and (iii) validated animal models of the target disease indication(s).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biological evaluation strategy for a dual-action antimicrobial program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rifamycins are a well-studied class of antibiotics with an extensive knowledge of structureâactivity relationships pertaining to in vitro and in vivo activity accumulated over the past 50 years. Recently, the details of the interaction between rifampin and its drug target, bacterial RNA polymerase, have been elucidated by high-resolution crystallization studies of the <i>Thermus aquaticus</i> core enzyme in complex with rifampin.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Both crystal structural interactions between rifampin and RNA polymerase and structureâactivity relationships suggest that the groups attached to the C-3 and C-25 positions of rifampin are pointing to open space and can therefore be explored as sites for attaching a secondary antibiotic group [<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>].</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structural interactions between rifampin and RNA polymerase (4a) and structureâactivity relationships (4b) suggest that the groups attached to the C-3 and C-25 positions of the rifamycin scaffold are pointing to open space and can be explored for attaching a secondary antibiotic motif. Image in (4a) reprinted from  <cite>Cell</cite> (<a href="http://www.sciencedirect.com/science/journal/00928674" class="extLink">http://www.sciencedirect.com/science/journal/00928674</a>), Vol. <em>104</em>, <contrib-group>Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S. A.</contrib-group>, Structural mechanism for rifampicin inhibition of bacterial RNA polymerase, pp 901â912, Copyright <span class="NLM_year">2001</span>, with permission from Elsevier.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The majority of rifamycin-based hybrid antibiotic compounds prepared to date utilize the C-3 position as the linking point. In addition to accessing an open space from the rifamycin scaffold docked into its binding site on RNA polymerase, the C-3 position is chemically versatile which can be easily functionalized to introduce various groups serving as linkers.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The C-3 position together with its adjacent C-4 position can also form a new heterocycle that in turn can serve as the linking point for a secondary antibiotic.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The carbonyl group at the C-11 position can be functionalized via an oxime group and serve as the linking point for a secondary antibiotic to access the same open space as that of the C-3 position.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The acetyl group at the C-25 position can be replaced with a carbamate group and serve as a linking point for further derivatization.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The positions on rifamycin that have been explored as linking points and the chemistry strategies utilized to link a secondary antibiotic functionality are summarized in <a class="ref internalNav" href="#fig5" aria-label="Figure 05">Figure 05</a>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Positions on the rifamycin scaffold and strategies that have been utilized for linking a secondary antibiotic group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The selection of the secondary antibiotic is important. From a mechanistic standpoint, the secondary antibiotic should be active against the target pathogen(s) that the resulting dual-acting compound is intended to treat and it should not have cross-resistance with the primary antibiotic. In addition, it should possess a well-defined structureâactivity relationship and/or high resolution cocrystal structural information allowing for the rapid assembly of hybrid molecules with dual mechanisms of action. Several antibiotic classes have been explored as matching partners for developing dual-acting rifamycins to date. They include quinolones (including non-fluoroquinolones, fluoroquinolones, and their bioisostere quinolizinones),<a onclick="showRef(event, 'ref23 cit25b cit25c ref27'); return false;" href="javascript:void(0);" class="ref ref23 cit25b cit25c ref27">(23, 25b, 25c, 27)</a> macrolides (including 14-, 15-, and 16-membered ring macrolides),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> oxazolidinones,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and nitroimidazoles.<a onclick="showRef(event, 'cit24c'); return false;" href="javascript:void(0);" class="ref cit24c">(24c)</a> In vitro minimum inhibitory concentration (MIC) data published in the cited patent literature indicate that these hybrid series are active against rifamycin-susceptible and resistant bacterial strains, an indicator of genuine dual-action.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Optimization and Development of RifamycinâQuinolone Dual-Acting Antimicrobials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Rifamycinâquinolone hybrid compounds have been studied the most extensively among those rifamycin-based hybrid series. A variety of quinolone core structures as depicted in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> have been explored as the matching partners for rifamycin.<a onclick="showRef(event, 'ref23 cit25a cit25c ref27'); return false;" href="javascript:void(0);" class="ref ref23 cit25a cit25c ref27">(23, 25a, 25c, 27)</a> These quinolone core structures are associated with various fluoroquinolone, non-fluoroquinolone, and quinolizinone subclasses. Quinolizinones (also known as 2-pyridones) are close analogs of quinolones where the N-1 nitrogen atom is switched with the C-5 carbon atom to produce a family of highly active bioisosteres.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Quinolizinones, exemplified by <b>4</b> (ABT-719), are potent and balanced inhibitors of bacterial DNA gyrase and topoisomerase IV and exhibit potent antibacterial activities against both Gram-positive and Gram-negative pathogens.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> However, no quinolizinone class of antibacterial agents has been commercialized to date. The positions on the rifamycin scaffold that have been utilized for attaching the quinolone structures are C-3, C-3/C-4, C-11, and C-25 using the strategy discussed previously (<a class="ref internalNav" href="#fig5" aria-label="Figure 05">Figure 05</a>). The structures for the linker group vary widely based on published patent literature and appear to have significant impact on the antibacterial activity of the hybrid compounds. However, the detailed structureâactivity relationships around the rifamycinâquinolone series have yet to be reported.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Quinolone core structures that have been explored as matching partners for rifamycins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b> is the leading molecule from the rifamycinâquinolone hybrid series currently in clinical development.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The compound is formed by a rifamycin and a quinolizinone core connected via the C-3 position from the rifamycin side and the C-8 position from the quinolizinone side. The linker group resembles the structural characteristics of the side chains of rifampin and <b>4</b> joined together covalently (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of rifampin, quinolizinone <b>4</b>, and dual-acting molecule <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b> was synthesized by connecting the rifamycin core (<b>14</b>), quinolizinone core (<b>11</b>), and linker group (<b>10</b>) together (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Starting from commercially available (<i>S</i>)-1-benzyl-3-hydroxypyrrolidine, linker group <b>10</b> was prepared in 5 steps. 8-Chloro-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4<i>H</i>-quinolizinone-3-carboxylate (<b>11</b>) was prepared according to published procedures.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Coupling of <b>10</b> and <b>11</b> provided compound <b>12</b>. Hydrolysis of the ethyl ester and deprotection of the amine protecting group provided compound <b>13</b>. Finally, <b>13</b> was attached to the rifamycin core by first converting the piperidine amino group to a hydrazine, followed by coupling with 3-formalrifamycin (<b>14</b>). Compound <b>1</b> has been manufactured in kilogram quantities in a similar fashion for multiple times. The synthesis of <b>1</b> is illustrated in the <a class="ref internalNav" href="#sec7" aria-label="Experimental Section">Experimental Section</a>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dual-Acting Molecule <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MsCl, Et<sub>3</sub>N, toluene, 0 Â°C, 2 h; (ii) Bu<sub>4</sub>N<sup>+</sup>CN<sup>â</sup>, CH<sub>3</sub>CN, 65 Â°C, 16 h; (iii) Ti(O-<i>i</i>-Pr)<sub>4</sub>, EtMgBr, Et<sub>2</sub>O/THF, â78 Â°C, 20 min; warm to rt, BF<sub>3</sub>Â·Et<sub>2</sub>O, 2 h; (iv) <b>8</b>, THF/AcOH, rt, 1 h, then NaBH(OAc)<sub>3</sub>, rt, overnight, then 37% aq HCHO, 2 h; (v) H<sub>2</sub>, Pd/C, AcOH, 60 psi, rt, 18 h; (vi) <b>11</b>, NaHCO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 5 h; (vii) LiOH, EtOH, 60 Â°C, 1 h; (viii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 1 h; (ix) NaOH, H<sub>2</sub>NâOSO<sub>3</sub>H, 0 Â°C, 1 h; (x) 3-formal rifamycin (<b>14</b>), MeOH/THF, rt, 30 min.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Preclinical Characterization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Preclinical studies of the in vitro and in vivo activities of <b>1</b> were described in a series of posters presented at the 47th (2007) Interscience Conference on Antimicrobial Agents and Chemotherapy<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and in two subsequent publications.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">As is shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, biochemical studies using <i>S. aureus</i> enzymes indicate that <b>1</b> retains rifampin-like potency as an inhibitor of RNA polymerase (RNAP) and exhibits balanced (equipotent) activity against DNA gyrase and DNA topoisomerase IV (Topo IV) while retaining activity against a common quinolone-resistant (FQ-R) variant (ParC<sup>S80F</sup>) of DNA topoisomerase IV.<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> No inhibition of human topoisomerase II-Î± (Top2a) by <b>1</b> was observed. As is shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, minimum inhibitory concentration (MIC) values determined for otherwise isogenic strains of <i>S. aureus</i> ATCC 29213 bearing rifamycin (<i>rpoB</i><sup>H481Y</sup>) and/or quinolone (<i>parC</i><sup>S80F</sup> and <i>gyrA</i><sup>S84L</sup>) resistance alleles confirm that <b>1</b> retains rifampin-like potency against quinolone-resistant strains and gatifloxacin-like potency against rifampin-resistant strains. Again, these data support the notion that <b>1</b> exhibits antimicrobial activity via combined contributions from both the rifamycin and quinolizinone functions and are consistent with triple targeting of RNA polymerase, DNA gyrase, and DNA topoisomerase IV. A serial stepwise passage resistance study conducted with <b>1</b> over a period of 26 days yielded a terminal isolate with broth and agar MICs of >16 and 4 Î¼g/mL, respectively, that possessed five target mutations (<i>rpoB</i><sup>R484H</sup>, <i>gyrA</i><sup>ÎL520,S84L</sup>, <i>parC</i><sup><R236>,H103Y</sup>) but was unaltered in efflux properties. Data from time-kill and metabolic labeling experiments also support the notion that the primary activity of <b>1</b> in <i>S. aureus</i> is driven by its rifamycin function and that activity against rifamycin-resistant strains is mediated by the quinolizinone function. In metabolic labeling experiments, <b>1</b> has a primary effect on de novo RNA synthesis with delayed, secondary effects on DNA, protein, and cell wall synthesis. The more pronounced effect of <b>1</b> on DNA synthesis than that observed with rifampin presumably reflects the secondary mode of action conferred by the quinolizinone part of the molecule.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biochemical Characterization of <b>1</b> and Comparators</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub>Â (Î¼M)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">CC<sub>50</sub>Â (Î¼M)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">RNAP (wildÂ type)</th><th class="colsep0 rowsep0" align="center" char=".">RNAP (Rif-R,Â RpoB<sup>H481Y</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">TopoÂ IV (wildÂ type)</th><th class="colsep0 rowsep0" align="center" char=".">gyrase (wildÂ type)</th><th class="colsep0 rowsep0" align="center" char=".">TopoÂ IV (FQ-R,Â ParC<sup>S80F</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">gyrase (FQ-R,Â GyrA<sup>S84L</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">human Topo2a</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">>25</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">>150</td><td class="colsep0 rowsep0" align="char" char=".">>150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">>25</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">>150</td><td class="colsep0 rowsep0" align="char" char=".">>150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gatifloxacin</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">>150</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The minimum concentration necessary to inhibit 50% (IC<sub>50</sub>) of the RNA product formed in the absence of test agents.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Minimum concentration necessary to induce 50% cleavage of a covalently closed DNA substrate (CC<sub>50</sub>).</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antibacterial Activity of <b>1</b> and Comparator Agents against Isogenic <i>Staphylococcus aureus</i> Strains Bearing Rifamycin and/or Quinolone Resistance Mutations</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="8" align="center"><i>Staphylococcus aureus</i> isogenic strain panel MIC (Î¼g/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">wild type</th><th class="colsep0 rowsep0" align="center"><i>gyrA</i><sup>S84L</sup></th><th class="colsep0 rowsep0" align="center"><i>parC</i><sup>S80F</sup></th><th class="colsep0 rowsep0" align="center"><i>gyrA</i><sup>S84L</sup>, <i>parC</i><sup>S80F</sup></th><th class="colsep0 rowsep0" align="center"><i>rpoB</i><sup>H481Y</sup></th><th class="colsep0 rowsep0" align="center"><i>rpoB</i><sup>H481Y</sup>, <i>gyrA</i><sup>S84L</sup></th><th class="colsep0 rowsep0" align="center"><i>rpoB</i><sup>H481Y</sup>, <i>parC</i><sup>S80F</sup></th><th class="colsep0 rowsep0" align="center"><i>rpoB</i><sup>H481Y</sup>, <i>gyrA</i><sup>S84L</sup>, <i>parC</i><sup>S80F</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (agar)</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (broth)</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">levofloxacin</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gatifloxacin</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">8</td></tr></tbody></table></div></div><div class="NLM_p"><a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> lists the in vitro antimicrobial activity of <b>1</b> against 175 staphylococci and 125 streptococci compared to those determined in parallel for rifampin and ciprofloxacin. The broth microdilution MICs at which 90% of methicillin-susceptible or methicillin-resistant <i>S. aureus</i> (MSSA, MRSA) or <i>S. epidermidis</i> (MSSE, MRSE) isolates are inhibited (MIC<sub>90</sub>) by <b>1</b> are 0.015, 0.015, 0.008, and 0.5 Î¼g/mL, respectively. The activity of <b>1</b> against MSSA, MRSA, and MSSE was equivalent to rifampin and improved over ciprofloxacin, whereas <b>1</b> was improved over both rifampin and ciprofloxacin against MRSE. MIC<sub>90</sub> values for <b>1</b> against <i>S. pyogenes</i>, <i>S. agalactiae</i>, and <i>S. pneumoniae</i> were 0.12, 0.25, and 0.12 Î¼g/mL, respectively, and again equivalent to rifampin and improved over ciprofloxacin.<a onclick="showRef(event, 'cit31b cit32c'); return false;" href="javascript:void(0);" class="ref cit31b cit32c">(31b, 32c)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antibacterial Activities of <b>1</b> against Clinical Isolates of Gram-Positive Bacteria</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">MICÂ (Î¼g/mL)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">organismÂ (<i>n</i>)</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">range</th><th class="colsep0 rowsep0" align="center">50%</th><th class="colsep0 rowsep0" align="center">90%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S.Â aureus</i></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MSSAÂ (51)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">â¤0.004â0.03</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">â¤0.008â0.06</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.06 to >4</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRSA (54)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">â¤0.004â2</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">â¤0.008 to >4</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.12 to >4</td><td class="colsep0 rowsep0" align="left">>4</td><td class="colsep0 rowsep0" align="left">>4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S.Â epidermidis</i></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MSSE (35)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">â¤0.004â0.015</td><td class="colsep0 rowsep0" align="left">â¤0.008</td><td class="colsep0 rowsep0" align="left">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">â¤0.004â0.06</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.12 to >4</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRSE (35)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">â¤0.004â1</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">â¤0.004 to >4</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">>4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.12 to >4</td><td class="colsep0 rowsep0" align="left">>4</td><td class="colsep0 rowsep0" align="left">>4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S.Â pyogenes</i>Â (35)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.008â0.12</td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">â¤0.008â0.25</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.12â2</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S.Â agalactiae</i>Â (35)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.06â2</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">0.03â2</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.25â1</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S.Â pneumoniae</i>Â (55)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.06â0.25</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">rifampin</td><td class="colsep0 rowsep0" align="left">0.12â1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">0.5 to >4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Broth microdilution method.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Tested in MHII broth with 0.002% (vol/vol) polysorbate-80.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Tested in MHII broth with 5% (vol/vol) LHB and 0.002% (vol/vol) polysorbate-80.</p></div></div></div><div class="NLM_p">Compound <b>1</b> also exhibited prolonged postantibiotic and sub-MIC effects in <i>S. aureus</i> and are indicative of efficient intracellular uptake and retention. In time-kill studies, <b>1</b> exhibited bactericidal activity against both staphylococci and streptococci with rapid, quinolone-like killing of rifampin-resistant strains observed. In spontaneous resistance studies, <b>1</b> exhibited activity consistent with balanced contributions from its composite parent antibiotics with a mutant prevention concentration (MPC) of 0.12 Î¼g/mL and a resistance frequency of <10<sup>â12</sup> determined at 1 Î¼g/mL in agar for <i>S. aureus</i> ATCC 29213. Finally, in studies of the killing of <i>S. aureus</i> residing intracellularly in murine macrophage cells, <b>1</b> exhibited prolonged bactericidal activity.<a onclick="showRef(event, 'ref31 cit32c cit32d'); return false;" href="javascript:void(0);" class="ref ref31 cit32c cit32d">(31, 32c, 32d)</a></div><div class="NLM_p">The comparative in vitro activity of <b>1</b> and rifampin + quinolone combinations was assessed using a series of checkerboard assays with fractional inhibitory concentration (FIC) indices determined by the broth microdilution method, time-kill studies, biofilm killing assays and through determination of MPCs.<a onclick="showRef(event, 'cit32b'); return false;" href="javascript:void(0);" class="ref cit32b">(32b)</a> Antagonism of the rapid killing of <i>S. aureus</i> by quinolones in the presence of rifampin was apparent in checkerboard assays via minimal bactericidal concentration (MBC) end points and in high density time-kill assays. In the latter, a rifampin + ciprofloxacin combination (1 + 0.25 Î¼g/mL) is bacteriostatic (<99.9% kill at 24 h) against <i>S. aureus</i> ATCC 29213 and resulted in the outgrowth of rifampin-resistant isolates. In contrast, <b>1</b> was observed to be bactericidal (â¥99.9% kill at 24 h at 0.25 Î¼g/mL) without the emergence of rifampin resistance. Also in contrast to tested rifampin + quinolone cocktails, <b>1</b> promoted eradication of colony biofilms formed by <i>S. aureus</i> MSSA or MRSA isolates and exhibited bactericidal activity (>99% kill at 24 h at 4 Î¼g/mL) that is greater than that of rifampin + moxifloxacin (â¤99% kill at 4 + 4 Î¼g/mL) combination in killing <i>S. aureus</i> cells within murine macrophages.</div><div class="NLM_p">In further in vitro studies, <b>1</b> was found to exhibit antibiofilm activity in a number of alternative assays and retains potent bactericidal activity against staphylococcal cells in the biofilm state.<a onclick="showRef(event, 'cit32d'); return false;" href="javascript:void(0);" class="ref cit32d">(32d)</a> In contrast to existing rifamycin class agents, resistance development in biofilm populations was not observed with <b>1</b>. These studies hold promise for the potential of <b>1</b> in the treatment of biofilm-associated infections.</div><div class="NLM_p">Pharmacokinetic (PK) properties of <b>1</b> were determined following intravenous (iv) administration to mice, rats, rabbits, and dogs and indicated a plasma <i>T</i><sub>1/2</sub> of 0.4â4.1 h in mice, rats, and rabbits and 1.6â11.7 h in dogs.<a onclick="showRef(event, 'cit32f'); return false;" href="javascript:void(0);" class="ref cit32f">(32f)</a> The calculated volume of distribution of <b>1</b> ranged from 0.08 to 0.52 and from 0.09 to 0.17 L/kg in rodents/rabbits and dogs, respectively. Plasma clearance ranged from 0.07 to 0.36 and from 0.01 to 0.08 L h<sup>â1</sup> kg<sup>â1</sup> in rodents/rabbits and dogs, respectively. Calculated AUC and <i>C</i><sub>max</sub> values were dose proportional for all species. Data from the neutropenic thigh infection model and the drip flow biofilm reactor identified the 24 h AUC/MIC ratio as the PD index best correlated with efficacy.<a onclick="showRef(event, 'cit32f'); return false;" href="javascript:void(0);" class="ref cit32f">(32f)</a></div><div class="NLM_p">The in vivo efficacy of <b>1</b> was determined in various rodent models of staphylococcal and streptococcal infections including acute systemic infections and chronic biofilm-associated infections of indwelling medical devices.<a onclick="showRef(event, 'cit32e'); return false;" href="javascript:void(0);" class="ref cit32e">(32e)</a> In a mouse septicemia model, ED<sub>50</sub> values for <b>1</b> ranged from 1.4 to 3.8 mg/kg for MSSA, MRSA, and FQ-resistant <i>S. aureus</i> and from 4.8 to 10.7 mg/kg for <i>S. epidermidis</i> and <i>S. pyogenes</i> infections. In a mouse skin abscess model, <b>1</b> exhibited efficacy comparable to rifampin or comparators used to treat complicated skin and skin structure infections (cSSSIs) with log<sub>10</sub>Â CFU reductions of >3.1 to 5.3 observed for MRSA, <i>S. epidermidis</i>, or <i>S. pyogenes</i>. In the rat central venous catheter (CVC) infection model, <b>1</b> exhibited equivalent efficacy to rifampin but significantly improved over cSSSI comparator agents with log<sub>10</sub>Â CFU reductions of 2.8â3.4 observed for MSSA and FQ-resistant <i>S. aureus</i>. Compound <b>1</b> showed effective penetration into granuloma pouch fluid and reduced <i>S. aureus</i> counts by 1â3.4 log<sub>10</sub>Â CFU after single iv doses of 5â25 mg/kg. In the mouse subcutaneous catheter implant model, <b>1</b> was more efficacious than rifampin and cSSSI comparators achieving log<sub>10</sub>Â CFU reductions of 5.03, 3.98, and 2.51 against susceptible, FQ-resistant, and rifampin-resistant <i>S. aureus</i> isolates, respectively. In addition, <b>1</b> exhibited continued suppression of the catheter-localized biofilm infections after therapy was withdrawn.</div><div class="NLM_p">The in vivo efficacy of <b>1</b> was further investigated in a rabbit model of infective endocarditis (IE) mediated by MRSA.<a onclick="showRef(event, 'cit32g cit32h'); return false;" href="javascript:void(0);" class="ref cit32g cit32h">(32g, 32h)</a> In these studies, rabbit IE was induced with MRSA strain 67-0, following transcarotidâtransaortic valve indwelling catheterization. At 24 h postinfection, animals received either (i) no therapy (control), (ii) <b>1</b> at 10, 25, or 40 mg/kg, iv, b.i.d., or (iii) vancomycin at 15 mg/kg, iv, b.i.d. All treatments were for 3 days and 24 h after the last dose, target tissues were quantitatively cultured; relapse of infection was also investigated 3 d after treatment was discontinued. MICs/MBCs of <b>1</b> and vancomycin for MRSA 67-0 were 0.008/0.5 mg/mL and 1/1 mg/mL, respectively. In these studies, all regimens significantly decreased MRSA densities vs controls with <b>1</b> at 25 and 40 mg/kg exhibiting the greatest efficacy and also prevented relapse. In contrast to vancomycin, sterile tissue cultures were observed in vegetations, kidneys, and spleens for all <b>1</b> treatment groups following the relapse period with no resistance development to <b>1</b> observed.</div><div class="NLM_p last">The comparative efficacy of <b>1</b> and rifampin + quinolone combinations was also determined in the rabbit IE model including studies of a quinolone-resistant variant of MRSA 67-0 (QMRSA) bearing both <i>norA</i><sup>up</sup> (efflux) and DNA topoisomerase IV (<i>parC</i><sup>S80F</sup>) mutations.<a onclick="showRef(event, 'cit32h'); return false;" href="javascript:void(0);" class="ref cit32h">(32h)</a> At 24 h postinfection, animals received either (i) no therapy (control), (ii) <b>1</b> 40 mg/kg, iv, b.i.d., (iii) ciprofloxacin 20 mg/kg, iv, t.i.d. + rifampin 10 mg/kg, im, b.i.d., or (iv) levofloxacin 20 mg/kg, iv, b.i.d. + rifampin 10 mg/kg, im, b.i.d., all for 3 days. At 24 h postdose, target tissues were cultured. Relapse of infection was investigated 3 d after treatment was discontinued. MICs/MBCs of <b>1</b>, ciprofloxacin, levofloxacin, and rifampin were 0.008/0.5, 16/16, 2/2, and 0.008/2 mg/mL, respectively. Compound <b>1</b> significantly reduced QMRSA densities in all target tissues at the end of therapy and relapse. Levofloxacin + rifampin significantly reduced densities but to a lower extent than observed with <b>1</b>, and ciprofloxacin + rifampin exhibited the lowest overall efficacy.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Summary and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11788" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11788" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of rifamycin based dual-acting antibacterial agents represents a promising strategy for the treatment of persistent bacterial infections such as PJIs. The dual-action approach could potentially address several major issues associated with the use of rifamycin drug combinations and therefore provide a better therapeutic solution in treating persistent bacterial infections where the standard-of-care requires a rifamycin combination therapy.</div><div class="NLM_p">The dual-action molecule <b>1</b> has demonstrated advantages over rifampin and fluoroquinolone combinations in several aspects. First, it possesses potent and balanced activity against three cellular targets RNA polymerase, DNA gyrase, and topoisomerase IV in <i>S. aureus</i> and CoNS.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Second, it is not a substrate of fluoroquinolone efflux systems and has a low propensity for resistance development. Third, <b>1</b> exhibits potent activity against drug resistant pathogens including those resistant to one or both parent drugs and demonstrates better efficacy and resistance development profile than rifamycin + fluoroquinolone combinations in both in vitro and in vivo biofilm models. Fourth, <b>1</b> appears able to alleviate certain safety concerns associated with its parent antibiotic classes such as CYP3A4 induction and hERG inhibition. In completed human phase I single and multiple ascending dose clinical trials of an intravenous formulation, <b>1</b> demonstrates good pharmacokinetic and safety profiles supporting further clinical development for the treatment of PJIs and other persistent bacterial infections.</div><div class="NLM_p">One of the unexpected observations during the development of rifamycin based dual-action compounds such as <b>1</b> is that such dual-action molecules exhibit synergistic effects in vitro and in vivo improved over the simple parent drug combinations. Such synergies are apparent with several dual-action classes and may represent a general benefit of the dual-action approach. The source and mechanism for such synergy is unclear at this time and represents a direction of ongoing research for rifamycinâquinolone hybrid agents. Understanding the mechanisms of this synergistic effect may help to design better dual-acting molecules in the future.</div><div class="NLM_p">The spectrum of the antibacterial activity of a dual-acting molecule can be very different from its parental antibiotics. RNA polymerase and DNA gyrase/topoisomerase IV, the respective drug targets for rifamycins and fluoroquinolones, are essential enzymes in all pathogens. The spectra of activity for rifamycins and fluoroquinolones are largely a reflection of their ability to reach their intracellular targets. Rifamycins are mainly active against Gram-positive pathogens with difficulties to penetrate the outer cell membrane of Gram-negative organisms, while fluoroquinolones are broad spectrum and active against both Gram-positive and Gram-negative pathogens. The dual-action hybrid molecule <b>1</b> is mainly active against Gram-positive pathogens with a spectrum similar to rifampin. However, <b>1</b> also demonstrates a better activity than rifampin against certain Gram-negative bacteria such as <i>Escherichia coli</i> and <i>Acinetobacter baumannii</i>, indicating that <b>1</b> may have improved membrane permeability and/or be able to avoid the native efflux systems of these organisms.</div><div class="NLM_p last">A dual-action molecule generally possesses very different absorption, distribution, metabolism, and excretion (ADME) properties from its parental antibiotics, and its clinical application should be optimized based on its ADME characteristics. Indeed, dual-action molecules such as <b>1</b> typically have high molecular weights and exhibit low oral bioavailability and therefore may not be suitable for the development of oral dosage formulations for systemic delivery. However, this low oral absorption could become an advantage for the treatment of diseases associated with gastrointestinal tract infections, and this strategy is currently being actively pursued in clinical trials.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>1</b> has been synthesized many times from milligram to kilogram quantities. The following procedure reproduced from a patent publication is a representation of the process used for large quantity manufacturing of <b>1</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> All starting materials used are either purchased from commercial sources or prepared according to published procedures. Operations involving moisture and/or oxygen sensitive materials are conducted under an atmosphere of nitrogen. Flash chromatography is performed using silica gel 60 as normal phase adsorbent or C18 silica gel as reverse phase adsorbent. Thin layer chromatography (TLC) and preparative thin layer chromatography (PTLC) are performed using precoated plates purchased from E. Merck, and spots are visualized with ultraviolet light followed by an appropriate staining reagent. Nuclear magnetic resonance (NMR) spectra are recorded on a Varian 400 MHz magnetic resonance spectrometer. <sup>1</sup>H NMR chemical shift are given in parts per million (Î´) downfield from TMS using the residual solvent signal (CHCl<sub>3</sub> = Î´ 7.27, CH<sub>3</sub>OH = Î´ 3.31) as internal standard. <sup>1</sup>H NMR information is tabulated in the following format: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; td, triplet of doublet; dt, doublet of triplet), coupling constant(s) (<i>J</i>) in hertz. The prefix app is occasionally applied in cases where the true signal multiplicity is unresolved, and prefix br indicates a broad signal. Electrospray ionization mass spectra are recorded on a Finnegan LCQ advantage spectrometer. High-performance liquid chromatography (HPLC) analysis for the final compound is performed on Agilent 1100 instrument using a Waters Xterra RP18 column (5 Î¼m, 4.6 mm Ã 250 mm) and gradient elution (solvent A, 20 mM NaH<sub>2</sub>PO<sub>4</sub>/acetonitrile, 60:40 v/v; solvent B, acetonitrile). HPLC purities for the final compound are â¥95%.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Synthesis of (<i>S</i>)-Methanesulfonic Acid 1-Benzylpyrrolidin-3-yl Ester (<b>A</b>)</h3><div class="NLM_p last">(<i>S</i>)-1-Benzyl-3-hydroxypyrrolidine (<b>5</b>, 20.2 g, 114 mmol) was dissolved in toluene (200 mL). To this stirred solution, triethylamine (20 mL, 142 mmol) was added followed by methanesulfonyl chloride (10.5 mL, 136 mmol) during a period of 40 min at 0 Â°C. The resultant slurry was allowed to stir for 2 h at 0 Â°C, and 7% sodium bicarbonate (200 mL) was then added to the reaction mixture. The organic layer was then separated and the aqueous layer extracted with toluene (3 Ã 100 mL). The combined organic layers were washed with saturated sodium bicarbonate (3 Ã 200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give (<i>S</i>)-methanesulfonic acid 1-benzylpyrrolidin-3-yl ester as a yellow oil (28 g, 96%). The material was used directly for the next step without purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.34â7.17 (m, 5H), 5.24â5.18 (m, 1H), 3.71 (d, <i>J</i><sub>AB</sub> = 13.0 Hz, 1H), 3.64 (d, <i>J</i><sub>AB</sub> = 13.0 Hz, 1H), 3.01 (s, 3H), 2.89â2.80 (m, 3H), 2.56â2.50 (m, 1H), 2.38â2.31 (m, 1H), 2.14â2.07 (m, 1H).</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of (<i>R</i>)-1-Benzyl-3-cyanopyrrolidine (<b>6</b>)</h3><div class="NLM_p last">(<i>S</i>)-Methanesulfonic acid 1-benzylpyrrolidin-3-yl ester (28 g, 110 mmol) was dissolved in anhydrous acetonitrile (60 mL), and solid tetrabutylammonium cyanide (59 g, 220 mmol) was added at once at room temperature. The resulting mixture was heated at 65 Â°C for 16 h and cooled to room temperature. Saturated NaHCO<sub>3</sub> (100 mL) solution was added. The organic layer was then separated and the aqueous layer extracted with toluene (3 Ã 100 mL). The combined organic layers were washed with water (3 Ã 100 mL), brine, and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give (<i>R</i>)-1-benzyl-3-cyanopyrrolidine as brown oil (21 g), which was vacuum distilled at 150 Â°C/5 mmHg to give a colorless liquid (19 g, 85%): [Î±]<sup>23</sup> â22.0Â° (<i>c</i> 2.5, MeOH); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.36â7.17 (m, 5H), 3.66 (app s, 2H), 3.05â2.99 (m, 1H), 2.93 (app t, <i>J</i> = 8.8 Hz, 1H), 2.72â2.60 (m, 3H), 2.31â2.22 (m, 1H), 2.17â2.11 (m, 1H).</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis of (<i>R</i>)-1-(1-Benzylpyrrolidin-3-yl)cyclopropylamine (<b>7</b>)</h3><div class="NLM_p last">To a solution of (<i>R</i>)-1-benzyl-3-cyanopyrrolidine (<b>6</b>, 10 g, 53.4 mmol) in anhydrous ether (200 mL) was added Ti(OiPr)<sub>4</sub> (17.2 mL, 58.8 mmol), and the resulting solution was cooled to â78 Â°C. EtMgBr (3.0 M in Et<sub>2</sub>O, 35 mL, 105 mmol, Aldrich) was added dropwise during a period of 40 min at â78 Â°C. Anhydrous THF (50 mL) was added to the resultant yellow suspension to facilitate stirring, and the solution was stirred for 20 min at â78 Â°C. The reaction mixture was allowed slowly to warm up to room temperature, then BF<sub>3</sub>Â·Et<sub>2</sub>O (13.4 mL, 107 mmol) was added and the resultant dark brown suspension was stirred at room temperature for 2 h. Both 1 N HCl (100 mL) and Et<sub>2</sub>O (200 mL) were introduced subsequently to the reaction mixture, and stirring was kept for 20 min until both organic and aqueous phases became clear. It was then basified using aqueous 20% NaOH (100 mL) and stirred for 30 min. The organic phase was separated, and the aqueous phase was extracted with Et<sub>2</sub>O (2 Ã 100 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give (<i>R</i>)-1-(1-benzylpyrrolidin-3-yl)cyclopropylamine as brown oil (10.5 g, 90%), which was vacuum distilled to give a colorless liquid (9 g, 77%). The product is sufficiently pure to use in next step. For characterization, a small amount of sample was purified by PTLC using solvent NH<sub>4</sub>OH/MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1/60/340): [Î±]<sup>23</sup> â10.0Â° (<i>c</i> 2.5, MeOH); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.33â7.23 (m, 5H), 3.62 (d, <i>J</i><sub>AB</sub> = 12.8 Hz, 1H), 3.56 (d, <i>J</i><sub>AB</sub> = 12.8 Hz, 1H), 2.66â2.57 (m, 3H), 2.40â2.37 (m, 1H), 1.96â1.91 (m, 2H), 1.69â1.62 (m, 1H), 0.55â0.48 (m, 2H), 0.41â0.36 (m, 2H).</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis of (<i>R</i>)-4-{[1-(1-Benzylpyrrolidin-3-yl)cyclopropyl]methylamino}piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>9</b>)</h3><div class="NLM_p last">To a solution of (<i>R</i>)-1-(1-benzyl-pyrrolidin-3-yl)cyclopropylamine (<b>7</b>, 18.6 g, 87 mmol) and 4-oxopiperidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>8</b>, 22.7 g, 113 mmol) in THF (500 mL) was added glacial HOAc (31 mL). The solution was stirred at room temperature for 1 h, and then NaBH(OAc)<sub>3</sub> (65 g, 306 mmol) was added. The resulting suspension was stirred at room temperature overnight before 37% aqueous solution of formaldehyde (30 mL, 262 mmol) was added. The reaction mixture was allowed to stir for 3 h and then to it was added aqueous 20% NaOH (300 mL) at 0 Â°C. The mixture was allowed to stir for 2 h, and layers were separated. The aqueous layer was extracted with EtOAc (3 Ã 300 mL). The combined organic phase was dried over sodium sulfate, concentrated in vacuo. The residue was purified by flash chromatography (gradient elution, 1% to 10% methanol in dichloromethane) to give the title compound as a pale yellow oil (27 g): ESI MS <i>m</i>/<i>z</i> 414.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.33â7.23 (m, 5H), 4.24â4.02 (m, 2H), 3.88â3.80 (m, 1H), 3.60 (d, <i>J</i><sub>AB</sub> = 12.8 Hz, 1H), 3.53 (d, <i>J</i><sub>AB</sub> = 12.8 Hz, 1H), 2.82â2.57 (m, 5H), 2.31 (s, 3H), 2.28â2.22 (m, 1H), 1.94â1.80 (m, 4H), 1.44 (s, 9H), 1.42â1.28 (m, 3H), 0.55â0.53 (m, 4H). The chiral purity of the product was analyzed by Chiral-Cel OD column (0.46 cm Ã 25 cm, Daicel Chemical industries, Ltd., column catalog no. OD00CE-E1031) with acetonitrile in the presence of 0.1% diethylamine as mobile phase (flow rate 1 mL/min; retention time 5.23 min desired, 5.93 isomer) to be 95% ee.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthesis of (<i>R</i>)-4-[Methyl-(1-pyrrolidin-3-ylcyclopropyl)amino]piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10</b>)</h3><div class="NLM_p last">(<i>R</i>)-4-{[1-(1-Benzylpyrrolidin-3-yl)cyclopropyl]methylamino}piperidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>9</b>, 14 g) was dissolved in 150 mL of glacial acetic acid at room temperature in a hydrogenation flask, air was evacuated, and the flask was filled with nitrogen. To this was added 30% Pd/C (5 g). The flask was mounted to Parr shaker, nitrogen was evacuated and filled with hydrogen, and the mixture was shaken under hydrogen atmosphere at 60 psi in a Parr for 18 h. Reaction mixture was diluted with toluene (300 mL), filtered through a pad of Celite. The filtrate was concentrated in vacuo, residue was digested in cold 30% NaOH at 0 Â°C, and the product was extracted with ethyl acetate. The combined ethyl acetate solution was charged with 50 g of charcoal (Darco G-60), allowed to stir for 2 h, filtered, concentrated to give pale yellow oil, which can be vacuum distilled to give a clear oil (9.6 g). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 4.04 (br s, 1H), 3.01 (dd, <i>J</i> = 10.4 and 7.6 Hz, 1H), 2.84 (dd, <i>J</i> = 8.0 and 5.2 Hz, 2H), 2.64â2.55 (m, 3H), 2.48â2.43 (m, 2H), 2.30 (s, 3H), 2.28â2.23 (m, 1H), 2.23â1.74 (m, 3H), 1.40 (s, 9H), 1.35â1.28 (m, 2H), 1.18â1.12 (m, 2H), 0.53â0.45 (m, 4H).</div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of 8-(3-{1-[(1-<i>tert</i>-Butoxycarbonylpiperidin-4-yl)methylamino]cyclopropyl}pyrrolidin-1-yl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4<i>H</i>-quinolizine-3-carboxylic Acid Ethyl Ester (<b>12</b>)</h3><div class="NLM_p last">A stirred solution of ethyl 8-chloro-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4<i>H</i>-quinolizinone-3-carboxylate (<b>11</b>, 8.4 g, 25 mmol) and 4-[methyl-(1-pyrrolidin-3-ylcyclopropyl)amino]piperidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>10</b>, 10.6 g, 25 mmol) in the presence of sodium bicarbonate (8 g) in acetonitrile (150 mL) in a round-bottom flask was heated under reflux for 5 h. The solvent was removed in vacuo, residue was partitioned into 1 N NaOH and ethyl acetate and well-shaken. The organic layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography (75% ethyl acetate in hexane, then 10% MeOH in dichloromethane) to give a yellow solid (15 g, 99%). ESI MS <i>m</i>/<i>z</i> 611.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.25 (d, <i>J</i> = 10.8 Hz, 1H), 8.18 (s, 1H), 4.42â4.37 (m, 2H), 4.15â4.10 (m, 3H), 3.92â3.88 (m, 1H), 3.58â3.56 (m, 2H), 3.48â3.44 (m, 1H), 2.73â2.62 (m, 5H), 2.57 (s, 3H), 2.39 (s, 3H), 2.18â2.13 (m, 1H), 2.00â1.94 (m, 1H), 1.84â1.78 (m, 2H), 1.46 (s, 9H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H), 1.28â1.25 (m, 1H), 1.07â0.93 (m, 2H), 0.84â0.68 (m, 4H), 0.60â0.52 (m, 2H).</div></div><div id="sec7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of 1-Cyclopropyl-7-fluoro-9-methyl-8-{3-[1-(methylpiperidin-4-ylamino)cyclopropyl]pyrrolidin-1-yl}-4-oxo-4<i>H</i>-quinolizine-3-carboxylic Acid (<b>13</b>)</h3><div class="NLM_p last">To a solution of 8-(3-{1-[(1-<i>tert</i>-butoxycarbonylpiperidin-4-yl)methylamino]cyclopropyl}pyrrolidin-1-yl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4<i>H</i>-quinolizine-3-carboxylic acid ethyl ester (<b>12</b>, 15 g, 24 mmol) in ethanol (200 mL) was added the solution of LiOH (10 g, 238 mmol) in water (100 mL) in a round-bottom flask. The solution was heated at 60 Â°C for 1 h. The resulting solution was partitioned between dichloromethane (400 mL) and saturated aqueous NH<sub>4</sub>Cl (200 mL) and well shaken. The organic layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo to yield a yellow solid (14 g). This was used without further purification. To a stirred solution of above compound (14 g) in dichloroethane (100 mL) was added trifluoroacetic acid (30 mL) at 0 Â°C slowly. The resulting solution was stirred at 0 Â°C to room temperature for 1 h. The solvent was removed in vacuo to yield yellow oil, which was dissolved in 20% IPA in dichloromethane, and the solution was neutralized by sat. aq NaHCO<sub>3</sub> resulting in two clear phases, and the two phases were well shaken. The organic layer was separated, and the aqueous phase was extracted with 20% IPA/CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated in vacuo to give yellow solid (10 g). The solid was crystallized from methanol/water to give crystalline solid (8 g). ESI MS <i>m</i>/<i>z</i> 483.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 8.88 (d, <i>J</i> = 10.0 Hz, 1H), 7.93 (s, 1H), 4.03â3.98 (m, 1H), 3.79â3.75 (m, 1H), 3.66â3.62 (m, 1H), 3.58â3.52(m, 1H), 3.47â3.44 (m, 2H), 3.05â2.88 (m, 4H), 2.62 (s, 3H), 2.49 (s, 3H), 2.35â2.23 (m, 3H), 2.06â2.02 (m, 1H), 1.70â1.58 (m, 2H), 1.51â1.44 (m, 1H), 0.93â0.64 (m, 8H).</div></div><div id="sec7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis of (<i>R</i>)-3-[(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo<i>-</i>4<i>H-</i>quinolizine-8-yl)pyrrolidin-3-ylcyclopropyl]methylamino}piperidin-1-ylimino)methylenyl]rifamycin SV (<b>1</b>)</h3><div class="NLM_p last">1-Cyclopropyl-7-fluoro-9-methyl-8-{3-[1-(methylpiperidin-4-ylamino)cyclopropyl]pyrrolidin-1-yl}-4-oxo-4<i>H</i>-quinolizine-3-carboxylic acid (<b>13</b>, 9.2 g, 19 mmol) was dissolved in 1 N NaOH solution (120 mL) at room temperature. This was cooled to 0 Â°C and under argon atmosphere. To this homogeneous solution was added a freshly prepared solution of hydroxylamine-<i>O</i>-sulfuric acid (H<sub>2</sub>N-OSO<sub>3</sub>H, 2 g, 18.5 mmol) in H<sub>2</sub>O (10 mL) dropwise at 0 Â°C. The resultant solution was stirred at this temperature for 1 h, and excess acetic acid (22 mL) was added to acidify to pH 5, followed by ascorbic acid (1 g). The solution was then diluted with methanol (280 mL). To the stirred resultant solution at room temperature was added a homogeneous solution of 3-formylrifamycin (<b>14</b>, 8.2 g, 11.3 mmol in 40 mL of methanol/THF (3:1) slowly in 30 min. The product slowly precipitates out of homogeneous reaction mixture. After addition, the stirred reaction mixture was kept for 30 min at room temperature and cooled to 0 Â°C for 1 h, and precipitate was collected and washed with cold methanol (3 Ã 20 mL) to give 9.5 g. The collected precipitate was dissolved in dichloromethane (100 mL). This solution was stirred with 5% citric acid solution (100 mL) in the presence of 0.5% ascorbic acid for 2 h, and the two phases were shaken. Organic phase was separated, washed with the same aqueous solution, dried over sodium sulfate. To the dried filtrate was added half the volume of ethanol, and the mixture was concentrated in vacuo to give an orange solid (8.5 g). One gram of the orange solid was crystallized as follows: The solid (1 g) was dissolved in 5 mL of acetone and water (95:5), and the stirred solution was heated on an oil bath at 55â60 Â°C until homogeneous. The solution was slowly cooled with stirring (200 rpm) to room temperature. Once precipitate forms, the mixture was allowed to stir at room temperature for 2 h and cooled to 0 Â°C on ice bath for 2 h, before collecting the precipitate using a Buchner funnel with the aid of cold solvent. The cake was pressed dry and washed with 5 mL cold acetone/water (95:5) and pressed dry again. The cake was vacuum-dried to a constant weight (830 mg obtained) to produce the title compound. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 13.82 (s, 1H), 13.52 (br s, 1 H), 13.25 (singlet, 1H), 11.98 (singlet, 1H), 9.04 (d, <i>J</i> = 9.2 Hz, 1H), 8.22 (s 1H), 7.97 (s, 1H), 6.58â6.50 (m, 1H), 6.37â6.34 (m, 1H), 6.18 (d, <i>J</i> = 12.4 Hz, 1H), 5.94â5.87 (m, 1H), 5.07 (dd, <i>J</i> = 6.8, 12.8 Hz, 1H), 4.89 (d, <i>J</i> = 10.8 Hz, 1H), 3.93â3.87 (m, 1H), 3.72 (d, <i>J</i> = 9.6 Hz, 1H), 3.66â3.52 (m, 4H), 3.48â3.42 (m, 3H), 3.00 (s, 3H), 3.00â2.95 (m, 1H), 2.65â2.50 (m, 6H), 2.37 (s, 3H), 2.36â2.30 (m, 1H), 2.19 (s, 3H), 2.18â2.10 (m, 1H), 2.02 (app s, 6H), 2.00â1.82 (m, 2H), 1.76 (s, 3H), 1.65â1.40 (m, â¼10H), 1.32â1.17 (m, 2H), 1.08â1.02 (m, 1H), 0.96 (d, <i>J</i> = 6.8 Hz, 3H), 0.90â0.85 (m, 1H), 0.82 (d, <i>J</i> = 6.8 Hz, 3H), 0.78â0.62 (m, 3H), 0.56 (d, <i>J</i> = 6.4 Hz, 3H), â0.35 (d, <i>J</i> = 6.8 Hz, 3H). MS: ESI <i>m</i>/<i>z</i> 1173.6 (M â MeO, most abundant)<sup>+</sup>, 1205.6 (M + H, parent)<sup>+</sup>. HPLC purity: 98.9%.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00485">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00485" class="ext-link">10.1021/acs.jmedchem.6b00485</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and biochemical activity data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00485/suppl_file/jm6b00485_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00485/suppl_file/jm6b00485_si_001.csv">jm6b00485_si_001.csv (0.66 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00485" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenkun Ma</span> - <span class="hlFld-Affiliation affiliation">TenNor
Therapeutics Ltd., 218
Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a40525f54514f5414575b7a4e5f545455484214595557"><span class="__cf_email__" data-cfemail="f18b99949f9a849fdf9c90b185949f9f9e8389df929e9c">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Simon Lynch</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research & Development LLC., 1400 McKean Road, Spring House, Pennsylvania 18940, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Ma and Lynch were both employees of Cumbre Pharmaceuticals where dual-acting compound 1 was discovered. Ma is a founder and employee of TenNor Therapeutics currently developing compound 1.<br /></br></div></li></ul></div><div class="ack" id="ACK-d45e2282-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The work reviewed in this article represents many years of effort by a large number of distinguished colleagues, first at Cumbre Pharmaceuticals and now continued at TenNor Therapeutics. Their tremendous contribution to the discovery and development of dual-acting antimicrobial series is greatly appreciated.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i22" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i22"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">ATCC</td><td class="NLM_def"><p class="first last">American Type Culture Collection</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony forming unit</p></td></tr><tr><td class="NLM_term">CoNS</td><td class="NLM_def"><p class="first last">coagulase-negative staphylococci</p></td></tr><tr><td class="NLM_term">cSSSI</td><td class="NLM_def"><p class="first last">complicated skin and skin structure infection</p></td></tr><tr><td class="NLM_term">CVC</td><td class="NLM_def"><p class="first last">central venous catheter</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">FIC</td><td class="NLM_def"><p class="first last">fractional inhibitory concentration</p></td></tr><tr><td class="NLM_term">FQ</td><td class="NLM_def"><p class="first last">fluoroquinolone</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IDSA</td><td class="NLM_def"><p class="first last">Infectious Diseases Society of America</p></td></tr><tr><td class="NLM_term">IE</td><td class="NLM_def"><p class="first last">infective endocarditis</p></td></tr><tr><td class="NLM_term">MBC</td><td class="NLM_def"><p class="first last">minimum bactericidal concentration</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MPC</td><td class="NLM_def"><p class="first last">mutant prevention concentration</p></td></tr><tr><td class="NLM_term">MRSA</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">MSSA</td><td class="NLM_def"><p class="first last">methicillin-sensitive <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">PJI</td><td class="NLM_def"><p class="first last">prosthetic joint infection</p></td></tr><tr><td class="NLM_term">QMRSA</td><td class="NLM_def"><p class="first last">quinolone-resistant, methicillin-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">RNAP</td><td class="NLM_def"><p class="first last">RNA polymerase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kapadia, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhave, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mont, M. A.</span><span> </span><span class="NLM_article-title">Periprosthetic joint infection</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x"> (</span><span class="NLM_issue">10016</span><span class="NLM_x">) </span> <span class="NLM_fpage">386</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(14)61798-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0140-6736%2814%2961798-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=386-394&issue=10016&author=B.+H.+Kapadiaauthor=R.+A.+Bergauthor=J.+A.+Daleyauthor=J.+Fritzauthor=A.+Bhaveauthor=M.+A.+Mont&title=Periprosthetic+joint+infection&doi=10.1016%2FS0140-6736%2814%2961798-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961798-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961798-0%26sid%3Dliteratum%253Aachs%26aulast%3DKapadia%26aufirst%3DB.%2BH.%26aulast%3DBerg%26aufirst%3DR.%2BA.%26aulast%3DDaley%26aufirst%3DJ.%2BA.%26aulast%3DFritz%26aufirst%3DJ.%26aulast%3DBhave%26aufirst%3DA.%26aulast%3DMont%26aufirst%3DM.%2BA.%26atitle%3DPeriprosthetic%2520joint%2520infection%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26issue%3D10016%26spage%3D386%26epage%3D394%26doi%3D10.1016%2FS0140-6736%2814%2961798-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tande, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R.</span><span> </span><span class="NLM_article-title">Prosthetic joint infection</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">345</span><span class="refDoi">Â DOI: 10.1128/CMR.00111-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FCMR.00111-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=24696437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKnt7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=302-345&issue=2&author=A.+J.+Tandeauthor=R.+Patel&title=Prosthetic+joint+infection&doi=10.1128%2FCMR.00111-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prosthetic joint infection</span></div><div class="casAuthors">Tande, Aaron J.; Patel, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-345, 45 pp.</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Prosthetic joint infection (PJI) is a tremendous burden for individual patients as well as the global health care industry.  While a small minority of joint arthroplasties will be come infected, appropriate recognition and management are crit. to preserve or restore adequate function and prevent excess morbidity.  In this review, we describe the reported risk factors for and clin. manifestations of PJI.  We discuss the pathogenesis of PJI and the numerous microorganisms that can cause this devastating infection.  The recently proposed consensus definitions of PJI and approaches to accurate diagnosis are reviewed in detail.  An overview of the treatment and prevention of this challenging condition is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbRwazF4dKvLVg90H21EOLACvtfcHk0liQ4njvVcjvPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKnt7jO&md5=590d06768ca5603d06b443e7d5bc033f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FCMR.00111-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00111-13%26sid%3Dliteratum%253Aachs%26aulast%3DTande%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DR.%26atitle%3DProsthetic%2520joint%2520infection%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2014%26volume%3D27%26issue%3D2%26spage%3D302%26epage%3D345%26doi%3D10.1128%2FCMR.00111-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Osmon, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berbari, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berendt, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lew, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckelberg, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanssen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. R.</span><span> </span><span class="NLM_article-title">Executive summary: Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">10</span><span class="refDoi">Â DOI: 10.1093/cid/cis966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fcid%2Fcis966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23230301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ht1ShtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1-10&issue=1&author=D.+R.+Osmonauthor=E.+F.+Berbariauthor=A.+R.+Berendtauthor=D.+Lewauthor=W.+Zimmerliauthor=J.+M.+Steckelbergauthor=N.+Raoauthor=A.+Hanssenauthor=W.+R.+Wilson&title=Executive+summary%3A+Diagnosis+and+management+of+prosthetic+joint+infection%3A+Clinical+practice+guidelines+by+the+Infectious+Diseases+Society+of+America&doi=10.1093%2Fcid%2Fcis966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America</span></div><div class="casAuthors">Osmon Douglas R; Berbari Elie F; Berendt Anthony R; Lew Daniel; Zimmerli Werner; Steckelberg James M; Rao Nalini; Hanssen Arlen; Wilson Walter R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">These guidelines are intended for use by infectious disease specialists, orthopedists, and other healthcare professionals who care for patients with prosthetic joint infection (PJI).  They include evidence-based and opinion-based recommendations for the diagnosis and management of patients with PJI treated with debridement and retention of the prosthesis, resection arthroplasty with or without subsequent staged reimplantation, 1-stage reimplantation, and amputation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrx6uNmnrFPXO4gDb7JggCfW6udTcc2ea2ElglMyEq-bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ht1ShtQ%253D%253D&md5=3d76277fb0168e8dc498613d9a94235b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis966%26sid%3Dliteratum%253Aachs%26aulast%3DOsmon%26aufirst%3DD.%2BR.%26aulast%3DBerbari%26aufirst%3DE.%2BF.%26aulast%3DBerendt%26aufirst%3DA.%2BR.%26aulast%3DLew%26aufirst%3DD.%26aulast%3DZimmerli%26aufirst%3DW.%26aulast%3DSteckelberg%26aufirst%3DJ.%2BM.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DHanssen%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DW.%2BR.%26atitle%3DExecutive%2520summary%253A%2520Diagnosis%2520and%2520management%2520of%2520prosthetic%2520joint%2520infection%253A%2520Clinical%2520practice%2520guidelines%2520by%2520the%2520Infectious%2520Diseases%2520Society%2520of%2520America%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D56%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1093%2Fcid%2Fcis966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McConoughey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manring, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calhoun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirtliff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoodley, P.</span><span> </span><span class="NLM_article-title">Biofilms in periprosthetic orthopedic infections</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">987</span><span class="NLM_x">â</span> <span class="NLM_lpage">1007</span><span class="refDoi">Â DOI: 10.2217/fmb.14.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2217%2Ffmb.14.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25302955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=987-1007&issue=8&author=S.+J.+McConougheyauthor=R.+Howlinauthor=J.+F.+Grangerauthor=M.+M.+Manringauthor=J.+H.+Calhounauthor=M.+Shirtliffauthor=S.+Kathjuauthor=P.+Stoodley&title=Biofilms+in+periprosthetic+orthopedic+infections&doi=10.2217%2Ffmb.14.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Biofilms in periprosthetic orthopedic infections</span></div><div class="casAuthors">McConoughey, Stephen J.; Howlin, Rob; Granger, Jeff F.; Manring, Maurice M.; Calhoun, Jason H.; Shirtliff, Mark; Kathju, Sandeep; Stoodley, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">987-1007</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  As the no. of total joint arthroplasty and internal fixation procedures continues to rise, the threat of infection following surgery has significant clin. implications.  These infections may have highly morbid consequences to patients, who often endure addnl. surgeries and lengthy exposures to systemic antibiotics, neither of which are guaranteed to resolve the infection.  Of particular concern is the threat of bacterial biofilm development, since biofilm-mediated infections are difficult to diagnose and effective treatments are lacking.  Developing therapeutic strategies have targeted mechanisms of biofilm formation and the means by which these bacteria communicate with each other to take on specialized roles such as persister cells within the biofilm.  In addn., prevention of infection through novel coatings for prostheses and the local delivery of high concns. of antibiotics by absorbable carriers has shown promise in lab. and animal studies.  Biofilm development, esp. in an arthoplasty environment, and future diagnostic and treatment options are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbTZNokcvtrVg90H21EOLACvtfcHk0lgjEZcNMsWC7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalurnK&md5=b63598b88747e48d80403d640596ac03</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.64%26sid%3Dliteratum%253Aachs%26aulast%3DMcConoughey%26aufirst%3DS.%2BJ.%26aulast%3DHowlin%26aufirst%3DR.%26aulast%3DGranger%26aufirst%3DJ.%2BF.%26aulast%3DManring%26aufirst%3DM.%2BM.%26aulast%3DCalhoun%26aufirst%3DJ.%2BH.%26aulast%3DShirtliff%26aufirst%3DM.%26aulast%3DKathju%26aufirst%3DS.%26aulast%3DStoodley%26aufirst%3DP.%26atitle%3DBiofilms%2520in%2520periprosthetic%2520orthopedic%2520infections%26jtitle%3DFuture%2520Microbiol.%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D987%26epage%3D1007%26doi%3D10.2217%2Ffmb.14.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gbejuade, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, J. C.</span><span> </span><span class="NLM_article-title">The role of microbial biofilms in prosthetic joint infections</span> <span class="citation_source-journal">Acta Orthop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.3109/17453674.2014.966290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.3109%2F17453674.2014.966290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25238433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2M7jtVOjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=147-158&issue=2&author=H.+O.+Gbejuadeauthor=A.+M.+Loveringauthor=J.+C.+Webb&title=The+role+of+microbial+biofilms+in+prosthetic+joint+infections&doi=10.3109%2F17453674.2014.966290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of microbial biofilms in prosthetic joint infections</span></div><div class="casAuthors">Gbejuade Herbert O; Lovering Andrew M; Webb Jason C</div><div class="citationInfo"><span class="NLM_cas:title">Acta orthopaedica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prosthetic joint infection (PJI) still remains a significant problem.  In line with the forecasted rise in joint replacement procedures, the number of cases of PJI is also anticipated to rise.  The formation of biofilm by causative pathogens is central to the occurrence and the recalcitrance of PJI.  The subject of microbial biofilms is receiving increasing attention, probably as a result of the wide acknowledgement of the ubiquity of biofilms in the natural, industrial, and clinical contexts, as well as the notorious difficulty in eradicating them.  In this review, we discuss the pertinent issues surrounding PJI and the challenges posed by biofilms regarding diagnosis and treatment.  In addition, we discuss novel strategies of prevention and treatment of biofilm-related PJI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsgHQM7ju5cdFxYDaSSP8XfW6udTcc2eZ6vZWZLsRtJLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7jtVOjsg%253D%253D&md5=2f56e64d0e18871b4588b6b080e39fd7</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.3109%2F17453674.2014.966290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17453674.2014.966290%26sid%3Dliteratum%253Aachs%26aulast%3DGbejuade%26aufirst%3DH.%2BO.%26aulast%3DLovering%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520role%2520of%2520microbial%2520biofilms%2520in%2520prosthetic%2520joint%2520infections%26jtitle%3DActa%2520Orthop.%26date%3D2015%26volume%3D86%26issue%3D2%26spage%3D147%26epage%3D158%26doi%3D10.3109%2F17453674.2014.966290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ma, Z.; Morris, T. W.; Combrink, K. D.</span><span> </span><span class="NLM_article-title">Therapeutic opportunities for the treatment of biofilm-associated infections</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Elsevier</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">39</span>, pp  <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">210</span>. DOI: <span class="refDoi">Â DOI: 10.1016/S0065-7743(04)39016-0</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0065-7743%2804%2939016-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=197-210&author=Z.+Ma&author=T.+W.+Morris&author=K.+D.+Combrink&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2804%2939016-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-7743%252804%252939016-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DTherapeutic%2520opportunities%2520for%2520the%2520treatment%2520of%2520biofilm-associated%2520infections%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DElsevier%26date%3D2004%26volume%3D39%26spage%3D197%26epage%3D210%26doi%3D10.1016%2FS0065-7743%2804%2939016-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trampuz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis</span> <span class="citation_source-journal">Current infectious disease reports</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">403</span><span class="refDoi">Â DOI: 10.1007/s11908-008-0064-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs11908-008-0064-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=394-403&issue=5&author=A.+Trampuzauthor=W.+Zimmerli&title=Diagnosis+and+treatment+of+implant-associated+septic+arthritis+and+osteomyelitis&doi=10.1007%2Fs11908-008-0064-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2Fs11908-008-0064-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11908-008-0064-1%26sid%3Dliteratum%253Aachs%26aulast%3DTrampuz%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520implant-associated%2520septic%2520arthritis%2520and%2520osteomyelitis%26jtitle%3DCurrent%2520infectious%2520disease%2520reports%26date%3D2008%26volume%3D10%26issue%3D5%26spage%3D394%26epage%3D403%26doi%3D10.1007%2Fs11908-008-0064-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sendi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial treatment concepts for orthopaedic device-related infection</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1176</span><span class="NLM_x">â</span> <span class="NLM_lpage">1184</span><span class="refDoi">Â DOI: 10.1111/1469-0691.12003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1111%2F1469-0691.12003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23046277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1176-1184&issue=12&author=P.+Sendiauthor=W.+Zimmerli&title=Antimicrobial+treatment+concepts+for+orthopaedic+device-related+infection&doi=10.1111%2F1469-0691.12003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial treatment concepts for orthopaedic device-related infection</span></div><div class="casAuthors">Sendi, P.; Zimmerli, W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1184</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Abstract : Successful management of orthopaedic device-related infections requires combined surgical and antimicrobial therapy.  Because of the heterogeneity of clin. situations, controlled trials are lacking.  Although rational concepts for surgical treatment have been published, many aspects of antimicrobial therapy are still not well documented.  In this review, some of these knowledge gaps are discussed, and rational arguments for initial parenteral treatment are presented.  In addn., the interpretation of data regarding bone penetration is discussed.  Whereas rifampin is now a std. combination partner in the treatment of staphylococcal infections, its role against other microorganisms is still unclear.  Finally, in view of the increasing prevalence of methicillin-resistant staphylococci and their decreasing susceptibility to vancomycin, data are provided on linezolid and daptomycin, which can potentially be used in bone and joint infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvPGoeUN1-3bVg90H21EOLACvtfcHk0lg3AAD54xP0Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru7nJ&md5=4fedaf0f1bd42d2ae0e5d26df896ece5</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1111%2F1469-0691.12003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1469-0691.12003%26sid%3Dliteratum%253Aachs%26aulast%3DSendi%26aufirst%3DP.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520treatment%2520concepts%2520for%2520orthopaedic%2520device-related%2520infection%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D1176%26epage%3D1184%26doi%3D10.1111%2F1469-0691.12003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Holmberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ThÃ³rhallsdÃ³ttir, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">W-Dahl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StefÃ¡nsdÃ³ttir, A.</span><span> </span><span class="NLM_article-title">75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections</span> <span class="citation_source-journal">Acta Orthop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">457</span><span class="NLM_x">â</span> <span class="NLM_lpage">462</span><span class="refDoi">Â DOI: 10.3109/17453674.2015.1026756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.3109%2F17453674.2015.1026756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25753311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2MnitlGrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=457-462&issue=4&author=A.+Holmbergauthor=V.+G.+Th%C3%B3rhallsd%C3%B3ttirauthor=O.+Robertssonauthor=A.+W-Dahlauthor=A.+Stef%C3%A1nsd%C3%B3ttir&title=75%25+success+rate+after+open+debridement%2C+exchange+of+tibial+insert%2C+and+antibiotics+in+knee+prosthetic+joint+infections&doi=10.3109%2F17453674.2015.1026756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections</span></div><div class="casAuthors">Holmberg Anna; Thorhallsdottir Valdis Gudrun; Robertsson Otto; W-Dahl Annette; Stefansdottir Anna</div><div class="citationInfo"><span class="NLM_cas:title">Acta orthopaedica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Prosthetic joint infection (PJI) is a leading cause of early revision after total knee arthroplasty (TKA).  Open debridement with exchange of tibial insert allows treatment of infection with retention of fixed components.  We investigated the success rate of this procedure in the treatment of knee PJIs in a nationwide material, and determined whether the results were affected by microbiology, antibiotic treatment, or timing of debridement.  PATIENTS AND METHODS:  145 primary TKAs revised for the first time, due to infection, with debridement and exchange of the tibial insert were identified in the Swedish Knee Arthroplasty Register (SKAR).  Staphylococcus aureus was the most common pathogen (37%) followed by coagulase-negative staphylococci (CNS) (23%).  Failure was defined as death before the end of antibiotic treatment, revision of major components due to infection, life-long antibiotic treatment, or chronic infection.  RESULTS:  The overall healing rate was 75%.  The type of infecting pathogen did not statistically significantly affect outcome.  Staphylococcal infections treated without a combination of antibiotics including rifampin had a higher failure rate than those treated with rifampin (RR = 4, 95% CI: 2-10).  In the 16 cases with more than 3 weeks of symptoms before treatment, the healing rate was 62%, as compared to 77% in the other cases (p = 0.2).  The few patients with a revision model of prosthesis at primary operation had a high failure rate (5 of 8).  INTERPRETATION:  Good results can be achieved by open debridement with exchange of tibial insert.  It is important to use an antibiotic combination including rifampin in staphylococcal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXu_TmDUNwCXqj_yg7twvpfW6udTcc2eZ2rxS-l1lHZrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnitlGrtA%253D%253D&md5=f70ce216c274e0fddebcc49cb03e6fa2</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.3109%2F17453674.2015.1026756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17453674.2015.1026756%26sid%3Dliteratum%253Aachs%26aulast%3DHolmberg%26aufirst%3DA.%26aulast%3DTh%25C3%25B3rhallsd%25C3%25B3ttir%26aufirst%3DV.%2BG.%26aulast%3DRobertsson%26aufirst%3DO.%26aulast%3DW-Dahl%26aufirst%3DA.%26aulast%3DStef%25C3%25A1nsd%25C3%25B3ttir%26aufirst%3DA.%26atitle%3D75%2525%2520success%2520rate%2520after%2520open%2520debridement%252C%2520exchange%2520of%2520tibial%2520insert%252C%2520and%2520antibiotics%2520in%2520knee%2520prosthetic%2520joint%2520infections%26jtitle%3DActa%2520Orthop.%26date%3D2015%26volume%3D86%26issue%3D4%26spage%3D457%26epage%3D462%26doi%3D10.3109%2F17453674.2015.1026756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sensi, P.</span><span> </span><span class="NLM_article-title">History of the development of rifampin</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S402</span><span class="NLM_x">â</span> <span class="NLM_lpage">S406</span><span class="refDoi">Â DOI: 10.1093/clinids/5.Supplement_3.S402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fclinids%2F5.Supplement_3.S402" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1983&pages=S402-S406&issue=Suppl.+3&author=P.+Sensi&title=History+of+the+development+of+rifampin&doi=10.1093%2Fclinids%2F5.Supplement_3.S402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F5.Supplement_3.S402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F5.Supplement_3.S402%26sid%3Dliteratum%253Aachs%26aulast%3DSensi%26aufirst%3DP.%26atitle%3DHistory%2520of%2520the%2520development%2520of%2520rifampin%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1983%26volume%3D5%26issue%3DSuppl.%25203%26spage%3DS402%26epage%3DS406%26doi%3D10.1093%2Fclinids%2F5.Supplement_3.S402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ma, Z.; Ginsberg, A. M.; Spigelman, M.</span><span> </span><span class="NLM_article-title">Antimycobacterium agents</span>. In  <span class="citation_source-book">Comprehensive Medicinal Chemistry II</span>; <span class="NLM_contrib-group">Triggle, J. B. T. J.</span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Volume  <span class="NLM_volume">7</span>, Chapter 7.24, pp  <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">730</span>, DOI: <span class="refDoi">Â DOI: 10.1016/B0-08-045044-X/00224-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FB0-08-045044-X%2F00224-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=699-730&author=Z.+Ma&author=A.+M.+Ginsberg&author=M.+Spigelmanauthor=J.+B.+T.+J.+Triggle&title=Comprehensive+Medicinal+Chemistry+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FB0-08-045044-X%2F00224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB0-08-045044-X%252F00224-8%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DAntimycobacterium%2520agents%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520II%26aulast%3DTriggle%26aufirst%3DJ.%2BB.%2BT.%2BJ.%26pub%3DElsevier%26date%3D2007%26volume%3D7%26spage%3D699%26epage%3D730%26doi%3D10.1016%2FB0-08-045044-X%2F00224-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">DuPont, H. L.</span><span> </span><span class="NLM_article-title">Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1124</span><span class="refDoi">Â DOI: 10.1016/j.mayocp.2015.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.mayocp.2015.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26162610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOmtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=1116-1124&issue=8&author=H.+L.+DuPont&title=Therapeutic+effects+and+mechanisms+of+action+of+rifaximin+in+gastrointestinal+diseases&doi=10.1016%2Fj.mayocp.2015.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases</span></div><div class="casAuthors">DuPont, Herbert L.</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1116-1124</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Emerging preclin. and clinic evidence described herein suggests that the mechanism of action of rifaximin is not restricted to direct antibacterial effects within the gastrointestinal tract.  Data from this study were derived from general and clin. trial-specific PubMed searches of English-language articles on rifaximin available through Dec. 3, 2014.  Search terms included rifaximin alone and in combination (using the Boolean operation "AND") with travelers' diarrhea, hepatic encephalopathy, liver cirrhosis, irritable bowel syndrome, inflammatory bowel disease, and Crohn's disease.  Rifaximin appears to reduce bacterial virulence and pathogenicity by inhibiting bacterial translocation across the gastrointestinal epithelial lining.  Rifaximin was shown to decrease bacterial adherence to epithelial cells and subsequent internalization in a bacteria- and cell type-specific manner, without an alteration in bacterial counts, but with a down-regulation in epithelial proinflammatory cytokine expression.  Rifaximin also appears to modulate gut-immune signaling.  In animal models of inflammatory bowel disease, rifaximin produced therapeutic effects by activating the pregnane X receptor and thereby reducing levels of the proinflammatory transcription factor nuclear factor ÎºB.  Therefore, for a given disease state, rifaximin may act through several mechanisms of action to exert its therapeutic effects.  Clin., rifaximin 600 mg/d significantly reduced symptoms of travelers' diarrhea (eg, time to last unformed stool vs. placebo [32.0 h vs. 65.5 h, resp.; P=.001]).  For the prevention of hepatic encephalopathy recurrence, data indicate that treating 4 patients with rifaximin 1100 mg/d for 6 mo would prevent 1 episode of hepatic encephalopathy.  For diarrhea-predominant irritable bowel syndrome, a significantly greater percentage (40.7%) of patients treated with rifaximin 1650 mg/d for 2 wk experienced adequate global irritable bowel syndrome symptom relief vs. placebo (31.7%; P<.001).  Rifaximin may be best described as a gut microenvironment modulator with cytoprotection properties, and further studies are needed to det. whether these putative mechanisms of action play a direct role in clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2XC24xDEfLrVg90H21EOLACvtfcHk0lg3AAD54xP0Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOmtb8%253D&md5=d204c4a0767b0bb5e47b395e11b837a1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2015.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2015.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DDuPont%26aufirst%3DH.%2BL.%26atitle%3DTherapeutic%2520effects%2520and%2520mechanisms%2520of%2520action%2520of%2520rifaximin%2520in%2520gastrointestinal%2520diseases%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2015%26volume%3D90%26issue%3D8%26spage%3D1116%26epage%3D1124%26doi%3D10.1016%2Fj.mayocp.2015.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Campbell, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korzheva, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustaev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darst, S. A.</span><span> </span><span class="NLM_article-title">Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">â</span> <span class="NLM_lpage">912</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(01)00286-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0092-8674%2801%2900286-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=11290327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVyis7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=901-912&issue=6&author=E.+A.+Campbellauthor=N.+Korzhevaauthor=A.+Mustaevauthor=K.+Murakamiauthor=S.+Nairauthor=A.+Goldfarbauthor=S.+A.+Darst&title=Structural+mechanism+for+rifampicin+inhibition+of+bacterial+RNA+polymerase&doi=10.1016%2FS0092-8674%2801%2900286-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</span></div><div class="casAuthors">Campbell, Elizabeth A.; Korzheva, Nataliya; Mustaev, Arkady; Murakami, Katsuhiko; Nair, Satish; Goldfarb, Alex; Darst, Seth A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">901-912</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP).  We detd. the crystal structure of Thermus aquaticus core RNAP complexed with Rif.  The inhibitor binds in a pocket of the RNAP Î² subunit deep within the DNA/RNA channel, but more than 12 Ã away from the active site.  The structure, combined with biochem. results, explains the effects of Rif on RNAP function and indicates that the inhibitor acts by directly blocking the path of the elongating RNA when the transcript becomes 2 to 3 nt in length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCqXDvYkIB7Vg90H21EOLACvtfcHk0lj_XGKHR78SDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVyis7s%253D&md5=e64b9de4f4f6f832d481608b1324b48f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2801%2900286-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252801%252900286-0%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DE.%2BA.%26aulast%3DKorzheva%26aufirst%3DN.%26aulast%3DMustaev%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DA.%26aulast%3DDarst%26aufirst%3DS.%2BA.%26atitle%3DStructural%2520mechanism%2520for%2520rifampicin%2520inhibition%2520of%2520bacterial%2520RNA%2520polymerase%26jtitle%3DCell%26date%3D2001%26volume%3D104%26issue%3D6%26spage%3D901%26epage%3D912%26doi%3D10.1016%2FS0092-8674%2801%2900286-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goldstein, B. P.</span><span> </span><span class="NLM_article-title">Resistance to rifampicin: a review</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">625</span><span class="NLM_x">â</span> <span class="NLM_lpage">630</span><span class="refDoi">Â DOI: 10.1038/ja.2014.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1038%2Fja.2014.107" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=625-630&issue=9&author=B.+P.+Goldstein&title=Resistance+to+rifampicin%3A+a+review&doi=10.1038%2Fja.2014.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1038%2Fja.2014.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2014.107%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DB.%2BP.%26atitle%3DResistance%2520to%2520rifampicin%253A%2520a%2520review%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D9%26spage%3D625%26epage%3D630%26doi%3D10.1038%2Fja.2014.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mariam, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengistu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffner, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, D. I.</span><span> </span><span class="NLM_article-title">Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1289</span><span class="NLM_x">â</span> <span class="NLM_lpage">1294</span><span class="refDoi">Â DOI: 10.1128/AAC.48.4.1289-1294.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.48.4.1289-1294.2004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1289-1294&issue=4&author=D.+H.+Mariamauthor=Y.+Mengistuauthor=S.+E.+Hoffnerauthor=D.+I.+Andersson&title=Effect+of+rpoB+mutations+conferring+rifampin+resistance+on+fitness+of+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.48.4.1289-1294.2004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.4.1289-1294.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.4.1289-1294.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMariam%26aufirst%3DD.%2BH.%26aulast%3DMengistu%26aufirst%3DY.%26aulast%3DHoffner%26aufirst%3DS.%2BE.%26aulast%3DAndersson%26aufirst%3DD.%2BI.%26atitle%3DEffect%2520of%2520rpoB%2520mutations%2520conferring%2520rifampin%2520resistance%2520on%2520fitness%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D4%26spage%3D1289%26epage%3D1294%26doi%3D10.1128%2FAAC.48.4.1289-1294.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Koch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizrahi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. F.</span><span> </span><span class="NLM_article-title">The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?</span> <span class="citation_source-journal">Emerging Microbes Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e17</span><span class="refDoi">Â DOI: 10.1038/emi.2014.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1038%2Femi.2014.17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e17&issue=3&author=A.+Kochauthor=V.+Mizrahiauthor=D.+F.+Warner&title=The+impact+of+drug+resistance+on+Mycobacterium+tuberculosis+physiology%3A+what+can+we+learn+from+rifampicin%3F&doi=10.1038%2Femi.2014.17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Femi.2014.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femi.2014.17%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DThe%2520impact%2520of%2520drug%2520resistance%2520on%2520Mycobacterium%2520tuberculosis%2520physiology%253A%2520what%2520can%2520we%2520learn%2520from%2520rifampicin%253F%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2014%26volume%3D3%26issue%3D3%26spage%3De17%26doi%3D10.1038%2Femi.2014.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Al-Omari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrales-Medina, V. F.</span><span> </span><span class="NLM_article-title">Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review</span> <span class="citation_source-journal">BMC Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="refDoi">Â DOI: 10.1186/1471-2334-14-140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1186%2F1471-2334-14-140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=24624933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yms7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=140&author=A.+Al-Omariauthor=D.+W.+Cameronauthor=C.+Leeauthor=V.+F.+Corrales-Medina&title=Oral+antibiotic+therapy+for+the+treatment+of+infective+endocarditis%3A+a+systematic+review&doi=10.1186%2F1471-2334-14-140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review</span></div><div class="casAuthors">Al-Omari, Awad; Cameron, D. William; Lee, Craig; Corrales-Medina, Vicente F.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140/1-140/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">BIDMBJ</span>;
        ISSN:<span class="NLM_cas:issn">1471-2334</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.  Methods: We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE.  Results: Seven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates between 77% and 100%.  Two other observational studies using aureomycin or sulfonamide, however, had failure rates >75%.  One clin. trial comparing oral amoxicillin vs. i.v. ceftriaxone for streptococcal IE reported 100% cure in both arms but its reporting had serious methodol. limitations.  One small clin. trial (n = 85) comparing oral ciprofloxacin and rifampin vs. conventional i.v. antibiotic therapy for uncomplicated right-sided S. aureus IE in i.v. drug users (IVDUs) reported cure rates of 89% and 90% in each arm, resp. (P = 0.9); however, drug toxicities were more common in the latter group (62% vs. 3%; P <0.01).  Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s) and assessment of outcomes.  Conclusion: Reported cure rates for IE treated with oral antibiotic regimens vary widely.  The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clin. trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWGe_5XsAZ7Vg90H21EOLACvtfcHk0lj_XGKHR78SDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yms7zO&md5=7400e8e577e12c4c47b0744454db00e4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1186%2F1471-2334-14-140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2334-14-140%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Omari%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCorrales-Medina%26aufirst%3DV.%2BF.%26atitle%3DOral%2520antibiotic%2520therapy%2520for%2520the%2520treatment%2520of%2520infective%2520endocarditis%253A%2520a%2520systematic%2520review%26jtitle%3DBMC%2520Infect.%2520Dis.%26date%3D2014%26volume%3D14%26spage%3D140%26doi%3D10.1186%2F1471-2334-14-140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Coiffier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvieux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guggenbuhl, P.</span><span> </span><span class="NLM_article-title">Optimizing combination rifampin therapy for staphylococcal osteoarticular infections</span> <span class="citation_source-journal">Jt., Bone, Spine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><span class="refDoi">Â DOI: 10.1016/j.jbspin.2012.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.jbspin.2012.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23332140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFCksQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2013&pages=11-17&issue=1&author=G.+Coiffierauthor=J.-D.+Albertauthor=C.+Arvieuxauthor=P.+Guggenbuhl&title=Optimizing+combination+rifampin+therapy+for+staphylococcal+osteoarticular+infections&doi=10.1016%2Fj.jbspin.2012.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing combination rifampin therapy for staphylococcal osteoarticular infections</span></div><div class="casAuthors">Coiffier, Guillaume; Albert, Jean-David; Arvieux, Cedric; Guggenbuhl, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Joint, Bone, Spine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">JBSPFA</span>;
        ISSN:<span class="NLM_cas:issn">1297-319X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Staphylococcus spp. causes more than half of all osteoarticular infections of native structures or implanted material.  The ability of Staphylococcus spp. to persist within infected bone tissue and to produce a bacterial biofilm, most notably in infections of implanted material, can lead to treatment failures and microbiol. relapses.  Rifampin is a cornerstone of the treatment of staphylococcal osteoarticular infections, particularly those of implanted material.  Rifampin is a bactericidal antibiotic that diffuses very well within bone tissue and bacterial biofilms.  The mechanism of action is inhibition of bacterial DNA transcription to mRNA independently from bacterial division, which results in activity against even dormant Staphylococcus spp. organisms.  However, the high risk of emergence of rifampin-resistant mutants requires the concomitant administration of another antibiotic.  Several antibiotics are recommended in the French guidelines issued by the French-Speaking Society for Infectious Diseases (Societe de Pathologie Infectieuse de Langue FranÂ¸caise [SPILF]).  Here, we discuss the results from in vitro, animal, and clin. studies that explain the advantages and drawbacks of each antibiotic used with rifampin to treat osteoarticular infections due to Staphylococcus spp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqepuNBbP5jfbVg90H21EOLACvtfcHk0lg6wnkTsXTH1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFCksQ%253D%253D&md5=f37d7f93a8a07ac54163f5e12ab55241</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.jbspin.2012.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbspin.2012.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DCoiffier%26aufirst%3DG.%26aulast%3DAlbert%26aufirst%3DJ.-D.%26aulast%3DArvieux%26aufirst%3DC.%26aulast%3DGuggenbuhl%26aufirst%3DP.%26atitle%3DOptimizing%2520combination%2520rifampin%2520therapy%2520for%2520staphylococcal%2520osteoarticular%2520infections%26jtitle%3DJt.%252C%2520Bone%252C%2520Spine%26date%3D2013%26volume%3D80%26issue%3D1%26spage%3D11%26epage%3D17%26doi%3D10.1016%2Fj.jbspin.2012.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Forrest, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span> </span><span class="NLM_article-title">Rifampin combination therapy for nonmycobacterial infections</span> <span class="citation_source-journal">Clin Microbiol Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">14</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1128/CMR.00034-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FCMR.00034-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=20065324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1SktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=14-34&issue=1&author=G.+N.+Forrestauthor=K.+Tamura&title=Rifampin+combination+therapy+for+nonmycobacterial+infections&doi=10.1128%2FCMR.00034-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Rifampin combination therapy for nonmycobacterial infections</span></div><div class="casAuthors">Forrest, Graeme N.; Tamura, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-34</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  The increasing emergence of antimicrobial-resistant organisms, esp. methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy.  The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clin. studies.  Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations.  A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed.  The clin. data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-neg. staphylococci.  Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clin. or exptl.  Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections.  Lastly, an assessment of the risk-benefits is needed before the addn. of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOC5b2NQgkNrVg90H21EOLACvtfcHk0lg6wnkTsXTH1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1SktLg%253D&md5=bc52c4baff11b1f7a16c6eee5883c8b3</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1128%2FCMR.00034-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00034-09%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DG.%2BN.%26aulast%3DTamura%26aufirst%3DK.%26atitle%3DRifampin%2520combination%2520therapy%2520for%2520nonmycobacterial%2520infections%26jtitle%3DClin%2520Microbiol%2520Rev.%26date%3D2010%26volume%3D23%26issue%3D1%26spage%3D14%26epage%3D34%26doi%3D10.1128%2FCMR.00034-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sanchez, C. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiels, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tennent, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenke, J. C.</span><span> </span><span class="NLM_article-title">Rifamycin derivatives are effective against staphylococcal biofilms in vitro and elutable from PMMA</span> <span class="citation_source-journal">Clin. Orthop. Relat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">473</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2874</span><span class="NLM_x">â</span> <span class="NLM_lpage">2884</span><span class="refDoi">Â DOI: 10.1007/s11999-015-4300-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs11999-015-4300-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25896136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjmtlajtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2015&pages=2874-2884&issue=9&author=C.+J.+Sanchezauthor=S.+M.+Shielsauthor=D.+J.+Tennentauthor=S.+K.+Hardyauthor=C.+K.+Murrayauthor=J.+C.+Wenke&title=Rifamycin+derivatives+are+effective+against+staphylococcal+biofilms+in+vitro+and+elutable+from+PMMA&doi=10.1007%2Fs11999-015-4300-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA</span></div><div class="casAuthors">Sanchez Carlos J Jr; Shiels Stefanie M; Tennent David J; Hardy Sharanda K; Murray Clinton K; Wenke Joseph C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical orthopaedics and related research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">473</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2874-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Local antimicrobial delivery through polymethylmethacrylate beads (PMMA), commonly vancomycin, is used for the treatment of contaminated open fractures but has limited activity against Staphylococcus aureus biofilms, which occur commonly in such fractures.  Rifamycins have activity against biofilms and are an effective treatment for osteoarticular infections involving staphylococcal biofilms, but there are limited studies evaluating the activity of rifamycin derivatives, other than rifampin, against biofilms of S. aureus and evaluating incorporation of these drugs into PMMA for treatment of contaminated open fractures.  QUESTIONS/PURPOSES:  (1) Are rifamycin derivatives effective against established biofilms of clinical isolates of S. aureus? (2) Can PMMA be used as a carrier for rifamycin derivatives?  METHODS:  Biofilms were developed and evaluated for susceptibility to a panel of antimicrobials in vitro using the minimum biofilm eradication concentration high-throughput model.  Susceptibility was assessed by measuring bacterial recovery at 6 and 24 hours after antimicrobial treatment.  Activity of rifamycin derivatives against intracellular bacteria was also evaluated using a gentamicin protection assay.  Evaluation of PMMA as a carrier for rifampin and rifamycin derivatives was determined by assessing the curing time subsequent to loading of rifamycins and characterizing the release kinetics of rifamycins at daily intervals for 14 days from PMMA by performing bioassays.  RESULTS:  Rifamycin derivatives between 1 and 8 Î¼g/mL reduced bacteria within biofilms 5- to 9-logs and prevented bacterial recovery up to 24 hours post-treatment, indicating near to complete eradication of biofilms.  Rifamycin derivatives at 32 Î¼g/mL had activity against intracellular staphylococci, significantly reducing the number of internalized bacteria with limited effects on osteoblast viability.  Rifampin was the only rifamycin observed to have a suitable release profile from PMMA, releasing 49% of the total antibiotic and maintaining a sustained released profile up to 14 days at a mean 28 Â± 6 Î¼g/mL.  CONCLUSIONS:  Rifampin can be incorporated into PMMA and eluted at concentrations effective against biofilms and intracellular staphylococci.  CLINICAL RELEVANCE:  Our in vitro findings suggest that local delivery of rifampin may be an effective strategy for the prevention and/or treatment of open fractures where S. aureus biofilms might develop.  Clinical studies are needed to characterize what role this approach might have in the prevention and treatment of infections involving biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCIsTiAiYudkGy1nwu7K2mfW6udTcc2eZlEphwgBKzELntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjmtlajtw%253D%253D&md5=4cf2c744374c8eb2545bf6e22128878f</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2Fs11999-015-4300-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11999-015-4300-3%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%2BJ.%26aulast%3DShiels%26aufirst%3DS.%2BM.%26aulast%3DTennent%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DC.%2BK.%26aulast%3DWenke%26aufirst%3DJ.%2BC.%26atitle%3DRifamycin%2520derivatives%2520are%2520effective%2520against%2520staphylococcal%2520biofilms%2520in%2520vitro%2520and%2520elutable%2520from%2520PMMA%26jtitle%3DClin.%2520Orthop.%2520Relat.%2520Res.%26date%3D2015%26volume%3D473%26issue%3D9%26spage%3D2874%26epage%3D2884%26doi%3D10.1007%2Fs11999-015-4300-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hall Snyder, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidaillac, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRoberts, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, M. J.</span><span> </span><span class="NLM_article-title">Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK/PD model of bacterial biofilm</span> <span class="citation_source-journal">Infect. Dis. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">65</span><span class="refDoi">Â DOI: 10.1007/s40121-014-0055-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs40121-014-0055-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26362295" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=51-65&issue=1&author=A.+D.+Hall+Snyderauthor=C.+Vidaillacauthor=W.+Roseauthor=J.+P.+McRobertsauthor=M.+J.+Rybak&title=Evaluation+of+high-dose+daptomycin+versus+vancomycin+alone+or+combined+with+clarithromycin+or+rifampin+against+Staphylococcus+aureus+and+S.+epidermidis+in+a+novel+in+vitro+PK%2FPD+model+of+bacterial+biofilm&doi=10.1007%2Fs40121-014-0055-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1007%2Fs40121-014-0055-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40121-014-0055-5%26sid%3Dliteratum%253Aachs%26aulast%3DHall%2BSnyder%26aufirst%3DA.%2BD.%26aulast%3DVidaillac%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DW.%26aulast%3DMcRoberts%26aufirst%3DJ.%2BP.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520high-dose%2520daptomycin%2520versus%2520vancomycin%2520alone%2520or%2520combined%2520with%2520clarithromycin%2520or%2520rifampin%2520against%2520Staphylococcus%2520aureus%2520and%2520S.%2520epidermidis%2520in%2520a%2520novel%2520in%2520vitro%2520PK%252FPD%2520model%2520of%2520bacterial%2520biofilm%26jtitle%3DInfect.%2520Dis.%2520Ther.%26date%3D2015%26volume%3D4%26issue%3D1%26spage%3D51%26epage%3D65%26doi%3D10.1007%2Fs40121-014-0055-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mihailescu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furustrand Tafin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvec, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betrisey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trampuz, A.</span><span> </span><span class="NLM_article-title">High activity of fosfomycin and rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2547</span><span class="NLM_x">â</span> <span class="NLM_lpage">2553</span><span class="refDoi">Â DOI: 10.1128/AAC.02420-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.02420-12" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=2547-2553&issue=5&author=R.+Mihailescuauthor=U.+Furustrand+Tafinauthor=S.+Corvecauthor=A.+Olivaauthor=B.+Betriseyauthor=O.+Borensauthor=A.+Trampuz&title=High+activity+of+fosfomycin+and+rifampin+against+methicillin-resistant+staphylococcus+aureus+biofilm+in+vitro+and+in+an+experimental+foreign-body+infection+model&doi=10.1128%2FAAC.02420-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1128%2FAAC.02420-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02420-12%26sid%3Dliteratum%253Aachs%26aulast%3DMihailescu%26aufirst%3DR.%26aulast%3DFurustrand%2BTafin%26aufirst%3DU.%26aulast%3DCorvec%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DBetrisey%26aufirst%3DB.%26aulast%3DBorens%26aufirst%3DO.%26aulast%3DTrampuz%26aufirst%3DA.%26atitle%3DHigh%2520activity%2520of%2520fosfomycin%2520and%2520rifampin%2520against%2520methicillin-resistant%2520staphylococcus%2520aureus%2520biofilm%2520in%2520vitro%2520and%2520in%2520an%2520experimental%2520foreign-body%2520infection%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D5%26spage%3D2547%26epage%3D2553%26doi%3D10.1128%2FAAC.02420-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Minassian, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osmon, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berendt, A. R.</span><span> </span><span class="NLM_article-title">Clinical guidelines in the management of prosthetic joint infection</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">i29</span><span class="NLM_x">â</span> <span class="NLM_lpage">i35</span><span class="refDoi">Â DOI: 10.1093/jac/dku253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fjac%2Fdku253" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=i29-i35&issue=Suppl.+1&author=A.+M.+Minassianauthor=D.+R.+Osmonauthor=A.+R.+Berendt&title=Clinical+guidelines+in+the+management+of+prosthetic+joint+infection&doi=10.1093%2Fjac%2Fdku253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdku253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdku253%26sid%3Dliteratum%253Aachs%26aulast%3DMinassian%26aufirst%3DA.%2BM.%26aulast%3DOsmon%26aufirst%3DD.%2BR.%26aulast%3DBerendt%26aufirst%3DA.%2BR.%26atitle%3DClinical%2520guidelines%2520in%2520the%2520management%2520of%2520prosthetic%2520joint%2520infection%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26issue%3DSuppl.%25201%26spage%3Di29%26epage%3Di35%26doi%3D10.1093%2Fjac%2Fdku253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Widmer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaechter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsner, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1251</span><span class="NLM_x">â</span> <span class="NLM_lpage">1253</span><span class="refDoi">Â DOI: 10.1093/clinids/14.6.1251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fclinids%2F14.6.1251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1623081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADyaK38zit1yhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1992&pages=1251-1253&issue=6&author=A.+F.+Widmerauthor=A.+Gaechterauthor=P.+E.+Ochsnerauthor=W.+Zimmerli&title=Antimicrobial+treatment+of+orthopedic+implant-related+infections+with+rifampin+combinations&doi=10.1093%2Fclinids%2F14.6.1251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations</span></div><div class="casAuthors">Widmer A F; Gaechter A; Ochsner P E; Zimmerli W</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-3</span>
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    </div><div class="casAbstract">The purpose of this prospective clinical study is to evaluate the role of combination chemotherapy with rifampin in the treatment of orthopedic device-related infections in which the implant could not be removed.  Eleven patients with orthopedic implant-related infections due to staphylococci or streptococci were treated with the implant in situ.  Each antimicrobial regimen included rifampin in combination with a beta-lactam antibiotic or ciprofloxacin.  The median duration of treatment with rifampin was 86 days (range, 15-336 days) with a median follow-up of greater than 24 months after cessation of therapy.  Treatment was successful for 82% of patients.  Failures were associated with documented inappropriate treatment.  These preliminary clinical data are supported by data from in vitro studies and animal experiments.  Combination therapy with rifampin, in particular rifampin and a quinolone, should be considered for patients with orthopedic implant-related infections if the implant cannot be removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSS5VLZ8K7rPIW7hznt0zpfW6udTcc2eY9pXXq1VMambntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zit1yhsQ%253D%253D&md5=956e60b6bedafffc179d3b790a446616</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F14.6.1251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F14.6.1251%26sid%3Dliteratum%253Aachs%26aulast%3DWidmer%26aufirst%3DA.%2BF.%26aulast%3DGaechter%26aufirst%3DA.%26aulast%3DOchsner%26aufirst%3DP.%2BE.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520treatment%2520of%2520orthopedic%2520implant-related%2520infections%2520with%2520rifampin%2520combinations%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1992%26volume%3D14%26issue%3D6%26spage%3D1251%26epage%3D1253%26doi%3D10.1093%2Fclinids%2F14.6.1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zimmerli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsner, P. E.</span><span> </span><span class="NLM_article-title">Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">1537</span><span class="NLM_x">â</span> <span class="NLM_lpage">1541</span><span class="refDoi">Â DOI: 10.1001/jama.279.19.1537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1001%2Fjama.279.19.1537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=9605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1ygurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=1537-1541&issue=19&author=W.+Zimmerliauthor=A.+F.+Widmerauthor=M.+Blatterauthor=R.+R.+Freiauthor=P.+E.+Ochsner&title=Role+of+rifampin+for+treatment+of+orthopedic+implant-related+staphylococcal+infections%3A+A+randomized+controlled+trial.+Foreign-Body+Infection+%28FBI%29+Study+Group&doi=10.1001%2Fjama.279.19.1537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial</span></div><div class="casAuthors">Zimmerli, Werner; Widmer, Andreas F.; Blatter, Marianne; Frei, R.; Ochsner, Peter E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1537-1541</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The clin. efficacy of a rifampin combination with ciprofloxacin was investigated in patients with staphylococcal infections assocd. with stable orthopedic devices.  Patients were allocated to receive ciprofloxacin-rifampin or a ciprofloxacin-placebo combination.  The cure rate was 12 (100%) of 12 in the ciprofloxacin-rifampin group compared with 7 (58%) of 12 in the ciprofloxacin-placebo group.  The results showed that among patients with stable implants, short duration of infection, and initial debridement, those patients able to tolerate long-term (3-6-mo) therapy with rifampin-ciprofloxacin experienced cure of the infection without removal of the implant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvI7iFfKEE3bVg90H21EOLACvtfcHk0ljs7R1pLK9f8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1ygurk%253D&md5=37b0737e3d9a23dfe1e95c0119f0e671</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1001%2Fjama.279.19.1537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.279.19.1537%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerli%26aufirst%3DW.%26aulast%3DWidmer%26aufirst%3DA.%2BF.%26aulast%3DBlatter%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DR.%2BR.%26aulast%3DOchsner%26aufirst%3DP.%2BE.%26atitle%3DRole%2520of%2520rifampin%2520for%2520treatment%2520of%2520orthopedic%2520implant-related%2520staphylococcal%2520infections%253A%2520A%2520randomized%2520controlled%2520trial.%2520Foreign-Body%2520Infection%2520%2528FBI%2529%2520Study%2520Group%26jtitle%3DJAMA%26date%3D1998%26volume%3D279%26issue%3D19%26spage%3D1537%26epage%3D1541%26doi%3D10.1001%2Fjama.279.19.1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Trampuz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1105</span><span class="refDoi">Â DOI: 10.2165/00003495-200666080-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2165%2F00003495-200666080-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=16789794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKgsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1089-1105&issue=8&author=A.+Trampuzauthor=W.+Zimmerli&title=Antimicrobial+agents+in+orthopaedic+surgery%3A+Prophylaxis+and+treatment&doi=10.2165%2F00003495-200666080-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial agents in orthopedic surgery: prophylaxis and treatment</span></div><div class="casAuthors">Trampuz, Andrej; Zimmerli, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1089-1105</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The pathogenesis of implant-assocd. infection involves interaction between the microorganisms (biofilm formation), the implant and the host.  Despite improvement of perioperative prophylaxis, orthopedic implants still remain highly susceptible to bacterial or fungal contamination, generally resulting in persistent implant-assocd. infection.  Therefore, perioperative and life-long prevention of infection is important.  For perioperative prophylaxis, a first- or second-generation cephalosporin is recommended, which should be administered between 60 and 30 min before incision.  The duration of prophylaxis should not exceed 1 day.  In centers with a low incidence of infection, a single dose is sufficient.  Treatment of infections assocd. with orthopedic devices usually requires appropriate surgical intervention combined with prolonged antimicrobial therapy.  The choice of the antimicrobial regimen depends on the duration and pathogenesis of infection, stability of the implant, antimicrobial susceptibility of the pathogen and condition of the surrounding soft tissue.  The role of rifampicin (rifampin), which has excellent activity on adherent staphylococci, in combination with Î²-lactams, glycopeptides, fluoroquinolones, minocycline, cotrimoxazole or fusidic acid, in the treatment of staphylococcal infections is outlined.  Increasing antimicrobial resistance requires the use of alternative agents, such as quinupristin/dalfopristin, linezolid and daptomycin, but results of clin. trials with these agents are limited.  Also reviewed are potential new antimicrobial agents currently undergoing investigation, such as the novel oxazolidinone RWJ-416457, the new glycopeptide dalbavancin, the glycylcycline compd. tigecycline, the new carbacephem BP-102 and novel rifamycin derivs.  Vaccination against Staphylococcus aureus with StaphVAX induced specific antibodies potentially preventing bacteremia; however, there are no studies on efficacy in the prophylaxis of device-assocd. infections with this vaccine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxNxD3kJqzLVg90H21EOLACvtfcHk0lhIkHUsrswHfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKgsLg%253D&md5=0fc0166368ad53d0148c7e739882e64b</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666080-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666080-00005%26sid%3Dliteratum%253Aachs%26aulast%3DTrampuz%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520agents%2520in%2520orthopaedic%2520surgery%253A%2520Prophylaxis%2520and%2520treatment%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26issue%3D8%26spage%3D1089%26epage%3D1105%26doi%3D10.2165%2F00003495-200666080-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tang, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, P.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toh, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, S.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, Y.-C.</span><span> </span><span class="NLM_article-title">RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment</span> <span class="citation_source-journal">J. Microbiol., Immunol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">401</span><span class="refDoi">Â DOI: 10.1016/j.jmii.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.jmii.2015.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26303044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCisrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=394-401&issue=3&author=H.-J.+Tangauthor=C.-C.+Laiauthor=P.-R.+Hsuehauthor=C.-C.+Chenauthor=K.-Y.+Wuauthor=Y.-C.+Linauthor=C.-C.+Zhangauthor=T.-C.+Wengauthor=Y.-H.+Chiuauthor=H.-S.+Tohauthor=S.-R.+Chiangauthor=W.-L.+Yuauthor=W.-C.+Koauthor=Y.-C.+Chuang&title=RNA+polymerase+B+subunit+gene+mutations+in+biofilm-embedded+methicillin-resistant+Staphylococcus+aureus+following+rifampin+treatment&doi=10.1016%2Fj.jmii.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment</span></div><div class="casAuthors">Tang, Hung-Jen; Lai, Chih-Cheng; Hsueh, Po-Ren; Chen, Chi-Chung; Wu, Kuan-Ying; Lin, Yi-Chung; Zhang, Chun-Cheng; Weng, Tzu-Chieh; Chiu, Yu-Hsin; Toh, Han-Siong; Chiang, Shyh-Ren; Yu, Wen-Liang; Ko, Wen-Chien; Chuang, Yin-Ching</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">394-401</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">This study was conducted to compare the mutation rates of different rpoB sites and rifampin min. inhibitory concn. (MIC) changes prior to and after rifampin therapy for biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) isolates.  The screening of rifampin-resistant MRSA isolates, from the biofilm at Day 5 with or without exposure to the susceptible breakpoint concn. of rifampin recommended by the Clin. and Lab. Stds. Institute (1 mg/L), was conducted using agar plates contg. rifampin.  A partial fragment of RNA polymerase B subunit gene (rpoB), including clusters I and II, was amplified and sequenced.  The rifampin MIC values and mutation frequencies at different sites of rpoB were measured and evaluated in rifampicin-resistant isolates.Rifampin-resistant mutants could be selected from all of 39 randomly selected rifampin-susceptible MRSA isolates in the biofilm model.  The spontaneous mutation frequency ranged from 1.00 Ã 10-4 to 3.85 Ã 10-7.  Mutation at codon 481 was most commonly found at 35 (89.7%) of 39 MRSA isolates.  Without rifampin induction, the MIC ranged between 0.125 mg/L and1024 mg/L and mutation sites included cluster I 464, 466, 468, 471, 474, 477, 481, 484, 486 and cluster II 519, 527, 529 with the percentage of 471 (35.9%), 477 (33.3%), 481 (53.8%), and 484 (35.9%).  Conversely, with the induction of rifampin, the MIC value ranged â¼256-1024 mg/L.  The mutation sites that were more concd. included 468 (17.9%), 477 (30.8%), 481 (89.7%), 484 (17.9%), and 486 (33.3%).We documented high rifampin resistance induction activity when MRSA was engaged in biofilm with rifampin exposure.  Monotherapy seems to be inadequate for MRSA in biofilm.  There is an urgent need for developing effective combination therapies with less rifampin resistance-inducing activities for treating MRSA in biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtdSdt1F4LjrVg90H21EOLACvtfcHk0lhIkHUsrswHfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCisrjE&md5=ca52467a4d2b9f493270ae72672ccd48</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.-J.%26aulast%3DLai%26aufirst%3DC.-C.%26aulast%3DHsueh%26aufirst%3DP.-R.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DWu%26aufirst%3DK.-Y.%26aulast%3DLin%26aufirst%3DY.-C.%26aulast%3DZhang%26aufirst%3DC.-C.%26aulast%3DWeng%26aufirst%3DT.-C.%26aulast%3DChiu%26aufirst%3DY.-H.%26aulast%3DToh%26aufirst%3DH.-S.%26aulast%3DChiang%26aufirst%3DS.-R.%26aulast%3DYu%26aufirst%3DW.-L.%26aulast%3DKo%26aufirst%3DW.-C.%26aulast%3DChuang%26aufirst%3DY.-C.%26atitle%3DRNA%2520polymerase%2520B%2520subunit%2520gene%2520mutations%2520in%2520biofilm-embedded%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520following%2520rifampin%2520treatment%26jtitle%3DJ.%2520Microbiol.%252C%2520Immunol.%2520Infect.%26date%3D2016%26volume%3D49%26issue%3D3%26spage%3D394%26epage%3D401%26doi%3D10.1016%2Fj.jmii.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bahl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leviton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gialanella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. H.</span><span> </span><span class="NLM_article-title">In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1293</span><span class="NLM_x">â</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1293-1297&issue=6&author=D.+Bahlauthor=D.+A.+Millerauthor=I.+Levitonauthor=P.+Gialanellaauthor=M.+J.+Wolinauthor=W.+Liuauthor=R.+Perkinsauthor=M.+H.+Miller&title=In+vitro+activities+of+ciprofloxacin+and+rifampin+alone+and+in+combination+against+growing+and+nongrowing+strains+of+methicillin-susceptible+and+methicillin-resistant+Staphylococcus+aureus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBahl%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BA.%26aulast%3DLeviton%26aufirst%3DI.%26aulast%3DGialanella%26aufirst%3DP.%26aulast%3DWolin%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPerkins%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DM.%2BH.%26atitle%3DIn%2520vitro%2520activities%2520of%2520ciprofloxacin%2520and%2520rifampin%2520alone%2520and%2520in%2520combination%2520against%2520growing%2520and%2520nongrowing%2520strains%2520of%2520methicillin-susceptible%2520and%2520methicillin-resistant%2520Staphylococcus%2520aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26issue%3D6%26spage%3D1293%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Murillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachon, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Euba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdaguer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabellos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudiol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariza, J.</span><span> </span><span class="NLM_article-title">Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">3681</span><span class="NLM_x">â</span> <span class="NLM_lpage">3686</span><span class="refDoi">Â DOI: 10.1128/AAC.00458-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.00458-08" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=3681-3686&issue=10&author=O.+Murilloauthor=M.+E.+Pachonauthor=G.+Eubaauthor=R.+Verdaguerauthor=F.+Tubauauthor=C.+Cabellosauthor=J.+Caboauthor=F.+Gudiolauthor=J.+Ariza&title=Antagonistic+effect+of+rifampin+on+the+efficacy+of+high-dose+levofloxacin+in+staphylococcal+experimental+foreign-body+infection&doi=10.1128%2FAAC.00458-08"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1128%2FAAC.00458-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00458-08%26sid%3Dliteratum%253Aachs%26aulast%3DMurillo%26aufirst%3DO.%26aulast%3DPachon%26aufirst%3DM.%2BE.%26aulast%3DEuba%26aufirst%3DG.%26aulast%3DVerdaguer%26aufirst%3DR.%26aulast%3DTubau%26aufirst%3DF.%26aulast%3DCabellos%26aufirst%3DC.%26aulast%3DCabo%26aufirst%3DJ.%26aulast%3DGudiol%26aufirst%3DF.%26aulast%3DAriza%26aufirst%3DJ.%26atitle%3DAntagonistic%2520effect%2520of%2520rifampin%2520on%2520the%2520efficacy%2520of%2520high-dose%2520levofloxacin%2520in%2520staphylococcal%2520experimental%2520foreign-body%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D10%26spage%3D3681%26epage%3D3686%26doi%3D10.1128%2FAAC.00458-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Balasubramanian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solapure, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahesh Kumar, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandil, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwas, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panduga, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drusano, G. L.</span><span> </span><span class="NLM_article-title">Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">3054</span><span class="NLM_x">â</span> <span class="NLM_lpage">3057</span><span class="refDoi">Â DOI: 10.1128/AAC.06383-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.06383-11" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3054-3057&issue=6&author=V.+Balasubramanianauthor=S.+Solapureauthor=S.+Gaonkarauthor=K.+N.+Mahesh+Kumarauthor=R.+K.+Shandilauthor=A.+Deshpandeauthor=N.+Kumarauthor=K.+G.+Vishwasauthor=V.+Pandugaauthor=J.+Reddyauthor=S.+Gangulyauthor=A.+Louieauthor=G.+L.+Drusano&title=Effect+of+coadministration+of+moxifloxacin+and+rifampin+on+Mycobacterium+tuberculosis+in+a+murine+aerosol+infection+model&doi=10.1128%2FAAC.06383-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1128%2FAAC.06383-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06383-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DGaonkar%26aufirst%3DS.%26aulast%3DMahesh%2BKumar%26aufirst%3DK.%2BN.%26aulast%3DShandil%26aufirst%3DR.%2BK.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DVishwas%26aufirst%3DK.%2BG.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DDrusano%26aufirst%3DG.%2BL.%26atitle%3DEffect%2520of%2520coadministration%2520of%2520moxifloxacin%2520and%2520rifampin%2520on%2520Mycobacterium%2520tuberculosis%2520in%2520a%2520murine%2520aerosol%2520infection%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26issue%3D6%26spage%3D3054%26epage%3D3057%26doi%3D10.1128%2FAAC.06383-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bremner, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrus, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samosorn, S.</span><span> </span><span class="NLM_article-title">Dual action-based approaches to antibacterial agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1459</span><span class="NLM_x">â</span> <span class="NLM_lpage">1477</span><span class="refDoi">Â DOI: 10.2174/092986707780831168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2174%2F092986707780831168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=17584056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVWmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1459-1477&issue=13&author=J.+B.+Bremnerauthor=J.+I.+Ambrusauthor=S.+Samosorn&title=Dual+action-based+approaches+to+antibacterial+agents&doi=10.2174%2F092986707780831168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Dual action-based approaches to antibacterial agents</span></div><div class="casAuthors">Bremner, John B.; Ambrus, Joseph I.; Samosorn, Siritron</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1459-1477</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review collates and analyses recent work done on dual action approaches to tackling the mounting health problem of resistance by human pathogenic bacteria to antibacterial agents.  In particular the areas reviewed include the use of two drugs in combination, dual action prodrugs, and dual action drugs (or hybrid drugs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL_6fdwziaVLVg90H21EOLACvtfcHk0lgolQO9lNRVzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVWmtLw%253D&md5=33b2f161bafbd816a529c3fd1ea98a9f</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.2174%2F092986707780831168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707780831168%26sid%3Dliteratum%253Aachs%26aulast%3DBremner%26aufirst%3DJ.%2BB.%26aulast%3DAmbrus%26aufirst%3DJ.%2BI.%26aulast%3DSamosorn%26aufirst%3DS.%26atitle%3DDual%2520action-based%2520approaches%2520to%2520antibacterial%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26issue%3D13%26spage%3D1459%26epage%3D1477%26doi%3D10.2174%2F092986707780831168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pokrovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baasov, T.</span><span> </span><span class="NLM_article-title">Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">883</span><span class="NLM_x">â</span> <span class="NLM_lpage">902</span><span class="refDoi">Â DOI: 10.1517/17460441.2010.508069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1517%2F17460441.2010.508069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=22823262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCntrfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=883-902&issue=9&author=V.+Pokrovskayaauthor=T.+Baasov&title=Dual-acting+hybrid+antibiotics%3A+a+promising+strategy+to+combat+bacterial+resistance&doi=10.1517%2F17460441.2010.508069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance</span></div><div class="casAuthors">Pokrovskaya, Varvara; Baasov, Timor</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">883-902</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The emerging and sustained resistance to currently available antibiotics and the poor pipeline of new antibacterials urgently call for the development of new strategies that can address the problem of growing antibacterial resistance.  One such strategy is the development of dual-action hybrid antibiotics: two antibiotics that inhibit dissimilar targets in a bacterial cell covalently linked into one mol.  The possible benefits include: (i) activity against drug-resistant bacteria, (ii) expanded spectrum of activity and (iii) reduced potential for generating bacterial resistance.Areas covered in this review: In this article, we detail the recent activity in the design and development of dual-action hybrid drugs with a non-cleavable linker.  We explore newly developed synergistic and antagonistic hybrid compds. with emphases on their potential to reduce resistance development.What the reader will gain: Recently developed synergistic and antagonistic antibacterial drug-drug interactions and the impact of such interactions on the evolution of antibiotic drug resistance are described.  Addnl., we discuss the implications of the latter observations on the development of hybrid antibiotics with the emphases on whether their synergistic or antagonistic effect will be more efficient at forestalling/reducing the development of new resistances.Take home message: The approach of dual-acting hybrid antibiotics holds significant current promise in overcoming existing resistance mechanisms, as three of such compds. are entering clin. trials.  However, the key challenge in this area should be a broader exptl. demonstration of whether the "synergistic effect" or the "antagonistic effect" of the developed hybrid drug is better at preventing/reducing the evolution of resistance.  This fundamental challenge must be overcome before yielding a successful drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx_MW95x-xTbVg90H21EOLACvtfcHk0lgolQO9lNRVzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCntrfL&md5=9f693a57f8b49d61c1ede4f2eaeeccb6</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2010.508069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2010.508069%26sid%3Dliteratum%253Aachs%26aulast%3DPokrovskaya%26aufirst%3DV.%26aulast%3DBaasov%26aufirst%3DT.%26atitle%3DDual-acting%2520hybrid%2520antibiotics%253A%2520a%2520promising%2520strategy%2520to%2520combat%2520bacterial%2520resistance%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26issue%3D9%26spage%3D883%26epage%3D902%26doi%3D10.1517%2F17460441.2010.508069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tevyashova, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsufyeva, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preobrazhenskaya, M. N.</span><span> </span><span class="NLM_article-title">Design of dual action antibiotics as an approach to search for new promising drugs</span> <span class="citation_source-journal">Russ. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">97</span><span class="refDoi">Â DOI: 10.1070/RCR4448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1070%2FRCR4448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVOmurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2015&pages=61-97&issue=1&author=A.+N.+Tevyashovaauthor=E.+N.+Olsufyevaauthor=M.+N.+Preobrazhenskaya&title=Design+of+dual+action+antibiotics+as+an+approach+to+search+for+new+promising+drugs&doi=10.1070%2FRCR4448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Design of dual action antibiotics as an approach to search for new promising drugs</span></div><div class="casAuthors">Tevyashova, A. N.; Olsufyeva, E. N.; Preobrazhenskaya, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-97</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The review is devoted to the latest achievements in the design of dual action antibiotics-heterodimeric (chimeric) structures based on antibacterial agents of different classes (fluoroquinolones, anthracyclines, oxazolidines, macrolides and so on).  Covalent binding can make the pharmacokinetic characteristics of these mols. more predictable and improve the penetration of each component into the cell.  Consequently, not only does the drug efficacy increase owing to inhibition of two targets but also the resistance to one or both antibiotics can be overcome.  The theor. grounds of elaboration, design principles and methods for the synthesis of dual action antibiotics are considered.  The structures are classified according to the type of covalent spacer (cleavable or not) connecting the moieties of two agents.  Dual action antibiotics with a spacer that can be cleaved in a living cell are considered as dual action prodrugs.  Data on the biol. action of heterodimeric compds. are presented and structure - activity relationships are analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKGGyMhEEC7Vg90H21EOLACvtfcHk0lj5ecPzSNlCew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVOmurk%253D&md5=c77b2fac7caa86151e238606f156a819</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1070%2FRCR4448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4448%26sid%3Dliteratum%253Aachs%26aulast%3DTevyashova%26aufirst%3DA.%2BN.%26aulast%3DOlsufyeva%26aufirst%3DE.%2BN.%26aulast%3DPreobrazhenskaya%26aufirst%3DM.%2BN.%26atitle%3DDesign%2520of%2520dual%2520action%2520antibiotics%2520as%2520an%2520approach%2520to%2520search%2520for%2520new%2520promising%2520drugs%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2015%26volume%3D84%26issue%3D1%26spage%3D61%26epage%3D97%26doi%3D10.1070%2FRCR4448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Barbachyn, M. R.</span>, <span> </span><span class="NLM_article-title">Recent advances in the discovery of hybrid antibacterial agents</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_contrib-group">John, E. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">43</span>, Chapter 17, pp  <span class="NLM_fpage">281</span><span class="NLM_x">â</span> <span class="NLM_lpage">290</span>, DOI: <span class="refDoi">Â DOI: 10.1016/S0065-7743(08)00017-1</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0065-7743%2808%2900017-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=281-290&author=M.+R.+Barbachynauthor=E.+M.+John&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2900017-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252900017-1%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520hybrid%2520antibacterial%2520agents%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DJohn%26aufirst%3DE.%2BM.%26pub%3DAcademic%2520Press%26date%3D2008%26volume%3D43%26spage%3D281%26epage%3D290%26doi%3D10.1016%2FS0065-7743%2808%2900017-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Georgopapadakou, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertasso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleeland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, D. D.</span><span> </span><span class="NLM_article-title">Mode of action of the dual-action cephalosporin Ro 23-9424</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1067</span><span class="NLM_x">â</span> <span class="NLM_lpage">1071</span><span class="refDoi">Â DOI: 10.1128/AAC.33.7.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.33.7.1067" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=1067-1071&issue=7&author=N.+H.+Georgopapadakouauthor=A.+Bertassoauthor=K.+K.+Chanauthor=J.+S.+Chapmanauthor=R.+Cleelandauthor=L.+M.+Cummingsauthor=B.+A.+Dixauthor=D.+D.+Keith&title=Mode+of+action+of+the+dual-action+cephalosporin+Ro+23-9424&doi=10.1128%2FAAC.33.7.1067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1128%2FAAC.33.7.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.33.7.1067%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgopapadakou%26aufirst%3DN.%2BH.%26aulast%3DBertasso%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DChapman%26aufirst%3DJ.%2BS.%26aulast%3DCleeland%26aufirst%3DR.%26aulast%3DCummings%26aufirst%3DL.%2BM.%26aulast%3DDix%26aufirst%3DB.%2BA.%26aulast%3DKeith%26aufirst%3DD.%2BD.%26atitle%3DMode%2520of%2520action%2520of%2520the%2520dual-action%2520cephalosporin%2520Ro%252023-9424%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1989%26volume%3D33%26issue%3D7%26spage%3D1067%26epage%3D1071%26doi%3D10.1128%2FAAC.33.7.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christenson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleeland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix-Holzknecht, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrish, H. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specian, A.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1895</span><span class="NLM_x">â</span> <span class="NLM_lpage">1900</span><span class="refDoi">Â DOI: 10.1128/AAC.34.10.1895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.34.10.1895" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=1895-1900&issue=10&author=J.+G.+Christensonauthor=K.+K.+Chanauthor=R.+Cleelandauthor=B.+Dix-Holzknechtauthor=H.+H.+Farrishauthor=I.+H.+Patelauthor=A.+Specian&title=Pharmacokinetics+of+Ro+23-9424%2C+a+dual-action+cephalosporin%2C+in+animals&doi=10.1128%2FAAC.34.10.1895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.10.1895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.10.1895%26sid%3Dliteratum%253Aachs%26aulast%3DChristenson%26aufirst%3DJ.%2BG.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DCleeland%26aufirst%3DR.%26aulast%3DDix-Holzknecht%26aufirst%3DB.%26aulast%3DFarrish%26aufirst%3DH.%2BH.%26aulast%3DPatel%26aufirst%3DI.%2BH.%26aulast%3DSpecian%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520of%2520Ro%252023-9424%252C%2520a%2520dual-action%2520cephalosporin%252C%2520in%2520animals%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26issue%3D10%26spage%3D1895%26epage%3D1900%26doi%3D10.1128%2FAAC.34.10.1895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gu, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">189</span><span class="NLM_x">â</span> <span class="NLM_lpage">195</span><span class="refDoi">Â DOI: 10.1128/AAC.34.2.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.34.2.189" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=189-195&issue=2&author=J.+W.+Guauthor=H.+C.+Neu&title=In+vitro+activity+of+Ro+23-9424%2C+a+dual-action+cephalosporin%2C+compared+with+activities+of+other+antibiotics&doi=10.1128%2FAAC.34.2.189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.2.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.2.189%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DJ.%2BW.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Ro%252023-9424%252C%2520a%2520dual-action%2520cephalosporin%252C%2520compared%2520with%2520activities%2520of%2520other%2520antibiotics%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26issue%3D2%26spage%3D189%26epage%3D195%26doi%3D10.1128%2FAAC.34.2.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Locher, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruyere, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritz, D.</span><span> </span><span class="NLM_article-title">Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">â</span> <span class="NLM_lpage">908</span><span class="refDoi">Â DOI: 10.1128/AAC.01831-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01831-13" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=901-908&issue=2&author=H.+H.+Locherauthor=P.+Caspersauthor=T.+Bruyereauthor=S.+Schroederauthor=P.+Pfaffauthor=A.+Knezevicauthor=W.+Keckauthor=D.+Ritz&title=Investigations+of+the+mode+of+action+and+resistance+development+of+cadazolid%2C+a+new+antibiotic+for+treatment+of+Clostridium+difficile+infections&doi=10.1128%2FAAC.01831-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.01831-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01831-13%26sid%3Dliteratum%253Aachs%26aulast%3DLocher%26aufirst%3DH.%2BH.%26aulast%3DCaspers%26aufirst%3DP.%26aulast%3DBruyere%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DPfaff%26aufirst%3DP.%26aulast%3DKnezevic%26aufirst%3DA.%26aulast%3DKeck%26aufirst%3DW.%26aulast%3DRitz%26aufirst%3DD.%26atitle%3DInvestigations%2520of%2520the%2520mode%2520of%2520action%2520and%2520resistance%2520development%2520of%2520cadazolid%252C%2520a%2520new%2520antibiotic%2520for%2520treatment%2520of%2520Clostridium%2520difficile%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D2%26spage%3D901%26epage%3D908%26doi%3D10.1128%2FAAC.01831-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ding, C. Z.; Ma, Z.; Li, J.; Harran, S.; He, Y.; Minor, K. P.; Kim, I. H.; Longgood, J. C.; Jin, Y.; Combrink, K. D.</span>, <span> </span><span class="NLM_article-title">(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions</span>. U.S. Patent 7,226,931,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Z.+Ding&author=Z.+Ma&author=J.+Li&author=S.+Harran&author=Y.+He&author=K.+P.+Minor&author=I.+H.+Kim&author=J.+C.+Longgood&author=Y.+Jin&author=K.+D.+Combrink&title=%28R%2FS%29+rifamycin+derivatives%2C+their+preparations+and+pharmaceutical+compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3D%2528R%252FS%2529%2520rifamycin%2520derivatives%252C%2520their%2520preparations%2520and%2520pharmaceutical%2520compositions%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simecka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1181</span><span class="NLM_x">â</span> <span class="NLM_lpage">1184</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2006.12.026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1181-1184&issue=5&author=I.+H.+Kimauthor=K.+D.+Combrinkauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=P.+Renickauthor=T.+W.+Morrisauthor=M.+Pulseauthor=J.+W.+Simeckaauthor=C.+Z.+Ding&title=Synthesis+and+antibacterial+evaluation+of+a+novel+series+of+rifabutin-like+spirorifamycins&doi=10.1016%2Fj.bmcl.2006.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DRenick%26aufirst%3DP.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DPulse%26aufirst%3DM.%26aulast%3DSimecka%26aufirst%3DJ.%2BW.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520a%2520novel%2520series%2520of%2520rifabutin-like%2520spirorifamycins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D5%26spage%3D1181%26epage%3D1184%26doi%3D10.1016%2Fj.bmcl.2006.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ma, Z.; Kim, I. H.; Li, J.</span><span> </span><span class="NLM_article-title">Spiro-rifamycin derivatives targeting RNA polymerase</span>. U.S. Patent 7,202,246,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Z.+Ma&author=I.+H.+Kim&author=J.+Li&title=Spiro-rifamycin+derivatives+targeting+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DSpiro-rifamycin%2520derivatives%2520targeting%2520RNA%2520polymerase%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ding, C. Z.; Kim, I. H.; Wang, J.; Ma, Z.; Jin, Y.; Combrink, K. D.; Lu, G.; Lynch, A. S.</span><span> </span><span class="NLM_article-title">Nitroheteroaryl-containing rifamycin derivatives</span>. U.S. Patent 7,678,791,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Z.+Ding&author=I.+H.+Kim&author=J.+Wang&author=Z.+Ma&author=Y.+Jin&author=K.+D.+Combrink&author=G.+Lu&author=A.+S.+Lynch&title=Nitroheteroaryl-containing+rifamycin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DNitroheteroaryl-containing%2520rifamycin%2520derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span> </span><span class="NLM_article-title">Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5510</span><span class="NLM_x">â</span> <span class="NLM_lpage">5513</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2007.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2007.08.048" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5510-5513&issue=20&author=J.+Liauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=A.+S.+Lynchauthor=C.+Z.+Ding&title=Preparation+and+in+vitro+anti-staphylococcal+activity+of+novel+11-deoxy-11-hydroxyiminorifamycins&doi=10.1016%2Fj.bmcl.2007.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DPreparation%2520and%2520in%2520vitro%2520anti-staphylococcal%2520activity%2520of%2520novel%252011-deoxy-11-hydroxyiminorifamycins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D20%26spage%3D5510%26epage%3D5513%26doi%3D10.1016%2Fj.bmcl.2007.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Li, J.; Ding, C. Z.; Ma, Z.</span><span> </span><span class="NLM_article-title">Rifamycin C-11 oxime derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,265,107,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Li&author=C.+Z.+Ding&author=Z.+Ma&title=Rifamycin+C-11+oxime+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRifamycin%2520C-11%2520oxime%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, J.; Ma, Z.</span>, <span> </span><span class="NLM_article-title">Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,256,187,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Li&author=Z.+Ma&title=Rifamycin+C-11+oxime+cyclo+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRifamycin%2520C-11%2520oxime%2520cyclo%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denton, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">522</span><span class="NLM_x">â</span> <span class="NLM_lpage">526</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2006.10.016" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=522-526&issue=2&author=K.+D.+Combrinkauthor=D.+A.+Dentonauthor=S.+Harranauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=E.+Bonventreauthor=E.+D.+Rocheauthor=T.+B.+Doyleauthor=G.+T.+Robertsonauthor=A.+S.+Lynch&title=New+C25+carbamate+rifamycin+derivatives+are+resistant+to+inactivation+by+ADP-ribosyl+transferases&doi=10.1016%2Fj.bmcl.2006.10.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DDenton%26aufirst%3DD.%2BA.%26aulast%3DHarran%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DBonventre%26aufirst%3DE.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DNew%2520C25%2520carbamate%2520rifamycin%2520derivatives%2520are%2520resistant%2520to%2520inactivation%2520by%2520ADP-ribosyl%2520transferases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D2%26spage%3D522%26epage%3D526%26doi%3D10.1016%2Fj.bmcl.2006.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Combrink, K.; Harran, S.; Denton, D.; Ma, Z.</span><span> </span><span class="NLM_article-title">C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes</span>. U.S. Patent 7,250,413,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Combrink&author=S.+Harran&author=D.+Denton&author=Z.+Ma&title=C-25+carbamate+rifamycin+derivatives+with+activity+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%26atitle%3DC-25%2520carbamate%2520rifamycin%2520derivatives%2520with%2520activity%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Ding, C. Z.; Jin, Y.; Combrink, K.; Kim, I. H.</span><span> </span><span class="NLM_article-title">Quinolone carboxylic acid-substituted rifamycin derivatives</span>. U.S. Patent 7,884,099,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+Z.+Ding&author=Y.+Jin&author=K.+Combrink&author=I.+H.+Kim&title=Quinolone+carboxylic+acid-substituted+rifamycin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DQuinolone%2520carboxylic%2520acid-substituted%2520rifamycin%2520derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ma, Z.; Jin, Y.; Li, J.; Ding, C. Z.; Minor, K. P.; Longgood, J. C.; Kim, I. H.; Harran, S.; Combrink, K.; Morris, T. W.</span><span> </span><span class="NLM_article-title">Rifamycin derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,247,634,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Z.+Ma&author=Y.+Jin&author=J.+Li&author=C.+Z.+Ding&author=K.+P.+Minor&author=J.+C.+Longgood&author=I.+H.+Kim&author=S.+Harran&author=K.+Combrink&author=T.+W.+Morris&title=Rifamycin+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DRifamycin%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitscher, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L. L.</span><span> </span><span class="NLM_article-title">The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">231</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span><span class="refDoi">Â DOI: 10.1002/1098-1128(200007)20:4<231::AID-MED1>3.0.CO;2-N</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10861727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFSksLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=231-293&issue=4&author=Q.+Liauthor=L.+A.+Mitscherauthor=L.+L.+Shen&title=The+2-pyridone+antibacterial+agents%3A+bacterial+topoisomerase+inhibitors&doi=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The 2-pyridone antibacterial agents: Bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Li, Qun; Mitscher, Lester A.; Shen, Linus L.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-293</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 132 refs.  Many attempts have been made to prep. analogs of 4-quinolone antibacterial agents bearing novel ring systems, which might retain the favorable properties of these widely used antibacterial agents and at the same time increase activity against multidrug-resistant bacteria, streptococci, and anaerobic microorganisms.  One such attempt involved bioisosteric exchange of the 1-N atom and 4a-C atom of naphthyridones, quinolones, and benzoxazines to produce a family of highly active pyridopyrimidines, quinolizines, and ofloxacin bioisosteres.  These new antibacterial agents have been named collectively as the 2-pyridones.  Many hundreds of 2-pyridones have been synthesized and evaluated in vitro and in vivo, and selected members are advancing toward human clin. trials.  Prepn. of these bioisosteres required the development of enabling chem., as previous methods were unsuccessful in producing the needed core structures.  This review compares the structure-activity relationships of these agents with known trends among 4-quinolones, from which it is seen that there are many parallels, but also some significant departures as well.  Generally, 2-pyridones are more highly active in vitro and in vivo and more water sol. than comparable 4-quinolones.  These properties are posited to arise from electronic and conformational alternations in these new substances.  Selected members show excellent pharmacodynamic properties, justifying the view that this is a very promising new class of totally synthetic antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPUqaRhDddcLVg90H21EOLACvtfcHk0lgcRB425vbphg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFSksLc%253D&md5=df6229ea2277351f35331c970cfa9eec</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-1128%2528200007%252920%253A4%253C231%253A%253AAID-MED1%253E3.0.CO%253B2-N%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMitscher%26aufirst%3DL.%2BA.%26aulast%3DShen%26aufirst%3DL.%2BL.%26atitle%3DThe%25202-pyridone%2520antibacterial%2520agents%253A%2520bacterial%2520topoisomerase%2520inhibitors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26issue%3D4%26spage%3D231%26epage%3D293%26doi%3D10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saiki, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, C. G.</span><span> </span><span class="NLM_article-title">DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1574</span><span class="NLM_x">â</span> <span class="NLM_lpage">1577</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=1574-1577&issue=7&author=A.+Y.+Saikiauthor=L.+L.+Shenauthor=C.+M.+Chenauthor=J.+Baranowskiauthor=C.+G.+Lerner&title=DNA+cleavage+activities+of+Staphylococcus+aureus+gyrase+and+topoisomerase+IV+stimulated+by+quinolones+and+2-pyridones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DShen%26aufirst%3DL.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BM.%26aulast%3DBaranowski%26aufirst%3DJ.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26atitle%3DDNA%2520cleavage%2520activities%2520of%2520Staphylococcus%2520aureus%2520gyrase%2520and%2520topoisomerase%2520IV%2520stimulated%2520by%2520quinolones%2520and%25202-pyridones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1999%26volume%3D43%26issue%3D7%26spage%3D1574%26epage%3D1577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oleksijew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alder, J. D.</span><span> </span><span class="NLM_article-title">Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">653</span><span class="refDoi">Â DOI: 10.1093/jac/38.4.641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fjac%2F38.4.641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=8937959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADyaK28XntFWiu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1996&pages=641-653&issue=4&author=J.+A.+Meulbroekauthor=A.+Oleksijewauthor=S.+K.+Tanakaauthor=J.+D.+Alder&title=Efficacy+of+ABT-719%2C+a+2-pyridone+antimicrobial%2C+against+enterococci%2C+Escherichia+coli%2C+and+Pseudomonas+aeruginosa+in+experimental+murine+pyelonephritis&doi=10.1093%2Fjac%2F38.4.641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis</span></div><div class="casAuthors">Meulbroek, Jonathan a.; Oleksijew, Anatol; Tanaka, S. Ken; Alder, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-653</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">ABT-719 is a 2-pyridone antimicrobial which inhibits DNA gyrase activity.  It has considerable s.c. and oral efficacy in the treatment of exptl. pyelonephritis induced in carrageenan-treated mice by clin. isolates of Enterococcus faecalis, Enterococcus faecium, Escherichia coli, and Pseudomonas aeruginosa.  Therapeutic ED50s, defined here as producing a 2 log10 redn. in kidney bacterial burden, provide a reliable end point for comparison of drug efficacy in this exptl. infection.  Therapeutic ED50s for ABT-719 against these infections were equal to or up to 10-fold lower than those for ciprofloxacin, used as a ref. because of similarity in mode of action.  Against E. faecalis, the therapeutic ED50s for ABT-719 were 4.5-13.6 mg/kg/day for s.c. administration and 6.8-8.9 mg/kg/day for oral administration.  ABT-719 was more potent than ciprofloxacin and vancomycin against the E. faecalis strains, which showed ciprofloxacin and vancomycin resistance covering a range of MICs.  Against E. faecium, the therapeutic ED50s for ABT-719 were 8.8 mg/kg/day (s.c.) and 9.4 mg/kg/day (oral).  Against an isolate of E. faecium showing ciprofloxacin and vancomycin resistance the ED50 for ABT-719 to achieve a 1 log10 redn. in kidney bacterial burden was 17.9 mg/kg/day by s.c. administration.  While ABT-719 had lower efficacy against this isolate than against orders, ciprofloxacin and vancomycin failed to show efficacy.  Against E. coli, the therapeutic ED50 for ABT-719 was 1.1 mg/kg/day (oral), and against P. aeruginosa, this value was 2.7 mg/kg/day (oral) with values against both of these pathogens similar to those for ciprofloxacin ABT-719, which represents the new 2-pyridone compd. class, has promise for the treatment of urinary tract infections, as suggested by the significant efficacy seen against exptl. pyelonephritis caused by E. coli, P. aeruginosa and susceptible and resistant enterococci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMxc3B0a2hrVg90H21EOLACvtfcHk0lgcRB425vbphg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFWiu7g%253D&md5=bc19cbba6698ca81905aaf682b28333d</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F38.4.641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F38.4.641%26sid%3Dliteratum%253Aachs%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DS.%2BK.%26aulast%3DAlder%26aufirst%3DJ.%2BD.%26atitle%3DEfficacy%2520of%2520ABT-719%252C%2520a%25202-pyridone%2520antimicrobial%252C%2520against%2520enterococci%252C%2520Escherichia%2520coli%252C%2520and%2520Pseudomonas%2520aeruginosa%2520in%2520experimental%2520murine%2520pyelonephritis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1996%26volume%3D38%26issue%3D4%26spage%3D641%26epage%3D653%26doi%3D10.1093%2Fjac%2F38.4.641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2313</span><span class="NLM_x">â</span> <span class="NLM_lpage">2323</span><span class="refDoi">Â DOI: 10.1128/AAC.01649-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01649-07" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2313-2323&issue=7&author=G.+T.+Robertsonauthor=E.+J.+Bonventreauthor=T.+B.+Doyleauthor=Q.+Duauthor=L.+Duncanauthor=T.+W.+Morrisauthor=E.+D.+Rocheauthor=D.+Yanauthor=A.+S.+Lynch&title=In+vitro+evaluation+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%3A+studies+of+the+mode+of+action+in+Staphylococcus+aureus&doi=10.1128%2FAAC.01649-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1128%2FAAC.01649-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01649-07%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DBonventre%26aufirst%3DE.%2BJ.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520evaluation%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%253A%2520studies%2520of%2520the%2520mode%2520of%2520action%2520in%2520Staphylococcus%2520aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D7%26spage%3D2313%26epage%3D2323%26doi%3D10.1128%2FAAC.01649-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2324</span><span class="NLM_x">â</span> <span class="NLM_lpage">2334</span><span class="refDoi">Â DOI: 10.1128/AAC.01651-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01651-07" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2324-2334&issue=7&author=G.+T.+Robertsonauthor=E.+J.+Bonventreauthor=T.+B.+Doyleauthor=Q.+Duauthor=L.+Duncanauthor=T.+W.+Morrisauthor=E.+D.+Rocheauthor=D.+Yanauthor=A.+S.+Lynch&title=In+vitro+evaluation+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%3A+microbiology+profiling+studies+with+staphylococci+and+streptococci&doi=10.1128%2FAAC.01651-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01651-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01651-07%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DBonventre%26aufirst%3DE.%2BJ.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520evaluation%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%253A%2520microbiology%2520profiling%2520studies%2520with%2520staphylococci%2520and%2520streptococci%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D7%26spage%3D2324%26epage%3D2334%26doi%3D10.1128%2FAAC.01651-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lynch, A. S.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Robertson, G. T.; Roche, E. D.</span><span> </span><span class="NLM_article-title">In vitro mode-of-action studies of CBR-2092: a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2101.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=A.+S.+Lynch&author=E.+J.+Bonventre&author=T.+B.+Doyle&author=Q.+Du&author=L.+Duncan&author=G.+T.+Robertson&author=E.+D.+Roche&title=In+vitro+mode-of-action+studies+of+CBR-2092%3A+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520mode-of-action%2520studies%2520of%2520CBR-2092%253A%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robertson, G. T.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Roche, E. D.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">Comparative in vitro activity of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and rifampin+quinolone combinations</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2102.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=G.+T.+Robertson&author=E.+J.+Bonventre&author=T.+B.+Doyle&author=Q.+Du&author=L.+Duncan&author=E.+D.+Roche&author=A.+S.+Lynch&title=Comparative+in+vitro+activity+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+and+rifampin%2Bquinolone+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26atitle%3DComparative%2520in%2520vitro%2520activity%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520and%2520rifampin%252Bquinolone%2520combinations%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Du, Q.; Doyle, T. B.; Duncan, L.; Robertson, G. T.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">In vitro microbiology profiling of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Q.+Du&author=T.+B.+Doyle&author=L.+Duncan&author=G.+T.+Robertson&author=A.+S.+Lynch&title=In+vitro+microbiology+profiling+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DQ.%26atitle%3DIn%2520vitro%2520microbiology%2520profiling%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Doyle, T. B.; Bonventre, E. J.; Du, Q.; Robertson, G. T.; Roche, E. D.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">In vitro studies of the efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in killing staphylococcal cells in biofilms</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2104.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+B.+Doyle&author=E.+J.+Bonventre&author=Q.+Du&author=G.+T.+Robertson&author=E.+D.+Roche&author=A.+S.+Lynch&title=In+vitro+studies+of+the+efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+in+killing+staphylococcal+cells+in+biofilms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26atitle%3DIn%2520vitro%2520studies%2520of%2520the%2520efficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520in%2520killing%2520staphylococcal%2520cells%2520in%2520biofilms%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Renick, P. J.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Weiss, W. J.</span><span> </span><span class="NLM_article-title">Efficacy of CBR-2092, a novel rifamycin-quinolone yybrid antibiotic, in rodent models of bacterial infection</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2105.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+J.+Renick&author=T.+W.+Morris&author=P.+M.+Nguyen&author=M.+E.+Pulse&author=W.+J.+Weiss&title=Efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+yybrid+antibiotic%2C+in+rodent+models+of+bacterial+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRenick%26aufirst%3DP.%2BJ.%26atitle%3DEfficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520yybrid%2520antibiotic%252C%2520in%2520rodent%2520models%2520of%2520bacterial%2520infection%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Weiss, W. J.; Bao, D.; Miller, G. A.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Renick, P. J.; Truong, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic studies with CBR-2092, a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2106.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=W.+J.+Weiss&author=D.+Bao&author=G.+A.+Miller&author=T.+W.+Morris&author=P.+M.+Nguyen&author=M.+E.+Pulse&author=P.+J.+Renick&author=T.+Truong&title=Pharmacokinetic+and+pharmacodynamic+studies+with+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DW.%2BJ.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520studies%2520with%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.</span><span> </span><span class="NLM_article-title">Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and vancomycin in experimental methicillin-resistant Staphylococcus aureus infective endocarditis</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2107.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Q.+Xiong&author=W.+J.+Weiss&author=T.+B.+Doyle&author=G.+A.+Abdelsayed&author=A.+S.+Bayer&title=Efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+and+vancomycin+in+experimental+methicillin-resistant+Staphylococcus+aureus+infective+endocarditis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BQ.%26atitle%3DEfficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520and%2520vancomycin%2520in%2520experimental%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520infective%2520endocarditis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.</span><span> </span><span class="NLM_article-title">Comparative efficacy of CBR-2092 and conventional rifampin+quinolone combinations in experimental infective endocarditis caused by a quinolone-resistant MRSA</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2108.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Q.+Xiong&author=W.+J.+Weiss&author=T.+B.+Doyle&author=G.+A.+Abdelsayed&author=A.+S.+Bayer&title=Comparative+efficacy+of+CBR-2092+and+conventional+rifampin%2Bquinolone+combinations+in+experimental+infective+endocarditis+caused+by+a+quinolone-resistant+MRSA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BQ.%26atitle%3DComparative%2520efficacy%2520of%2520CBR-2092%2520and%2520conventional%2520rifampin%252Bquinolone%2520combinations%2520in%2520experimental%2520infective%2520endocarditis%2520caused%2520by%2520a%2520quinolone-resistant%2520MRSA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19a','cit19b','cit19c','cit19d'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30b'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b','cit32c','cit32d','cit32e','cit32f','cit32g','cit32h']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mina Zare, Mohamad Zare, Jonathan A. Butler, <span class="NLM_string-name hlFld-ContribAuthor">Seeram Ramakrishna</span>. </span><span class="cited-content_cbyCitation_article-title">Nanoscience-Led Antimicrobial Surface Engineering to Prevent Infections. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Nano Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (5)
                                     , 4269-4283. <a href="https://doi.org/10.1021/acsanm.1c00466" title="DOI URL">https://doi.org/10.1021/acsanm.1c00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsanm.1c00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsanm.1c00466%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Nano%2520Materials%26atitle%3DNanoscience-Led%252BAntimicrobial%252BSurface%252BEngineering%252Bto%252BPrevent%252BInfections%26aulast%3DZare%26aufirst%3DMina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D14022021%26date%3D11052021%26date%3D19052021%26volume%3D4%26issue%3D5%26spage%3D4269%26epage%3D4283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Declan Alan Gray, <span class="NLM_string-name hlFld-ContribAuthor">Michaela Wenzel</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Approaches against Multiresistant Superbugs. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (6)
                                     , 1346-1365. <a href="https://doi.org/10.1021/acsinfecdis.0c00001" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00001%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DMultitarget%252BApproaches%252Bagainst%252BMultiresistant%252BSuperbugs%26aulast%3DGray%26aufirst%3DDeclan%2BAlan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01012020%26date%3D19032020%26date%3D10032020%26volume%3D6%26issue%3D6%26spage%3D1346%26epage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Abigail C. Jackson, Jacqueline M. Zaengle-Barone, Elena A. Puccio, <span class="NLM_string-name hlFld-ContribAuthor">Katherine J. Franz</span>. </span><span class="cited-content_cbyCitation_article-title">A Cephalosporin Prochelator Inhibits New Delhi Metallo-Î²-lactamase 1 without Removing Zinc. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (5)
                                     , 1264-1272. <a href="https://doi.org/10.1021/acsinfecdis.0c00083" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00083%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DA%252BCephalosporin%252BProchelator%252BInhibits%252BNew%252BDelhi%252BMetallo-%2525CE%2525B2-lactamase%252B1%252Bwithout%252BRemoving%252BZinc%26aulast%3DJackson%26aufirst%3DAbigail%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19022020%26date%3D29042020%26date%3D16042020%26volume%3D6%26issue%3D5%26spage%3D1264%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ying Yuan, Xiaomei Wang, Xiangyi Xu, Yu Liu, Cancan Li, Meng Yang, Yiqing Yang, <span class="NLM_string-name hlFld-ContribAuthor">Zhenkun Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (5)
                                     , 820-831. <a href="https://doi.org/10.1021/acsinfecdis.9b00374" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00374%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DEvaluation%252Bof%252Ba%252BDual-Acting%252BAntibacterial%252BAgent%25252C%252BTNP-2092%25252C%252Bon%252BGut%252BMicrobiota%252Band%252BPotential%252BApplication%252Bin%252Bthe%252BTreatment%252Bof%252BGastrointestinal%252Band%252BLiver%252BDisorders%26aulast%3DYuan%26aufirst%3DYing%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D28092019%26date%3D02012020%26date%3D18122019%26volume%3D6%26issue%3D5%26spage%3D820%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas BostrÃ¶m</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pasupathy  Saravanan</span>, <span class="hlFld-ContribAuthor ">V. N. Azger  Dusthackeer</span>, <span class="hlFld-ContribAuthor ">R. S.  Rajmani</span>, <span class="hlFld-ContribAuthor ">B.  Mahizhaveni</span>, <span class="hlFld-ContribAuthor ">Christy R.  Nirmal</span>, <span class="hlFld-ContribAuthor ">Sam Ebenezer  Rajadas</span>, <span class="hlFld-ContribAuthor ">Neerupma  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">C.  Ponnuraja</span>, <span class="hlFld-ContribAuthor ">Adhin  Bhaskar</span>, <span class="hlFld-ContribAuthor ">A. K.  Hemanthkumar</span>, <span class="hlFld-ContribAuthor ">Geetha  Ramachandran</span>, <span class="hlFld-ContribAuthor ">Srikanth P.  Tripathy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly potent novel rifampicin analog by preparing a hybrid of the precursors of the antibiotic drugs rifampicin and clofazimine. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-80439-2" title="DOI URL">https://doi.org/10.1038/s41598-020-80439-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-80439-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-80439-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bpotent%252Bnovel%252Brifampicin%252Banalog%252Bby%252Bpreparing%252Ba%252Bhybrid%252Bof%252Bthe%252Bprecursors%252Bof%252Bthe%252Bantibiotic%252Bdrugs%252Brifampicin%252Band%252Bclofazimine%26aulast%3DSaravanan%26aufirst%3DPasupathy%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Woojin  Yang</span>, <span class="hlFld-ContribAuthor ">Younggun  Yoon</span>, <span class="hlFld-ContribAuthor ">Yunjee  Lee</span>, <span class="hlFld-ContribAuthor ">Hyeongyeol  Oh</span>, <span class="hlFld-ContribAuthor ">Jieun  Choi</span>, <span class="hlFld-ContribAuthor ">Sujin  Shin</span>, <span class="hlFld-ContribAuthor ">Seongsoo  Lee</span>, <span class="hlFld-ContribAuthor ">Hohjai  Lee</span>, <span class="hlFld-ContribAuthor ">Yunho  Lee</span>, <span class="hlFld-ContribAuthor ">Jiwon  Seo</span>. </span><span class="cited-content_cbyCitation_article-title">Photosensitizerâpeptoid conjugates for photoinactivation of Gram-negative bacteria: structureâactivity relationship and mechanistic studies. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (29)
                                     , 6546-6557. <a href="https://doi.org/10.1039/D1OB00926E" title="DOI URL">https://doi.org/10.1039/D1OB00926E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00926E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00926E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DPhotosensitizer%2525E2%252580%252593peptoid%252Bconjugates%252Bfor%252Bphotoinactivation%252Bof%252BGram-negative%252Bbacteria%25253A%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Band%252Bmechanistic%252Bstudies%26aulast%3DYang%26aufirst%3DWoojin%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D29%26spage%3D6546%26epage%3D6557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdrrahman Shemsu  Surur</span>, <span class="hlFld-ContribAuthor ">Dianqing  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.659845" title="DOI URL">https://doi.org/10.3389/fchem.2021.659845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.659845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.659845%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DMacrocycle-Antibiotic%252BHybrids%25253A%252BA%252BPath%252Bto%252BClinical%252BCandidates%26aulast%3DSurur%26aufirst%3DAbdrrahman%2BShemsu%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniele R.  Giacobbe</span>, <span class="hlFld-ContribAuthor ">Laura  Labate</span>, <span class="hlFld-ContribAuthor ">Antonio  Vena</span>, <span class="hlFld-ContribAuthor ">Matteo  Bassetti</span>. </span><span class="cited-content_cbyCitation_article-title">Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Infectious Diseases</span><span> <strong>2021,</strong> <em>34 </em>
                                    (2)
                                     , 109-117. <a href="https://doi.org/10.1097/QCO.0000000000000708" title="DOI URL">https://doi.org/10.1097/QCO.0000000000000708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/QCO.0000000000000708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FQCO.0000000000000708%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Infectious%2520Diseases%26atitle%3DPotential%252Brole%252Bof%252Bnew-generation%252Bantibiotics%252Bin%252Bacute%252Bbacterial%252Bskin%252Band%252Bskin%252Bstructure%252Binfections%26aulast%3DGiacobbe%26aufirst%3DDaniele%2BR.%26date%3D2021%26date%3D2020%26volume%3D34%26issue%3D2%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John  Bremner</span>. </span><span class="cited-content_cbyCitation_article-title">Single Molecule Non-cleavable Multiply Active Antibacterials. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 51-119. <a href="https://doi.org/10.1007/978-981-16-0999-2_3" title="DOI URL">https://doi.org/10.1007/978-981-16-0999-2_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0999-2_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0999-2_3%26sid%3Dliteratum%253Aachs%26atitle%3DSingle%252BMolecule%252BNon-cleavable%252BMultiply%252BActive%252BAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26date%3D2021%26spage%3D51%26epage%3D119%26pub%3DSpringer%2520Singapore%26atitle%3DMultiple%252BAction-Based%252BDesign%252BApproaches%252Bto%252BAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liam J  Stephens</span>, <span class="hlFld-ContribAuthor ">Melissa V  Werrett</span>, <span class="hlFld-ContribAuthor ">Adam C  Sedgwick</span>, <span class="hlFld-ContribAuthor ">Steven D  Bull</span>, <span class="hlFld-ContribAuthor ">Philip C  Andrews</span>. </span><span class="cited-content_cbyCitation_article-title">Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (22)
                                     , 2035-2065. <a href="https://doi.org/10.4155/fmc-2020-0225" title="DOI URL">https://doi.org/10.4155/fmc-2020-0225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0225%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAntimicrobial%252Binnovation%25253A%252Ba%252Bcurrent%252Bupdate%252Band%252Bperspective%252Bon%252Bthe%252Bantibiotic%252Bdrug%252Bdevelopment%252Bpipeline%26aulast%3DStephens%26aufirst%3DLiam%2BJ%26date%3D2020%26volume%3D12%26issue%3D22%26spage%3D2035%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anand Babu  Velappan</span>, <span class="hlFld-ContribAuthor ">Dhrubajyoti  Datta</span>, <span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Shiwani  Rana</span>, <span class="hlFld-ContribAuthor ">Kalyan Sundar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Natarajan  Hari</span>, <span class="hlFld-ContribAuthor ">Scott G.  Franzblau</span>, <span class="hlFld-ContribAuthor ">Joy  Debnath</span>. </span><span class="cited-content_cbyCitation_article-title">2-Aryl benzazole derived new class of anti-tubercular compounds: Endowed to eradicate mycobacterium tuberculosis in replicating and non-replicating forms. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104170. <a href="https://doi.org/10.1016/j.bioorg.2020.104170" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104170%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D2-Aryl%252Bbenzazole%252Bderived%252Bnew%252Bclass%252Bof%252Banti-tubercular%252Bcompounds%25253A%252BEndowed%252Bto%252Beradicate%252Bmycobacterium%252Btuberculosis%252Bin%252Breplicating%252Band%252Bnon-replicating%252Bforms%26aulast%3DVelappan%26aufirst%3DAnand%2BBabu%26date%3D2020%26volume%3D103%26spage%3D104170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ursula  Theuretzbacher</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-mechanism antibiotics. </span><span class="cited-content_cbyCitation_journal-name">Nature Microbiology</span><span> <strong>2020,</strong> <em>5 </em>
                                    (8)
                                     , 984-985. <a href="https://doi.org/10.1038/s41564-020-0767-0" title="DOI URL">https://doi.org/10.1038/s41564-020-0767-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41564-020-0767-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41564-020-0767-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Microbiology%26atitle%3DDual-mechanism%252Bantibiotics%26aulast%3DTheuretzbacher%26aufirst%3DUrsula%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D8%26spage%3D984%26epage%3D985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cody R.  Fisher</span>, <span class="hlFld-ContribAuthor ">Suzannah M.  Schmidt-Malan</span>, <span class="hlFld-ContribAuthor ">Zhenkun  Ma</span>, <span class="hlFld-ContribAuthor ">Ying  Yuan</span>, <span class="hlFld-ContribAuthor ">Shijie  He</span>, <span class="hlFld-ContribAuthor ">Robin  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro activity of TNP-2092 against periprosthetic joint infectionâassociated staphylococci. </span><span class="cited-content_cbyCitation_journal-name">Diagnostic Microbiology and Infectious Disease</span><span> <strong>2020,</strong> <em>97 </em>
                                    (3)
                                     , 115040. <a href="https://doi.org/10.1016/j.diagmicrobio.2020.115040" title="DOI URL">https://doi.org/10.1016/j.diagmicrobio.2020.115040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.diagmicrobio.2020.115040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.diagmicrobio.2020.115040%26sid%3Dliteratum%253Aachs%26jtitle%3DDiagnostic%2520Microbiology%2520and%2520Infectious%2520Disease%26atitle%3DIn%252Bvitro%252Bactivity%252Bof%252BTNP-2092%252Bagainst%252Bperiprosthetic%252Bjoint%252Binfection%2525E2%252580%252593associated%252Bstaphylococci%26aulast%3DFisher%26aufirst%3DCody%2BR.%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D115040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark S.  Butler</span>, <span class="hlFld-ContribAuthor ">David L.  Paterson</span>. </span><span class="cited-content_cbyCitation_article-title">Antibiotics in the clinical pipeline in October 2019. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Antibiotics</span><span> <strong>2020,</strong> <em>73 </em>
                                    (6)
                                     , 329-364. <a href="https://doi.org/10.1038/s41429-020-0291-8" title="DOI URL">https://doi.org/10.1038/s41429-020-0291-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41429-020-0291-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41429-020-0291-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Antibiotics%26atitle%3DAntibiotics%252Bin%252Bthe%252Bclinical%252Bpipeline%252Bin%252BOctober%252B2019%26aulast%3DButler%26aufirst%3DMark%2BS.%26date%3D2020%26date%3D2020%26volume%3D73%26issue%3D6%26spage%3D329%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matteo  Bassetti</span>, <span class="hlFld-ContribAuthor ">Filippo  Del Puente</span>, <span class="hlFld-ContribAuthor ">Laura  Magnasco</span>, <span class="hlFld-ContribAuthor ">Daniele Roberto  Giacobbe</span>. </span><span class="cited-content_cbyCitation_article-title">Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant
              Staphylococcus aureus
              : advances in phase I and II trials. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (5)
                                     , 495-506. <a href="https://doi.org/10.1080/13543784.2020.1750595" title="DOI URL">https://doi.org/10.1080/13543784.2020.1750595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1750595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1750595%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInnovative%252Btherapies%252Bfor%252Bacute%252Bbacterial%252Bskin%252Band%252Bskin-structure%252Binfections%252B%252528ABSSSI%252529%252Bcaused%252Bby%252Bmethicillin-resistant%252BStaphylococcus%252Baureus%252B%25253A%252Badvances%252Bin%252Bphase%252BI%252Band%252BII%252Btrials%26aulast%3DBassetti%26aufirst%3DMatteo%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D5%26spage%3D495%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhijun  Zhuang</span>, <span class="hlFld-ContribAuthor ">Dawei  Wan</span>, <span class="hlFld-ContribAuthor ">Jun  Ding</span>, <span class="hlFld-ContribAuthor ">Shijie  He</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Yuan</span>, <span class="hlFld-ContribAuthor ">Yu  Lu</span>, <span class="hlFld-ContribAuthor ">Charles  Z. Ding</span>, <span class="hlFld-ContribAuthor ">Anthony Simon  Lynch</span>, <span class="hlFld-ContribAuthor ">Anna  M. Upton</span>, <span class="hlFld-ContribAuthor ">Christopher  B. Cooper</span>, <span class="hlFld-ContribAuthor ">William  A. Denny</span>, <span class="hlFld-ContribAuthor ">Zhenkun  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (10)
                                     , 2431. <a href="https://doi.org/10.3390/molecules25102431" title="DOI URL">https://doi.org/10.3390/molecules25102431</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25102431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25102431%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynergistic%252BActivity%252Bof%252BNitroimidazole-Oxazolidinone%252BConjugates%252Bagainst%252BAnaerobic%252BBacteria%26aulast%3DZhuang%26aufirst%3DZhijun%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D10%26spage%3D2431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Insuasty</span>, <span class="hlFld-ContribAuthor ">Juan  Castillo</span>, <span class="hlFld-ContribAuthor ">Diana  Becerra</span>, <span class="hlFld-ContribAuthor ">Hugo  Rojas</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Abonia</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Biologically Active Molecules through Multicomponent Reactions. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (3)
                                     , 505. <a href="https://doi.org/10.3390/molecules25030505" title="DOI URL">https://doi.org/10.3390/molecules25030505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25030505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25030505%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Bof%252BBiologically%252BActive%252BMolecules%252Bthrough%252BMulticomponent%252BReactions%26aulast%3DInsuasty%26aufirst%3DDaniel%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D3%26spage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Temilolu  Idowu</span>, <span class="hlFld-ContribAuthor ">Gilbert  Arthur</span>, <span class="hlFld-ContribAuthor ">George G.  Zhanel</span>, <span class="hlFld-ContribAuthor ">Frank  Schweizer</span>. </span><span class="cited-content_cbyCitation_article-title">Heterodimeric RifampicinâTobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol inÂ vitro and in a Galleria mellonella inÂ vivo model. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>174 </em>, 16-32. <a href="https://doi.org/10.1016/j.ejmech.2019.04.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterodimeric%252BRifampicin%2525E2%252580%252593Tobramycin%252Bconjugates%252Bbreak%252Bintrinsic%252Bresistance%252Bof%252BPseudomonas%252Baeruginosa%252Bto%252Bdoxycycline%252Band%252Bchloramphenicol%252Bin%2525C2%2525A0vitro%252Band%252Bin%252Ba%252BGalleria%252Bmellonella%252Bin%2525C2%2525A0vivo%252Bmodel%26aulast%3DIdowu%26aufirst%3DTemilolu%26date%3D2019%26volume%3D174%26spage%3D16%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hend A. A.  Ezelarab</span>, <span class="hlFld-ContribAuthor ">Samar H.  Abbas</span>, <span class="hlFld-ContribAuthor ">Heba A.  Hassan</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent updates of fluoroquinolones as antibacterial agents. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2018,</strong> <em>351 </em>
                                    (9)
                                     , 1800141. <a href="https://doi.org/10.1002/ardp.201800141" title="DOI URL">https://doi.org/10.1002/ardp.201800141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201800141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201800141%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DRecent%252Bupdates%252Bof%252Bfluoroquinolones%252Bas%252Bantibacterial%252Bagents%26aulast%3DEzelarab%26aufirst%3DHend%2BA.%2BA.%26date%3D2018%26date%3D2018%26volume%3D351%26issue%3D9%26spage%3D1800141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">4-Quinolone Derivatives and Their Activities Against Gram-negative Pathogens. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2018,</strong> <em>55 </em>
                                    (9)
                                     , 2003-2018. <a href="https://doi.org/10.1002/jhet.3244" title="DOI URL">https://doi.org/10.1002/jhet.3244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3244%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3D4-Quinolone%252BDerivatives%252Band%252BTheir%252BActivities%252BAgainst%252BGram-negative%252BPathogens%26aulast%3DJiang%26aufirst%3DDan%26date%3D2018%26date%3D2018%26volume%3D55%26issue%3D9%26spage%3D2003%26epage%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuan  Gao</span>, <span class="hlFld-ContribAuthor ">Yi-Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Feng  Zhao</span>, <span class="hlFld-ContribAuthor ">Qing-Cheng  Ren</span>, <span class="hlFld-ContribAuthor ">Xiang  Wu</span>, <span class="hlFld-ContribAuthor ">Le  Chang</span>, <span class="hlFld-ContribAuthor ">Feng  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1081-1095. <a href="https://doi.org/10.1016/j.ejmech.2018.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinolone%252Bderivatives%252Band%252Btheir%252Bactivities%252Bagainst%252Bmethicillin-resistant%252BStaphylococcus%252Baureus%252B%252528MRSA%252529%26aulast%3DGao%26aufirst%3DChuan%26date%3D2018%26volume%3D157%26spage%3D1081%26epage%3D1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Gao</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Qing  Miao</span>, <span class="hlFld-ContribAuthor ">Long  Ma</span>, <span class="hlFld-ContribAuthor ">Guangming  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of quinolone-based derivatives and their activities against Escherichia coli. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1223-1248. <a href="https://doi.org/10.1016/j.ejmech.2018.08.095" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.095%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252Bquinolone-based%252Bderivatives%252Band%252Btheir%252Bactivities%252Bagainst%252BEscherichia%252Bcoli%26aulast%3DGao%26aufirst%3DFeng%26date%3D2018%26volume%3D157%26spage%3D1223%26epage%3D1248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amalia  Stefaniu</span>, <span class="hlFld-ContribAuthor ">Lucia  Pintilie</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Descriptors and Properties of Organic Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,<a href="https://doi.org/10.5772/intechopen.72840" title="DOI URL">https://doi.org/10.5772/intechopen.72840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.72840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.72840%26sid%3Dliteratum%253Aachs%26atitle%3DMolecular%252BDescriptors%252Band%252BProperties%252Bof%252BOrganic%252BMolecules%26aulast%3DStefaniu%26aufirst%3DAmalia%26date%3D2018%26date%3D2018%26pub%3DInTech%26atitle%3DSymmetry%252B%252528Group%252BTheory%252529%252Band%252BMathematical%252BTreatment%252Bin%252BChemistry%26aulast%3DAkitsu%26aufirst%3DTakashiro%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gui-Fu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, <span class="hlFld-ContribAuthor ">Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Baofeng  Pan</span>, <span class="hlFld-ContribAuthor ">Ming-Liang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Ciprofloxacin derivatives and their antibacterial activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 599-612. <a href="https://doi.org/10.1016/j.ejmech.2018.01.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCiprofloxacin%252Bderivatives%252Band%252Btheir%252Bantibacterial%252Bactivities%26aulast%3DZhang%26aufirst%3DGui-Fu%26date%3D2018%26volume%3D146%26spage%3D599%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gui-Fu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Baofeng  Pan</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, <span class="hlFld-ContribAuthor ">Lian-Shun  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">4-Quinolone derivatives and their activities against Gram positive pathogens. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 710-723. <a href="https://doi.org/10.1016/j.ejmech.2017.11.082" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.082%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Quinolone%252Bderivatives%252Band%252Btheir%252Bactivities%252Bagainst%252BGram%252Bpositive%252Bpathogens%26aulast%3DZhang%26aufirst%3DGui-Fu%26date%3D2018%26volume%3D143%26spage%3D710%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan-Qiang  Hu</span>, <span class="hlFld-ContribAuthor ">Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi  Xu</span>, <span class="hlFld-ContribAuthor ">Zao-Sheng  Lv</span>, <span class="hlFld-ContribAuthor ">Ming-Liang  Liu</span>, <span class="hlFld-ContribAuthor ">Lian-Shun  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">4-Quinolone hybrids and their antibacterial activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 335-345. <a href="https://doi.org/10.1016/j.ejmech.2017.09.050" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.050%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Quinolone%252Bhybrids%252Band%252Btheir%252Bantibacterial%252Bactivities%26aulast%3DHu%26aufirst%3DYuan-Qiang%26date%3D2017%26volume%3D141%26spage%3D335%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lynn L.  Silver</span>. </span><span class="cited-content_cbyCitation_article-title">The Antibiotic Future. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 31-67. <a href="https://doi.org/10.1007/7355_2017_24" title="DOI URL">https://doi.org/10.1007/7355_2017_24</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_24%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BAntibiotic%252BFuture%26aulast%3DSilver%26aufirst%3DLynn%2BL.%26date%3D2017%26date%3D2017%26spage%3D31%26epage%3D67%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntibacterials%26aulast%3DFisher%26aufirst%3DJed%2BF.%26date%3D2018%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Klahn</span>, <span class="hlFld-ContribAuthor ">M.  BrÃ¶nstrup</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional antimicrobial conjugates and hybrid antimicrobials. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Reports</span><span> <strong>2017,</strong> <em>34 </em>
                                    (7)
                                     , 832-885. <a href="https://doi.org/10.1039/C7NP00006E" title="DOI URL">https://doi.org/10.1039/C7NP00006E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7NP00006E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7NP00006E%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Reports%26atitle%3DBifunctional%252Bantimicrobial%252Bconjugates%252Band%252Bhybrid%252Bantimicrobials%26aulast%3DKlahn%26aufirst%3DP.%26date%3D2017%26date%3D2017%26volume%3D34%26issue%3D7%26spage%3D832%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Proposed enzymatic activation process for cephalosporinâfluoroquinolone hybrid compound <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of oxazolidinoneâfluoroquinolone hybrid compound <b>3</b> (Cadazolid).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biological evaluation strategy for a dual-action antimicrobial program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structural interactions between rifampin and RNA polymerase (4a) and structureâactivity relationships (4b) suggest that the groups attached to the C-3 and C-25 positions of the rifamycin scaffold are pointing to open space and can be explored for attaching a secondary antibiotic motif. Image in (4a) reprinted from  <cite>Cell</cite> (<a href="http://www.sciencedirect.com/science/journal/00928674" class="extLink">http://www.sciencedirect.com/science/journal/00928674</a>), Vol. <em>104</em>, <contrib-group>Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S. A.</contrib-group>, Structural mechanism for rifampicin inhibition of bacterial RNA polymerase, pp 901â912, Copyright <span class="NLM_year">2001</span>, with permission from Elsevier.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Positions on the rifamycin scaffold and strategies that have been utilized for linking a secondary antibiotic group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Quinolone core structures that have been explored as matching partners for rifamycins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of rifampin, quinolizinone <b>4</b>, and dual-acting molecule <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/medium/jm-2016-00485f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dual-Acting Molecule <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00485/20160722/images/large/jm-2016-00485f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00485&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MsCl, Et<sub>3</sub>N, toluene, 0 Â°C, 2 h; (ii) Bu<sub>4</sub>N<sup>+</sup>CN<sup>â</sup>, CH<sub>3</sub>CN, 65 Â°C, 16 h; (iii) Ti(O-<i>i</i>-Pr)<sub>4</sub>, EtMgBr, Et<sub>2</sub>O/THF, â78 Â°C, 20 min; warm to rt, BF<sub>3</sub>Â·Et<sub>2</sub>O, 2 h; (iv) <b>8</b>, THF/AcOH, rt, 1 h, then NaBH(OAc)<sub>3</sub>, rt, overnight, then 37% aq HCHO, 2 h; (v) H<sub>2</sub>, Pd/C, AcOH, 60 psi, rt, 18 h; (vi) <b>11</b>, NaHCO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 5 h; (vii) LiOH, EtOH, 60 Â°C, 1 h; (viii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 1 h; (ix) NaOH, H<sub>2</sub>NâOSO<sub>3</sub>H, 0 Â°C, 1 h; (x) 3-formal rifamycin (<b>14</b>), MeOH/THF, rt, 30 min.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kapadia, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhave, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mont, M. A.</span><span> </span><span class="NLM_article-title">Periprosthetic joint infection</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x"> (</span><span class="NLM_issue">10016</span><span class="NLM_x">) </span> <span class="NLM_fpage">386</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(14)61798-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0140-6736%2814%2961798-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=386-394&issue=10016&author=B.+H.+Kapadiaauthor=R.+A.+Bergauthor=J.+A.+Daleyauthor=J.+Fritzauthor=A.+Bhaveauthor=M.+A.+Mont&title=Periprosthetic+joint+infection&doi=10.1016%2FS0140-6736%2814%2961798-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961798-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961798-0%26sid%3Dliteratum%253Aachs%26aulast%3DKapadia%26aufirst%3DB.%2BH.%26aulast%3DBerg%26aufirst%3DR.%2BA.%26aulast%3DDaley%26aufirst%3DJ.%2BA.%26aulast%3DFritz%26aufirst%3DJ.%26aulast%3DBhave%26aufirst%3DA.%26aulast%3DMont%26aufirst%3DM.%2BA.%26atitle%3DPeriprosthetic%2520joint%2520infection%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26issue%3D10016%26spage%3D386%26epage%3D394%26doi%3D10.1016%2FS0140-6736%2814%2961798-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tande, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R.</span><span> </span><span class="NLM_article-title">Prosthetic joint infection</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">345</span><span class="refDoi">Â DOI: 10.1128/CMR.00111-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FCMR.00111-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=24696437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKnt7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=302-345&issue=2&author=A.+J.+Tandeauthor=R.+Patel&title=Prosthetic+joint+infection&doi=10.1128%2FCMR.00111-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prosthetic joint infection</span></div><div class="casAuthors">Tande, Aaron J.; Patel, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-345, 45 pp.</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Prosthetic joint infection (PJI) is a tremendous burden for individual patients as well as the global health care industry.  While a small minority of joint arthroplasties will be come infected, appropriate recognition and management are crit. to preserve or restore adequate function and prevent excess morbidity.  In this review, we describe the reported risk factors for and clin. manifestations of PJI.  We discuss the pathogenesis of PJI and the numerous microorganisms that can cause this devastating infection.  The recently proposed consensus definitions of PJI and approaches to accurate diagnosis are reviewed in detail.  An overview of the treatment and prevention of this challenging condition is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbRwazF4dKvLVg90H21EOLACvtfcHk0lhULXfeC433hg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKnt7jO&md5=590d06768ca5603d06b443e7d5bc033f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FCMR.00111-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00111-13%26sid%3Dliteratum%253Aachs%26aulast%3DTande%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DR.%26atitle%3DProsthetic%2520joint%2520infection%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2014%26volume%3D27%26issue%3D2%26spage%3D302%26epage%3D345%26doi%3D10.1128%2FCMR.00111-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Osmon, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berbari, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berendt, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lew, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckelberg, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanssen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. R.</span><span> </span><span class="NLM_article-title">Executive summary: Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">10</span><span class="refDoi">Â DOI: 10.1093/cid/cis966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fcid%2Fcis966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23230301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ht1ShtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1-10&issue=1&author=D.+R.+Osmonauthor=E.+F.+Berbariauthor=A.+R.+Berendtauthor=D.+Lewauthor=W.+Zimmerliauthor=J.+M.+Steckelbergauthor=N.+Raoauthor=A.+Hanssenauthor=W.+R.+Wilson&title=Executive+summary%3A+Diagnosis+and+management+of+prosthetic+joint+infection%3A+Clinical+practice+guidelines+by+the+Infectious+Diseases+Society+of+America&doi=10.1093%2Fcid%2Fcis966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America</span></div><div class="casAuthors">Osmon Douglas R; Berbari Elie F; Berendt Anthony R; Lew Daniel; Zimmerli Werner; Steckelberg James M; Rao Nalini; Hanssen Arlen; Wilson Walter R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">These guidelines are intended for use by infectious disease specialists, orthopedists, and other healthcare professionals who care for patients with prosthetic joint infection (PJI).  They include evidence-based and opinion-based recommendations for the diagnosis and management of patients with PJI treated with debridement and retention of the prosthesis, resection arthroplasty with or without subsequent staged reimplantation, 1-stage reimplantation, and amputation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrx6uNmnrFPXO4gDb7JggCfW6udTcc2eYLgZ4bFgQgYLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ht1ShtQ%253D%253D&md5=3d76277fb0168e8dc498613d9a94235b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis966%26sid%3Dliteratum%253Aachs%26aulast%3DOsmon%26aufirst%3DD.%2BR.%26aulast%3DBerbari%26aufirst%3DE.%2BF.%26aulast%3DBerendt%26aufirst%3DA.%2BR.%26aulast%3DLew%26aufirst%3DD.%26aulast%3DZimmerli%26aufirst%3DW.%26aulast%3DSteckelberg%26aufirst%3DJ.%2BM.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DHanssen%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DW.%2BR.%26atitle%3DExecutive%2520summary%253A%2520Diagnosis%2520and%2520management%2520of%2520prosthetic%2520joint%2520infection%253A%2520Clinical%2520practice%2520guidelines%2520by%2520the%2520Infectious%2520Diseases%2520Society%2520of%2520America%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D56%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1093%2Fcid%2Fcis966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McConoughey, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manring, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calhoun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirtliff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoodley, P.</span><span> </span><span class="NLM_article-title">Biofilms in periprosthetic orthopedic infections</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">987</span><span class="NLM_x">â</span> <span class="NLM_lpage">1007</span><span class="refDoi">Â DOI: 10.2217/fmb.14.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2217%2Ffmb.14.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25302955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=987-1007&issue=8&author=S.+J.+McConougheyauthor=R.+Howlinauthor=J.+F.+Grangerauthor=M.+M.+Manringauthor=J.+H.+Calhounauthor=M.+Shirtliffauthor=S.+Kathjuauthor=P.+Stoodley&title=Biofilms+in+periprosthetic+orthopedic+infections&doi=10.2217%2Ffmb.14.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Biofilms in periprosthetic orthopedic infections</span></div><div class="casAuthors">McConoughey, Stephen J.; Howlin, Rob; Granger, Jeff F.; Manring, Maurice M.; Calhoun, Jason H.; Shirtliff, Mark; Kathju, Sandeep; Stoodley, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">987-1007</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  As the no. of total joint arthroplasty and internal fixation procedures continues to rise, the threat of infection following surgery has significant clin. implications.  These infections may have highly morbid consequences to patients, who often endure addnl. surgeries and lengthy exposures to systemic antibiotics, neither of which are guaranteed to resolve the infection.  Of particular concern is the threat of bacterial biofilm development, since biofilm-mediated infections are difficult to diagnose and effective treatments are lacking.  Developing therapeutic strategies have targeted mechanisms of biofilm formation and the means by which these bacteria communicate with each other to take on specialized roles such as persister cells within the biofilm.  In addn., prevention of infection through novel coatings for prostheses and the local delivery of high concns. of antibiotics by absorbable carriers has shown promise in lab. and animal studies.  Biofilm development, esp. in an arthoplasty environment, and future diagnostic and treatment options are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbTZNokcvtrVg90H21EOLACvtfcHk0ljxA82sm1KKqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalurnK&md5=b63598b88747e48d80403d640596ac03</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.64%26sid%3Dliteratum%253Aachs%26aulast%3DMcConoughey%26aufirst%3DS.%2BJ.%26aulast%3DHowlin%26aufirst%3DR.%26aulast%3DGranger%26aufirst%3DJ.%2BF.%26aulast%3DManring%26aufirst%3DM.%2BM.%26aulast%3DCalhoun%26aufirst%3DJ.%2BH.%26aulast%3DShirtliff%26aufirst%3DM.%26aulast%3DKathju%26aufirst%3DS.%26aulast%3DStoodley%26aufirst%3DP.%26atitle%3DBiofilms%2520in%2520periprosthetic%2520orthopedic%2520infections%26jtitle%3DFuture%2520Microbiol.%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D987%26epage%3D1007%26doi%3D10.2217%2Ffmb.14.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gbejuade, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, J. C.</span><span> </span><span class="NLM_article-title">The role of microbial biofilms in prosthetic joint infections</span> <span class="citation_source-journal">Acta Orthop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.3109/17453674.2014.966290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.3109%2F17453674.2014.966290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25238433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2M7jtVOjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=147-158&issue=2&author=H.+O.+Gbejuadeauthor=A.+M.+Loveringauthor=J.+C.+Webb&title=The+role+of+microbial+biofilms+in+prosthetic+joint+infections&doi=10.3109%2F17453674.2014.966290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of microbial biofilms in prosthetic joint infections</span></div><div class="casAuthors">Gbejuade Herbert O; Lovering Andrew M; Webb Jason C</div><div class="citationInfo"><span class="NLM_cas:title">Acta orthopaedica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prosthetic joint infection (PJI) still remains a significant problem.  In line with the forecasted rise in joint replacement procedures, the number of cases of PJI is also anticipated to rise.  The formation of biofilm by causative pathogens is central to the occurrence and the recalcitrance of PJI.  The subject of microbial biofilms is receiving increasing attention, probably as a result of the wide acknowledgement of the ubiquity of biofilms in the natural, industrial, and clinical contexts, as well as the notorious difficulty in eradicating them.  In this review, we discuss the pertinent issues surrounding PJI and the challenges posed by biofilms regarding diagnosis and treatment.  In addition, we discuss novel strategies of prevention and treatment of biofilm-related PJI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsgHQM7ju5cdFxYDaSSP8XfW6udTcc2eYjNHe9ZrV8BLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7jtVOjsg%253D%253D&md5=2f56e64d0e18871b4588b6b080e39fd7</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.3109%2F17453674.2014.966290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17453674.2014.966290%26sid%3Dliteratum%253Aachs%26aulast%3DGbejuade%26aufirst%3DH.%2BO.%26aulast%3DLovering%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520role%2520of%2520microbial%2520biofilms%2520in%2520prosthetic%2520joint%2520infections%26jtitle%3DActa%2520Orthop.%26date%3D2015%26volume%3D86%26issue%3D2%26spage%3D147%26epage%3D158%26doi%3D10.3109%2F17453674.2014.966290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ma, Z.; Morris, T. W.; Combrink, K. D.</span><span> </span><span class="NLM_article-title">Therapeutic opportunities for the treatment of biofilm-associated infections</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Elsevier</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">39</span>, pp  <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">210</span>. DOI: <span class="refDoi">Â DOI: 10.1016/S0065-7743(04)39016-0</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0065-7743%2804%2939016-0" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=197-210&author=Z.+Ma&author=T.+W.+Morris&author=K.+D.+Combrink&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2804%2939016-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-7743%252804%252939016-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DTherapeutic%2520opportunities%2520for%2520the%2520treatment%2520of%2520biofilm-associated%2520infections%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DElsevier%26date%3D2004%26volume%3D39%26spage%3D197%26epage%3D210%26doi%3D10.1016%2FS0065-7743%2804%2939016-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trampuz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis</span> <span class="citation_source-journal">Current infectious disease reports</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">403</span><span class="refDoi">Â DOI: 10.1007/s11908-008-0064-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs11908-008-0064-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=394-403&issue=5&author=A.+Trampuzauthor=W.+Zimmerli&title=Diagnosis+and+treatment+of+implant-associated+septic+arthritis+and+osteomyelitis&doi=10.1007%2Fs11908-008-0064-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2Fs11908-008-0064-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11908-008-0064-1%26sid%3Dliteratum%253Aachs%26aulast%3DTrampuz%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520implant-associated%2520septic%2520arthritis%2520and%2520osteomyelitis%26jtitle%3DCurrent%2520infectious%2520disease%2520reports%26date%3D2008%26volume%3D10%26issue%3D5%26spage%3D394%26epage%3D403%26doi%3D10.1007%2Fs11908-008-0064-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sendi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial treatment concepts for orthopaedic device-related infection</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1176</span><span class="NLM_x">â</span> <span class="NLM_lpage">1184</span><span class="refDoi">Â DOI: 10.1111/1469-0691.12003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1111%2F1469-0691.12003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23046277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1176-1184&issue=12&author=P.+Sendiauthor=W.+Zimmerli&title=Antimicrobial+treatment+concepts+for+orthopaedic+device-related+infection&doi=10.1111%2F1469-0691.12003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial treatment concepts for orthopaedic device-related infection</span></div><div class="casAuthors">Sendi, P.; Zimmerli, W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1184</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Abstract : Successful management of orthopaedic device-related infections requires combined surgical and antimicrobial therapy.  Because of the heterogeneity of clin. situations, controlled trials are lacking.  Although rational concepts for surgical treatment have been published, many aspects of antimicrobial therapy are still not well documented.  In this review, some of these knowledge gaps are discussed, and rational arguments for initial parenteral treatment are presented.  In addn., the interpretation of data regarding bone penetration is discussed.  Whereas rifampin is now a std. combination partner in the treatment of staphylococcal infections, its role against other microorganisms is still unclear.  Finally, in view of the increasing prevalence of methicillin-resistant staphylococci and their decreasing susceptibility to vancomycin, data are provided on linezolid and daptomycin, which can potentially be used in bone and joint infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvPGoeUN1-3bVg90H21EOLACvtfcHk0lg--3PheKBjGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru7nJ&md5=4fedaf0f1bd42d2ae0e5d26df896ece5</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1111%2F1469-0691.12003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1469-0691.12003%26sid%3Dliteratum%253Aachs%26aulast%3DSendi%26aufirst%3DP.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520treatment%2520concepts%2520for%2520orthopaedic%2520device-related%2520infection%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D1176%26epage%3D1184%26doi%3D10.1111%2F1469-0691.12003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Holmberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ThÃ³rhallsdÃ³ttir, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">W-Dahl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StefÃ¡nsdÃ³ttir, A.</span><span> </span><span class="NLM_article-title">75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections</span> <span class="citation_source-journal">Acta Orthop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">457</span><span class="NLM_x">â</span> <span class="NLM_lpage">462</span><span class="refDoi">Â DOI: 10.3109/17453674.2015.1026756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.3109%2F17453674.2015.1026756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25753311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2MnitlGrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=457-462&issue=4&author=A.+Holmbergauthor=V.+G.+Th%C3%B3rhallsd%C3%B3ttirauthor=O.+Robertssonauthor=A.+W-Dahlauthor=A.+Stef%C3%A1nsd%C3%B3ttir&title=75%25+success+rate+after+open+debridement%2C+exchange+of+tibial+insert%2C+and+antibiotics+in+knee+prosthetic+joint+infections&doi=10.3109%2F17453674.2015.1026756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections</span></div><div class="casAuthors">Holmberg Anna; Thorhallsdottir Valdis Gudrun; Robertsson Otto; W-Dahl Annette; Stefansdottir Anna</div><div class="citationInfo"><span class="NLM_cas:title">Acta orthopaedica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Prosthetic joint infection (PJI) is a leading cause of early revision after total knee arthroplasty (TKA).  Open debridement with exchange of tibial insert allows treatment of infection with retention of fixed components.  We investigated the success rate of this procedure in the treatment of knee PJIs in a nationwide material, and determined whether the results were affected by microbiology, antibiotic treatment, or timing of debridement.  PATIENTS AND METHODS:  145 primary TKAs revised for the first time, due to infection, with debridement and exchange of the tibial insert were identified in the Swedish Knee Arthroplasty Register (SKAR).  Staphylococcus aureus was the most common pathogen (37%) followed by coagulase-negative staphylococci (CNS) (23%).  Failure was defined as death before the end of antibiotic treatment, revision of major components due to infection, life-long antibiotic treatment, or chronic infection.  RESULTS:  The overall healing rate was 75%.  The type of infecting pathogen did not statistically significantly affect outcome.  Staphylococcal infections treated without a combination of antibiotics including rifampin had a higher failure rate than those treated with rifampin (RR = 4, 95% CI: 2-10).  In the 16 cases with more than 3 weeks of symptoms before treatment, the healing rate was 62%, as compared to 77% in the other cases (p = 0.2).  The few patients with a revision model of prosthesis at primary operation had a high failure rate (5 of 8).  INTERPRETATION:  Good results can be achieved by open debridement with exchange of tibial insert.  It is important to use an antibiotic combination including rifampin in staphylococcal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXu_TmDUNwCXqj_yg7twvpfW6udTcc2eZ-cgkjA1eIjLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnitlGrtA%253D%253D&md5=f70ce216c274e0fddebcc49cb03e6fa2</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.3109%2F17453674.2015.1026756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17453674.2015.1026756%26sid%3Dliteratum%253Aachs%26aulast%3DHolmberg%26aufirst%3DA.%26aulast%3DTh%25C3%25B3rhallsd%25C3%25B3ttir%26aufirst%3DV.%2BG.%26aulast%3DRobertsson%26aufirst%3DO.%26aulast%3DW-Dahl%26aufirst%3DA.%26aulast%3DStef%25C3%25A1nsd%25C3%25B3ttir%26aufirst%3DA.%26atitle%3D75%2525%2520success%2520rate%2520after%2520open%2520debridement%252C%2520exchange%2520of%2520tibial%2520insert%252C%2520and%2520antibiotics%2520in%2520knee%2520prosthetic%2520joint%2520infections%26jtitle%3DActa%2520Orthop.%26date%3D2015%26volume%3D86%26issue%3D4%26spage%3D457%26epage%3D462%26doi%3D10.3109%2F17453674.2015.1026756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sensi, P.</span><span> </span><span class="NLM_article-title">History of the development of rifampin</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S402</span><span class="NLM_x">â</span> <span class="NLM_lpage">S406</span><span class="refDoi">Â DOI: 10.1093/clinids/5.Supplement_3.S402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fclinids%2F5.Supplement_3.S402" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1983&pages=S402-S406&issue=Suppl.+3&author=P.+Sensi&title=History+of+the+development+of+rifampin&doi=10.1093%2Fclinids%2F5.Supplement_3.S402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F5.Supplement_3.S402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F5.Supplement_3.S402%26sid%3Dliteratum%253Aachs%26aulast%3DSensi%26aufirst%3DP.%26atitle%3DHistory%2520of%2520the%2520development%2520of%2520rifampin%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1983%26volume%3D5%26issue%3DSuppl.%25203%26spage%3DS402%26epage%3DS406%26doi%3D10.1093%2Fclinids%2F5.Supplement_3.S402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ma, Z.; Ginsberg, A. M.; Spigelman, M.</span><span> </span><span class="NLM_article-title">Antimycobacterium agents</span>. In  <span class="citation_source-book">Comprehensive Medicinal Chemistry II</span>; <span class="NLM_contrib-group">Triggle, J. B. T. J.</span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Volume  <span class="NLM_volume">7</span>, Chapter 7.24, pp  <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">730</span>, DOI: <span class="refDoi">Â DOI: 10.1016/B0-08-045044-X/00224-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FB0-08-045044-X%2F00224-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=699-730&author=Z.+Ma&author=A.+M.+Ginsberg&author=M.+Spigelmanauthor=J.+B.+T.+J.+Triggle&title=Comprehensive+Medicinal+Chemistry+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FB0-08-045044-X%2F00224-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB0-08-045044-X%252F00224-8%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DAntimycobacterium%2520agents%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520II%26aulast%3DTriggle%26aufirst%3DJ.%2BB.%2BT.%2BJ.%26pub%3DElsevier%26date%3D2007%26volume%3D7%26spage%3D699%26epage%3D730%26doi%3D10.1016%2FB0-08-045044-X%2F00224-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">DuPont, H. L.</span><span> </span><span class="NLM_article-title">Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1124</span><span class="refDoi">Â DOI: 10.1016/j.mayocp.2015.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.mayocp.2015.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26162610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOmtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=1116-1124&issue=8&author=H.+L.+DuPont&title=Therapeutic+effects+and+mechanisms+of+action+of+rifaximin+in+gastrointestinal+diseases&doi=10.1016%2Fj.mayocp.2015.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases</span></div><div class="casAuthors">DuPont, Herbert L.</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1116-1124</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Emerging preclin. and clinic evidence described herein suggests that the mechanism of action of rifaximin is not restricted to direct antibacterial effects within the gastrointestinal tract.  Data from this study were derived from general and clin. trial-specific PubMed searches of English-language articles on rifaximin available through Dec. 3, 2014.  Search terms included rifaximin alone and in combination (using the Boolean operation "AND") with travelers' diarrhea, hepatic encephalopathy, liver cirrhosis, irritable bowel syndrome, inflammatory bowel disease, and Crohn's disease.  Rifaximin appears to reduce bacterial virulence and pathogenicity by inhibiting bacterial translocation across the gastrointestinal epithelial lining.  Rifaximin was shown to decrease bacterial adherence to epithelial cells and subsequent internalization in a bacteria- and cell type-specific manner, without an alteration in bacterial counts, but with a down-regulation in epithelial proinflammatory cytokine expression.  Rifaximin also appears to modulate gut-immune signaling.  In animal models of inflammatory bowel disease, rifaximin produced therapeutic effects by activating the pregnane X receptor and thereby reducing levels of the proinflammatory transcription factor nuclear factor ÎºB.  Therefore, for a given disease state, rifaximin may act through several mechanisms of action to exert its therapeutic effects.  Clin., rifaximin 600 mg/d significantly reduced symptoms of travelers' diarrhea (eg, time to last unformed stool vs. placebo [32.0 h vs. 65.5 h, resp.; P=.001]).  For the prevention of hepatic encephalopathy recurrence, data indicate that treating 4 patients with rifaximin 1100 mg/d for 6 mo would prevent 1 episode of hepatic encephalopathy.  For diarrhea-predominant irritable bowel syndrome, a significantly greater percentage (40.7%) of patients treated with rifaximin 1650 mg/d for 2 wk experienced adequate global irritable bowel syndrome symptom relief vs. placebo (31.7%; P<.001).  Rifaximin may be best described as a gut microenvironment modulator with cytoprotection properties, and further studies are needed to det. whether these putative mechanisms of action play a direct role in clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2XC24xDEfLrVg90H21EOLACvtfcHk0lhkmngCSRUzeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOmtb8%253D&md5=d204c4a0767b0bb5e47b395e11b837a1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2015.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2015.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DDuPont%26aufirst%3DH.%2BL.%26atitle%3DTherapeutic%2520effects%2520and%2520mechanisms%2520of%2520action%2520of%2520rifaximin%2520in%2520gastrointestinal%2520diseases%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2015%26volume%3D90%26issue%3D8%26spage%3D1116%26epage%3D1124%26doi%3D10.1016%2Fj.mayocp.2015.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Campbell, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korzheva, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustaev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darst, S. A.</span><span> </span><span class="NLM_article-title">Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">â</span> <span class="NLM_lpage">912</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(01)00286-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0092-8674%2801%2900286-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=11290327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVyis7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=901-912&issue=6&author=E.+A.+Campbellauthor=N.+Korzhevaauthor=A.+Mustaevauthor=K.+Murakamiauthor=S.+Nairauthor=A.+Goldfarbauthor=S.+A.+Darst&title=Structural+mechanism+for+rifampicin+inhibition+of+bacterial+RNA+polymerase&doi=10.1016%2FS0092-8674%2801%2900286-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</span></div><div class="casAuthors">Campbell, Elizabeth A.; Korzheva, Nataliya; Mustaev, Arkady; Murakami, Katsuhiko; Nair, Satish; Goldfarb, Alex; Darst, Seth A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">901-912</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP).  We detd. the crystal structure of Thermus aquaticus core RNAP complexed with Rif.  The inhibitor binds in a pocket of the RNAP Î² subunit deep within the DNA/RNA channel, but more than 12 Ã away from the active site.  The structure, combined with biochem. results, explains the effects of Rif on RNAP function and indicates that the inhibitor acts by directly blocking the path of the elongating RNA when the transcript becomes 2 to 3 nt in length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCqXDvYkIB7Vg90H21EOLACvtfcHk0lhkmngCSRUzeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVyis7s%253D&md5=e64b9de4f4f6f832d481608b1324b48f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2801%2900286-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252801%252900286-0%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DE.%2BA.%26aulast%3DKorzheva%26aufirst%3DN.%26aulast%3DMustaev%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DA.%26aulast%3DDarst%26aufirst%3DS.%2BA.%26atitle%3DStructural%2520mechanism%2520for%2520rifampicin%2520inhibition%2520of%2520bacterial%2520RNA%2520polymerase%26jtitle%3DCell%26date%3D2001%26volume%3D104%26issue%3D6%26spage%3D901%26epage%3D912%26doi%3D10.1016%2FS0092-8674%2801%2900286-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goldstein, B. P.</span><span> </span><span class="NLM_article-title">Resistance to rifampicin: a review</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">625</span><span class="NLM_x">â</span> <span class="NLM_lpage">630</span><span class="refDoi">Â DOI: 10.1038/ja.2014.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1038%2Fja.2014.107" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=625-630&issue=9&author=B.+P.+Goldstein&title=Resistance+to+rifampicin%3A+a+review&doi=10.1038%2Fja.2014.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1038%2Fja.2014.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2014.107%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DB.%2BP.%26atitle%3DResistance%2520to%2520rifampicin%253A%2520a%2520review%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D9%26spage%3D625%26epage%3D630%26doi%3D10.1038%2Fja.2014.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mariam, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengistu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffner, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, D. I.</span><span> </span><span class="NLM_article-title">Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1289</span><span class="NLM_x">â</span> <span class="NLM_lpage">1294</span><span class="refDoi">Â DOI: 10.1128/AAC.48.4.1289-1294.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.48.4.1289-1294.2004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=1289-1294&issue=4&author=D.+H.+Mariamauthor=Y.+Mengistuauthor=S.+E.+Hoffnerauthor=D.+I.+Andersson&title=Effect+of+rpoB+mutations+conferring+rifampin+resistance+on+fitness+of+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.48.4.1289-1294.2004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.4.1289-1294.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.4.1289-1294.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMariam%26aufirst%3DD.%2BH.%26aulast%3DMengistu%26aufirst%3DY.%26aulast%3DHoffner%26aufirst%3DS.%2BE.%26aulast%3DAndersson%26aufirst%3DD.%2BI.%26atitle%3DEffect%2520of%2520rpoB%2520mutations%2520conferring%2520rifampin%2520resistance%2520on%2520fitness%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D4%26spage%3D1289%26epage%3D1294%26doi%3D10.1128%2FAAC.48.4.1289-1294.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Koch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizrahi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. F.</span><span> </span><span class="NLM_article-title">The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?</span> <span class="citation_source-journal">Emerging Microbes Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e17</span><span class="refDoi">Â DOI: 10.1038/emi.2014.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1038%2Femi.2014.17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e17&issue=3&author=A.+Kochauthor=V.+Mizrahiauthor=D.+F.+Warner&title=The+impact+of+drug+resistance+on+Mycobacterium+tuberculosis+physiology%3A+what+can+we+learn+from+rifampicin%3F&doi=10.1038%2Femi.2014.17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Femi.2014.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femi.2014.17%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DThe%2520impact%2520of%2520drug%2520resistance%2520on%2520Mycobacterium%2520tuberculosis%2520physiology%253A%2520what%2520can%2520we%2520learn%2520from%2520rifampicin%253F%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2014%26volume%3D3%26issue%3D3%26spage%3De17%26doi%3D10.1038%2Femi.2014.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Al-Omari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrales-Medina, V. F.</span><span> </span><span class="NLM_article-title">Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review</span> <span class="citation_source-journal">BMC Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="refDoi">Â DOI: 10.1186/1471-2334-14-140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1186%2F1471-2334-14-140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=24624933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yms7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=140&author=A.+Al-Omariauthor=D.+W.+Cameronauthor=C.+Leeauthor=V.+F.+Corrales-Medina&title=Oral+antibiotic+therapy+for+the+treatment+of+infective+endocarditis%3A+a+systematic+review&doi=10.1186%2F1471-2334-14-140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review</span></div><div class="casAuthors">Al-Omari, Awad; Cameron, D. William; Lee, Craig; Corrales-Medina, Vicente F.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Infectious Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140/1-140/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">BIDMBJ</span>;
        ISSN:<span class="NLM_cas:issn">1471-2334</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.  Methods: We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE.  Results: Seven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates between 77% and 100%.  Two other observational studies using aureomycin or sulfonamide, however, had failure rates >75%.  One clin. trial comparing oral amoxicillin vs. i.v. ceftriaxone for streptococcal IE reported 100% cure in both arms but its reporting had serious methodol. limitations.  One small clin. trial (n = 85) comparing oral ciprofloxacin and rifampin vs. conventional i.v. antibiotic therapy for uncomplicated right-sided S. aureus IE in i.v. drug users (IVDUs) reported cure rates of 89% and 90% in each arm, resp. (P = 0.9); however, drug toxicities were more common in the latter group (62% vs. 3%; P <0.01).  Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s) and assessment of outcomes.  Conclusion: Reported cure rates for IE treated with oral antibiotic regimens vary widely.  The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clin. trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWGe_5XsAZ7Vg90H21EOLACvtfcHk0lg7QsTwHuSBYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yms7zO&md5=7400e8e577e12c4c47b0744454db00e4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1186%2F1471-2334-14-140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2334-14-140%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Omari%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCorrales-Medina%26aufirst%3DV.%2BF.%26atitle%3DOral%2520antibiotic%2520therapy%2520for%2520the%2520treatment%2520of%2520infective%2520endocarditis%253A%2520a%2520systematic%2520review%26jtitle%3DBMC%2520Infect.%2520Dis.%26date%3D2014%26volume%3D14%26spage%3D140%26doi%3D10.1186%2F1471-2334-14-140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Coiffier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arvieux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guggenbuhl, P.</span><span> </span><span class="NLM_article-title">Optimizing combination rifampin therapy for staphylococcal osteoarticular infections</span> <span class="citation_source-journal">Jt., Bone, Spine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><span class="refDoi">Â DOI: 10.1016/j.jbspin.2012.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.jbspin.2012.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=23332140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFCksQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2013&pages=11-17&issue=1&author=G.+Coiffierauthor=J.-D.+Albertauthor=C.+Arvieuxauthor=P.+Guggenbuhl&title=Optimizing+combination+rifampin+therapy+for+staphylococcal+osteoarticular+infections&doi=10.1016%2Fj.jbspin.2012.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing combination rifampin therapy for staphylococcal osteoarticular infections</span></div><div class="casAuthors">Coiffier, Guillaume; Albert, Jean-David; Arvieux, Cedric; Guggenbuhl, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Joint, Bone, Spine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">JBSPFA</span>;
        ISSN:<span class="NLM_cas:issn">1297-319X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Staphylococcus spp. causes more than half of all osteoarticular infections of native structures or implanted material.  The ability of Staphylococcus spp. to persist within infected bone tissue and to produce a bacterial biofilm, most notably in infections of implanted material, can lead to treatment failures and microbiol. relapses.  Rifampin is a cornerstone of the treatment of staphylococcal osteoarticular infections, particularly those of implanted material.  Rifampin is a bactericidal antibiotic that diffuses very well within bone tissue and bacterial biofilms.  The mechanism of action is inhibition of bacterial DNA transcription to mRNA independently from bacterial division, which results in activity against even dormant Staphylococcus spp. organisms.  However, the high risk of emergence of rifampin-resistant mutants requires the concomitant administration of another antibiotic.  Several antibiotics are recommended in the French guidelines issued by the French-Speaking Society for Infectious Diseases (Societe de Pathologie Infectieuse de Langue FranÂ¸caise [SPILF]).  Here, we discuss the results from in vitro, animal, and clin. studies that explain the advantages and drawbacks of each antibiotic used with rifampin to treat osteoarticular infections due to Staphylococcus spp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqepuNBbP5jfbVg90H21EOLACvtfcHk0liSPjQGuxZp0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFCksQ%253D%253D&md5=f37d7f93a8a07ac54163f5e12ab55241</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.jbspin.2012.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbspin.2012.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DCoiffier%26aufirst%3DG.%26aulast%3DAlbert%26aufirst%3DJ.-D.%26aulast%3DArvieux%26aufirst%3DC.%26aulast%3DGuggenbuhl%26aufirst%3DP.%26atitle%3DOptimizing%2520combination%2520rifampin%2520therapy%2520for%2520staphylococcal%2520osteoarticular%2520infections%26jtitle%3DJt.%252C%2520Bone%252C%2520Spine%26date%3D2013%26volume%3D80%26issue%3D1%26spage%3D11%26epage%3D17%26doi%3D10.1016%2Fj.jbspin.2012.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Forrest, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span> </span><span class="NLM_article-title">Rifampin combination therapy for nonmycobacterial infections</span> <span class="citation_source-journal">Clin Microbiol Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">14</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span><span class="refDoi">Â DOI: 10.1128/CMR.00034-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FCMR.00034-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=20065324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1SktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=14-34&issue=1&author=G.+N.+Forrestauthor=K.+Tamura&title=Rifampin+combination+therapy+for+nonmycobacterial+infections&doi=10.1128%2FCMR.00034-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Rifampin combination therapy for nonmycobacterial infections</span></div><div class="casAuthors">Forrest, Graeme N.; Tamura, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-34</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  The increasing emergence of antimicrobial-resistant organisms, esp. methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy.  The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clin. studies.  Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations.  A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed.  The clin. data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-neg. staphylococci.  Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clin. or exptl.  Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections.  Lastly, an assessment of the risk-benefits is needed before the addn. of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOC5b2NQgkNrVg90H21EOLACvtfcHk0liSPjQGuxZp0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1SktLg%253D&md5=bc52c4baff11b1f7a16c6eee5883c8b3</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1128%2FCMR.00034-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00034-09%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DG.%2BN.%26aulast%3DTamura%26aufirst%3DK.%26atitle%3DRifampin%2520combination%2520therapy%2520for%2520nonmycobacterial%2520infections%26jtitle%3DClin%2520Microbiol%2520Rev.%26date%3D2010%26volume%3D23%26issue%3D1%26spage%3D14%26epage%3D34%26doi%3D10.1128%2FCMR.00034-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sanchez, C. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiels, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tennent, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenke, J. C.</span><span> </span><span class="NLM_article-title">Rifamycin derivatives are effective against staphylococcal biofilms in vitro and elutable from PMMA</span> <span class="citation_source-journal">Clin. Orthop. Relat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">473</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2874</span><span class="NLM_x">â</span> <span class="NLM_lpage">2884</span><span class="refDoi">Â DOI: 10.1007/s11999-015-4300-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs11999-015-4300-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=25896136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjmtlajtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2015&pages=2874-2884&issue=9&author=C.+J.+Sanchezauthor=S.+M.+Shielsauthor=D.+J.+Tennentauthor=S.+K.+Hardyauthor=C.+K.+Murrayauthor=J.+C.+Wenke&title=Rifamycin+derivatives+are+effective+against+staphylococcal+biofilms+in+vitro+and+elutable+from+PMMA&doi=10.1007%2Fs11999-015-4300-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA</span></div><div class="casAuthors">Sanchez Carlos J Jr; Shiels Stefanie M; Tennent David J; Hardy Sharanda K; Murray Clinton K; Wenke Joseph C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical orthopaedics and related research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">473</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2874-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Local antimicrobial delivery through polymethylmethacrylate beads (PMMA), commonly vancomycin, is used for the treatment of contaminated open fractures but has limited activity against Staphylococcus aureus biofilms, which occur commonly in such fractures.  Rifamycins have activity against biofilms and are an effective treatment for osteoarticular infections involving staphylococcal biofilms, but there are limited studies evaluating the activity of rifamycin derivatives, other than rifampin, against biofilms of S. aureus and evaluating incorporation of these drugs into PMMA for treatment of contaminated open fractures.  QUESTIONS/PURPOSES:  (1) Are rifamycin derivatives effective against established biofilms of clinical isolates of S. aureus? (2) Can PMMA be used as a carrier for rifamycin derivatives?  METHODS:  Biofilms were developed and evaluated for susceptibility to a panel of antimicrobials in vitro using the minimum biofilm eradication concentration high-throughput model.  Susceptibility was assessed by measuring bacterial recovery at 6 and 24 hours after antimicrobial treatment.  Activity of rifamycin derivatives against intracellular bacteria was also evaluated using a gentamicin protection assay.  Evaluation of PMMA as a carrier for rifampin and rifamycin derivatives was determined by assessing the curing time subsequent to loading of rifamycins and characterizing the release kinetics of rifamycins at daily intervals for 14 days from PMMA by performing bioassays.  RESULTS:  Rifamycin derivatives between 1 and 8 Î¼g/mL reduced bacteria within biofilms 5- to 9-logs and prevented bacterial recovery up to 24 hours post-treatment, indicating near to complete eradication of biofilms.  Rifamycin derivatives at 32 Î¼g/mL had activity against intracellular staphylococci, significantly reducing the number of internalized bacteria with limited effects on osteoblast viability.  Rifampin was the only rifamycin observed to have a suitable release profile from PMMA, releasing 49% of the total antibiotic and maintaining a sustained released profile up to 14 days at a mean 28 Â± 6 Î¼g/mL.  CONCLUSIONS:  Rifampin can be incorporated into PMMA and eluted at concentrations effective against biofilms and intracellular staphylococci.  CLINICAL RELEVANCE:  Our in vitro findings suggest that local delivery of rifampin may be an effective strategy for the prevention and/or treatment of open fractures where S. aureus biofilms might develop.  Clinical studies are needed to characterize what role this approach might have in the prevention and treatment of infections involving biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCIsTiAiYudkGy1nwu7K2mfW6udTcc2eZR6pB5ZGrFHbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjmtlajtw%253D%253D&md5=4cf2c744374c8eb2545bf6e22128878f</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2Fs11999-015-4300-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11999-015-4300-3%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%2BJ.%26aulast%3DShiels%26aufirst%3DS.%2BM.%26aulast%3DTennent%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DC.%2BK.%26aulast%3DWenke%26aufirst%3DJ.%2BC.%26atitle%3DRifamycin%2520derivatives%2520are%2520effective%2520against%2520staphylococcal%2520biofilms%2520in%2520vitro%2520and%2520elutable%2520from%2520PMMA%26jtitle%3DClin.%2520Orthop.%2520Relat.%2520Res.%26date%3D2015%26volume%3D473%26issue%3D9%26spage%3D2874%26epage%3D2884%26doi%3D10.1007%2Fs11999-015-4300-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hall Snyder, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidaillac, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRoberts, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, M. J.</span><span> </span><span class="NLM_article-title">Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK/PD model of bacterial biofilm</span> <span class="citation_source-journal">Infect. Dis. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">65</span><span class="refDoi">Â DOI: 10.1007/s40121-014-0055-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1007%2Fs40121-014-0055-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26362295" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=51-65&issue=1&author=A.+D.+Hall+Snyderauthor=C.+Vidaillacauthor=W.+Roseauthor=J.+P.+McRobertsauthor=M.+J.+Rybak&title=Evaluation+of+high-dose+daptomycin+versus+vancomycin+alone+or+combined+with+clarithromycin+or+rifampin+against+Staphylococcus+aureus+and+S.+epidermidis+in+a+novel+in+vitro+PK%2FPD+model+of+bacterial+biofilm&doi=10.1007%2Fs40121-014-0055-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1007%2Fs40121-014-0055-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40121-014-0055-5%26sid%3Dliteratum%253Aachs%26aulast%3DHall%2BSnyder%26aufirst%3DA.%2BD.%26aulast%3DVidaillac%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DW.%26aulast%3DMcRoberts%26aufirst%3DJ.%2BP.%26aulast%3DRybak%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520high-dose%2520daptomycin%2520versus%2520vancomycin%2520alone%2520or%2520combined%2520with%2520clarithromycin%2520or%2520rifampin%2520against%2520Staphylococcus%2520aureus%2520and%2520S.%2520epidermidis%2520in%2520a%2520novel%2520in%2520vitro%2520PK%252FPD%2520model%2520of%2520bacterial%2520biofilm%26jtitle%3DInfect.%2520Dis.%2520Ther.%26date%3D2015%26volume%3D4%26issue%3D1%26spage%3D51%26epage%3D65%26doi%3D10.1007%2Fs40121-014-0055-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mihailescu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furustrand Tafin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvec, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betrisey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trampuz, A.</span><span> </span><span class="NLM_article-title">High activity of fosfomycin and rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2547</span><span class="NLM_x">â</span> <span class="NLM_lpage">2553</span><span class="refDoi">Â DOI: 10.1128/AAC.02420-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.02420-12" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=2547-2553&issue=5&author=R.+Mihailescuauthor=U.+Furustrand+Tafinauthor=S.+Corvecauthor=A.+Olivaauthor=B.+Betriseyauthor=O.+Borensauthor=A.+Trampuz&title=High+activity+of+fosfomycin+and+rifampin+against+methicillin-resistant+staphylococcus+aureus+biofilm+in+vitro+and+in+an+experimental+foreign-body+infection+model&doi=10.1128%2FAAC.02420-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1128%2FAAC.02420-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02420-12%26sid%3Dliteratum%253Aachs%26aulast%3DMihailescu%26aufirst%3DR.%26aulast%3DFurustrand%2BTafin%26aufirst%3DU.%26aulast%3DCorvec%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DBetrisey%26aufirst%3DB.%26aulast%3DBorens%26aufirst%3DO.%26aulast%3DTrampuz%26aufirst%3DA.%26atitle%3DHigh%2520activity%2520of%2520fosfomycin%2520and%2520rifampin%2520against%2520methicillin-resistant%2520staphylococcus%2520aureus%2520biofilm%2520in%2520vitro%2520and%2520in%2520an%2520experimental%2520foreign-body%2520infection%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D5%26spage%3D2547%26epage%3D2553%26doi%3D10.1128%2FAAC.02420-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Minassian, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osmon, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berendt, A. R.</span><span> </span><span class="NLM_article-title">Clinical guidelines in the management of prosthetic joint infection</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">i29</span><span class="NLM_x">â</span> <span class="NLM_lpage">i35</span><span class="refDoi">Â DOI: 10.1093/jac/dku253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fjac%2Fdku253" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=i29-i35&issue=Suppl.+1&author=A.+M.+Minassianauthor=D.+R.+Osmonauthor=A.+R.+Berendt&title=Clinical+guidelines+in+the+management+of+prosthetic+joint+infection&doi=10.1093%2Fjac%2Fdku253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdku253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdku253%26sid%3Dliteratum%253Aachs%26aulast%3DMinassian%26aufirst%3DA.%2BM.%26aulast%3DOsmon%26aufirst%3DD.%2BR.%26aulast%3DBerendt%26aufirst%3DA.%2BR.%26atitle%3DClinical%2520guidelines%2520in%2520the%2520management%2520of%2520prosthetic%2520joint%2520infection%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26issue%3DSuppl.%25201%26spage%3Di29%26epage%3Di35%26doi%3D10.1093%2Fjac%2Fdku253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Widmer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaechter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsner, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1251</span><span class="NLM_x">â</span> <span class="NLM_lpage">1253</span><span class="refDoi">Â DOI: 10.1093/clinids/14.6.1251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fclinids%2F14.6.1251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1623081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A280%3ADyaK38zit1yhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1992&pages=1251-1253&issue=6&author=A.+F.+Widmerauthor=A.+Gaechterauthor=P.+E.+Ochsnerauthor=W.+Zimmerli&title=Antimicrobial+treatment+of+orthopedic+implant-related+infections+with+rifampin+combinations&doi=10.1093%2Fclinids%2F14.6.1251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations</span></div><div class="casAuthors">Widmer A F; Gaechter A; Ochsner P E; Zimmerli W</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-3</span>
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    </div><div class="casAbstract">The purpose of this prospective clinical study is to evaluate the role of combination chemotherapy with rifampin in the treatment of orthopedic device-related infections in which the implant could not be removed.  Eleven patients with orthopedic implant-related infections due to staphylococci or streptococci were treated with the implant in situ.  Each antimicrobial regimen included rifampin in combination with a beta-lactam antibiotic or ciprofloxacin.  The median duration of treatment with rifampin was 86 days (range, 15-336 days) with a median follow-up of greater than 24 months after cessation of therapy.  Treatment was successful for 82% of patients.  Failures were associated with documented inappropriate treatment.  These preliminary clinical data are supported by data from in vitro studies and animal experiments.  Combination therapy with rifampin, in particular rifampin and a quinolone, should be considered for patients with orthopedic implant-related infections if the implant cannot be removed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSS5VLZ8K7rPIW7hznt0zpfW6udTcc2eZoW29GsTsnrrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zit1yhsQ%253D%253D&md5=956e60b6bedafffc179d3b790a446616</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1093%2Fclinids%2F14.6.1251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fclinids%252F14.6.1251%26sid%3Dliteratum%253Aachs%26aulast%3DWidmer%26aufirst%3DA.%2BF.%26aulast%3DGaechter%26aufirst%3DA.%26aulast%3DOchsner%26aufirst%3DP.%2BE.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520treatment%2520of%2520orthopedic%2520implant-related%2520infections%2520with%2520rifampin%2520combinations%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1992%26volume%3D14%26issue%3D6%26spage%3D1251%26epage%3D1253%26doi%3D10.1093%2Fclinids%2F14.6.1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zimmerli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frei, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsner, P. E.</span><span> </span><span class="NLM_article-title">Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">1537</span><span class="NLM_x">â</span> <span class="NLM_lpage">1541</span><span class="refDoi">Â DOI: 10.1001/jama.279.19.1537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1001%2Fjama.279.19.1537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=9605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1ygurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=1537-1541&issue=19&author=W.+Zimmerliauthor=A.+F.+Widmerauthor=M.+Blatterauthor=R.+R.+Freiauthor=P.+E.+Ochsner&title=Role+of+rifampin+for+treatment+of+orthopedic+implant-related+staphylococcal+infections%3A+A+randomized+controlled+trial.+Foreign-Body+Infection+%28FBI%29+Study+Group&doi=10.1001%2Fjama.279.19.1537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial</span></div><div class="casAuthors">Zimmerli, Werner; Widmer, Andreas F.; Blatter, Marianne; Frei, R.; Ochsner, Peter E.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1537-1541</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The clin. efficacy of a rifampin combination with ciprofloxacin was investigated in patients with staphylococcal infections assocd. with stable orthopedic devices.  Patients were allocated to receive ciprofloxacin-rifampin or a ciprofloxacin-placebo combination.  The cure rate was 12 (100%) of 12 in the ciprofloxacin-rifampin group compared with 7 (58%) of 12 in the ciprofloxacin-placebo group.  The results showed that among patients with stable implants, short duration of infection, and initial debridement, those patients able to tolerate long-term (3-6-mo) therapy with rifampin-ciprofloxacin experienced cure of the infection without removal of the implant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvI7iFfKEE3bVg90H21EOLACvtfcHk0liZlOOXbil5yQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1ygurk%253D&md5=37b0737e3d9a23dfe1e95c0119f0e671</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1001%2Fjama.279.19.1537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.279.19.1537%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerli%26aufirst%3DW.%26aulast%3DWidmer%26aufirst%3DA.%2BF.%26aulast%3DBlatter%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DR.%2BR.%26aulast%3DOchsner%26aufirst%3DP.%2BE.%26atitle%3DRole%2520of%2520rifampin%2520for%2520treatment%2520of%2520orthopedic%2520implant-related%2520staphylococcal%2520infections%253A%2520A%2520randomized%2520controlled%2520trial.%2520Foreign-Body%2520Infection%2520%2528FBI%2529%2520Study%2520Group%26jtitle%3DJAMA%26date%3D1998%26volume%3D279%26issue%3D19%26spage%3D1537%26epage%3D1541%26doi%3D10.1001%2Fjama.279.19.1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Trampuz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, W.</span><span> </span><span class="NLM_article-title">Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1105</span><span class="refDoi">Â DOI: 10.2165/00003495-200666080-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2165%2F00003495-200666080-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=16789794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslKgsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1089-1105&issue=8&author=A.+Trampuzauthor=W.+Zimmerli&title=Antimicrobial+agents+in+orthopaedic+surgery%3A+Prophylaxis+and+treatment&doi=10.2165%2F00003495-200666080-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial agents in orthopedic surgery: prophylaxis and treatment</span></div><div class="casAuthors">Trampuz, Andrej; Zimmerli, Werner</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1089-1105</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The pathogenesis of implant-assocd. infection involves interaction between the microorganisms (biofilm formation), the implant and the host.  Despite improvement of perioperative prophylaxis, orthopedic implants still remain highly susceptible to bacterial or fungal contamination, generally resulting in persistent implant-assocd. infection.  Therefore, perioperative and life-long prevention of infection is important.  For perioperative prophylaxis, a first- or second-generation cephalosporin is recommended, which should be administered between 60 and 30 min before incision.  The duration of prophylaxis should not exceed 1 day.  In centers with a low incidence of infection, a single dose is sufficient.  Treatment of infections assocd. with orthopedic devices usually requires appropriate surgical intervention combined with prolonged antimicrobial therapy.  The choice of the antimicrobial regimen depends on the duration and pathogenesis of infection, stability of the implant, antimicrobial susceptibility of the pathogen and condition of the surrounding soft tissue.  The role of rifampicin (rifampin), which has excellent activity on adherent staphylococci, in combination with Î²-lactams, glycopeptides, fluoroquinolones, minocycline, cotrimoxazole or fusidic acid, in the treatment of staphylococcal infections is outlined.  Increasing antimicrobial resistance requires the use of alternative agents, such as quinupristin/dalfopristin, linezolid and daptomycin, but results of clin. trials with these agents are limited.  Also reviewed are potential new antimicrobial agents currently undergoing investigation, such as the novel oxazolidinone RWJ-416457, the new glycopeptide dalbavancin, the glycylcycline compd. tigecycline, the new carbacephem BP-102 and novel rifamycin derivs.  Vaccination against Staphylococcus aureus with StaphVAX induced specific antibodies potentially preventing bacteremia; however, there are no studies on efficacy in the prophylaxis of device-assocd. infections with this vaccine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxNxD3kJqzLVg90H21EOLACvtfcHk0lgO-gy_GsKJ7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslKgsLg%253D&md5=0fc0166368ad53d0148c7e739882e64b</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666080-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666080-00005%26sid%3Dliteratum%253Aachs%26aulast%3DTrampuz%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DW.%26atitle%3DAntimicrobial%2520agents%2520in%2520orthopaedic%2520surgery%253A%2520Prophylaxis%2520and%2520treatment%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26issue%3D8%26spage%3D1089%26epage%3D1105%26doi%3D10.2165%2F00003495-200666080-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tang, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, P.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toh, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, S.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, Y.-C.</span><span> </span><span class="NLM_article-title">RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment</span> <span class="citation_source-journal">J. Microbiol., Immunol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">394</span><span class="NLM_x">â</span> <span class="NLM_lpage">401</span><span class="refDoi">Â DOI: 10.1016/j.jmii.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.jmii.2015.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=26303044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCisrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=394-401&issue=3&author=H.-J.+Tangauthor=C.-C.+Laiauthor=P.-R.+Hsuehauthor=C.-C.+Chenauthor=K.-Y.+Wuauthor=Y.-C.+Linauthor=C.-C.+Zhangauthor=T.-C.+Wengauthor=Y.-H.+Chiuauthor=H.-S.+Tohauthor=S.-R.+Chiangauthor=W.-L.+Yuauthor=W.-C.+Koauthor=Y.-C.+Chuang&title=RNA+polymerase+B+subunit+gene+mutations+in+biofilm-embedded+methicillin-resistant+Staphylococcus+aureus+following+rifampin+treatment&doi=10.1016%2Fj.jmii.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment</span></div><div class="casAuthors">Tang, Hung-Jen; Lai, Chih-Cheng; Hsueh, Po-Ren; Chen, Chi-Chung; Wu, Kuan-Ying; Lin, Yi-Chung; Zhang, Chun-Cheng; Weng, Tzu-Chieh; Chiu, Yu-Hsin; Toh, Han-Siong; Chiang, Shyh-Ren; Yu, Wen-Liang; Ko, Wen-Chien; Chuang, Yin-Ching</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">394-401</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">This study was conducted to compare the mutation rates of different rpoB sites and rifampin min. inhibitory concn. (MIC) changes prior to and after rifampin therapy for biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) isolates.  The screening of rifampin-resistant MRSA isolates, from the biofilm at Day 5 with or without exposure to the susceptible breakpoint concn. of rifampin recommended by the Clin. and Lab. Stds. Institute (1 mg/L), was conducted using agar plates contg. rifampin.  A partial fragment of RNA polymerase B subunit gene (rpoB), including clusters I and II, was amplified and sequenced.  The rifampin MIC values and mutation frequencies at different sites of rpoB were measured and evaluated in rifampicin-resistant isolates.Rifampin-resistant mutants could be selected from all of 39 randomly selected rifampin-susceptible MRSA isolates in the biofilm model.  The spontaneous mutation frequency ranged from 1.00 Ã 10-4 to 3.85 Ã 10-7.  Mutation at codon 481 was most commonly found at 35 (89.7%) of 39 MRSA isolates.  Without rifampin induction, the MIC ranged between 0.125 mg/L and1024 mg/L and mutation sites included cluster I 464, 466, 468, 471, 474, 477, 481, 484, 486 and cluster II 519, 527, 529 with the percentage of 471 (35.9%), 477 (33.3%), 481 (53.8%), and 484 (35.9%).  Conversely, with the induction of rifampin, the MIC value ranged â¼256-1024 mg/L.  The mutation sites that were more concd. included 468 (17.9%), 477 (30.8%), 481 (89.7%), 484 (17.9%), and 486 (33.3%).We documented high rifampin resistance induction activity when MRSA was engaged in biofilm with rifampin exposure.  Monotherapy seems to be inadequate for MRSA in biofilm.  There is an urgent need for developing effective combination therapies with less rifampin resistance-inducing activities for treating MRSA in biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtdSdt1F4LjrVg90H21EOLACvtfcHk0lgO-gy_GsKJ7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCisrjE&md5=ca52467a4d2b9f493270ae72672ccd48</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.-J.%26aulast%3DLai%26aufirst%3DC.-C.%26aulast%3DHsueh%26aufirst%3DP.-R.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DWu%26aufirst%3DK.-Y.%26aulast%3DLin%26aufirst%3DY.-C.%26aulast%3DZhang%26aufirst%3DC.-C.%26aulast%3DWeng%26aufirst%3DT.-C.%26aulast%3DChiu%26aufirst%3DY.-H.%26aulast%3DToh%26aufirst%3DH.-S.%26aulast%3DChiang%26aufirst%3DS.-R.%26aulast%3DYu%26aufirst%3DW.-L.%26aulast%3DKo%26aufirst%3DW.-C.%26aulast%3DChuang%26aufirst%3DY.-C.%26atitle%3DRNA%2520polymerase%2520B%2520subunit%2520gene%2520mutations%2520in%2520biofilm-embedded%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520following%2520rifampin%2520treatment%26jtitle%3DJ.%2520Microbiol.%252C%2520Immunol.%2520Infect.%26date%3D2016%26volume%3D49%26issue%3D3%26spage%3D394%26epage%3D401%26doi%3D10.1016%2Fj.jmii.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bahl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leviton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gialanella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. H.</span><span> </span><span class="NLM_article-title">In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1293</span><span class="NLM_x">â</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1293-1297&issue=6&author=D.+Bahlauthor=D.+A.+Millerauthor=I.+Levitonauthor=P.+Gialanellaauthor=M.+J.+Wolinauthor=W.+Liuauthor=R.+Perkinsauthor=M.+H.+Miller&title=In+vitro+activities+of+ciprofloxacin+and+rifampin+alone+and+in+combination+against+growing+and+nongrowing+strains+of+methicillin-susceptible+and+methicillin-resistant+Staphylococcus+aureus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBahl%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BA.%26aulast%3DLeviton%26aufirst%3DI.%26aulast%3DGialanella%26aufirst%3DP.%26aulast%3DWolin%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPerkins%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DM.%2BH.%26atitle%3DIn%2520vitro%2520activities%2520of%2520ciprofloxacin%2520and%2520rifampin%2520alone%2520and%2520in%2520combination%2520against%2520growing%2520and%2520nongrowing%2520strains%2520of%2520methicillin-susceptible%2520and%2520methicillin-resistant%2520Staphylococcus%2520aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26issue%3D6%26spage%3D1293%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Murillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachon, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Euba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdaguer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabellos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudiol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariza, J.</span><span> </span><span class="NLM_article-title">Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">3681</span><span class="NLM_x">â</span> <span class="NLM_lpage">3686</span><span class="refDoi">Â DOI: 10.1128/AAC.00458-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.00458-08" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=3681-3686&issue=10&author=O.+Murilloauthor=M.+E.+Pachonauthor=G.+Eubaauthor=R.+Verdaguerauthor=F.+Tubauauthor=C.+Cabellosauthor=J.+Caboauthor=F.+Gudiolauthor=J.+Ariza&title=Antagonistic+effect+of+rifampin+on+the+efficacy+of+high-dose+levofloxacin+in+staphylococcal+experimental+foreign-body+infection&doi=10.1128%2FAAC.00458-08"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1128%2FAAC.00458-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00458-08%26sid%3Dliteratum%253Aachs%26aulast%3DMurillo%26aufirst%3DO.%26aulast%3DPachon%26aufirst%3DM.%2BE.%26aulast%3DEuba%26aufirst%3DG.%26aulast%3DVerdaguer%26aufirst%3DR.%26aulast%3DTubau%26aufirst%3DF.%26aulast%3DCabellos%26aufirst%3DC.%26aulast%3DCabo%26aufirst%3DJ.%26aulast%3DGudiol%26aufirst%3DF.%26aulast%3DAriza%26aufirst%3DJ.%26atitle%3DAntagonistic%2520effect%2520of%2520rifampin%2520on%2520the%2520efficacy%2520of%2520high-dose%2520levofloxacin%2520in%2520staphylococcal%2520experimental%2520foreign-body%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D10%26spage%3D3681%26epage%3D3686%26doi%3D10.1128%2FAAC.00458-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Balasubramanian, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solapure, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahesh Kumar, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandil, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwas, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panduga, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drusano, G. L.</span><span> </span><span class="NLM_article-title">Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">3054</span><span class="NLM_x">â</span> <span class="NLM_lpage">3057</span><span class="refDoi">Â DOI: 10.1128/AAC.06383-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.06383-11" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3054-3057&issue=6&author=V.+Balasubramanianauthor=S.+Solapureauthor=S.+Gaonkarauthor=K.+N.+Mahesh+Kumarauthor=R.+K.+Shandilauthor=A.+Deshpandeauthor=N.+Kumarauthor=K.+G.+Vishwasauthor=V.+Pandugaauthor=J.+Reddyauthor=S.+Gangulyauthor=A.+Louieauthor=G.+L.+Drusano&title=Effect+of+coadministration+of+moxifloxacin+and+rifampin+on+Mycobacterium+tuberculosis+in+a+murine+aerosol+infection+model&doi=10.1128%2FAAC.06383-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1128%2FAAC.06383-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06383-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DGaonkar%26aufirst%3DS.%26aulast%3DMahesh%2BKumar%26aufirst%3DK.%2BN.%26aulast%3DShandil%26aufirst%3DR.%2BK.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DVishwas%26aufirst%3DK.%2BG.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DDrusano%26aufirst%3DG.%2BL.%26atitle%3DEffect%2520of%2520coadministration%2520of%2520moxifloxacin%2520and%2520rifampin%2520on%2520Mycobacterium%2520tuberculosis%2520in%2520a%2520murine%2520aerosol%2520infection%2520model%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26issue%3D6%26spage%3D3054%26epage%3D3057%26doi%3D10.1128%2FAAC.06383-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bremner, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrus, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samosorn, S.</span><span> </span><span class="NLM_article-title">Dual action-based approaches to antibacterial agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1459</span><span class="NLM_x">â</span> <span class="NLM_lpage">1477</span><span class="refDoi">Â DOI: 10.2174/092986707780831168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.2174%2F092986707780831168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=17584056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVWmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1459-1477&issue=13&author=J.+B.+Bremnerauthor=J.+I.+Ambrusauthor=S.+Samosorn&title=Dual+action-based+approaches+to+antibacterial+agents&doi=10.2174%2F092986707780831168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Dual action-based approaches to antibacterial agents</span></div><div class="casAuthors">Bremner, John B.; Ambrus, Joseph I.; Samosorn, Siritron</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1459-1477</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review collates and analyses recent work done on dual action approaches to tackling the mounting health problem of resistance by human pathogenic bacteria to antibacterial agents.  In particular the areas reviewed include the use of two drugs in combination, dual action prodrugs, and dual action drugs (or hybrid drugs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL_6fdwziaVLVg90H21EOLACvtfcHk0lhae9x_idgUjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVWmtLw%253D&md5=33b2f161bafbd816a529c3fd1ea98a9f</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.2174%2F092986707780831168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707780831168%26sid%3Dliteratum%253Aachs%26aulast%3DBremner%26aufirst%3DJ.%2BB.%26aulast%3DAmbrus%26aufirst%3DJ.%2BI.%26aulast%3DSamosorn%26aufirst%3DS.%26atitle%3DDual%2520action-based%2520approaches%2520to%2520antibacterial%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26issue%3D13%26spage%3D1459%26epage%3D1477%26doi%3D10.2174%2F092986707780831168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pokrovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baasov, T.</span><span> </span><span class="NLM_article-title">Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">883</span><span class="NLM_x">â</span> <span class="NLM_lpage">902</span><span class="refDoi">Â DOI: 10.1517/17460441.2010.508069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1517%2F17460441.2010.508069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=22823262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCntrfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=883-902&issue=9&author=V.+Pokrovskayaauthor=T.+Baasov&title=Dual-acting+hybrid+antibiotics%3A+a+promising+strategy+to+combat+bacterial+resistance&doi=10.1517%2F17460441.2010.508069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance</span></div><div class="casAuthors">Pokrovskaya, Varvara; Baasov, Timor</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">883-902</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The emerging and sustained resistance to currently available antibiotics and the poor pipeline of new antibacterials urgently call for the development of new strategies that can address the problem of growing antibacterial resistance.  One such strategy is the development of dual-action hybrid antibiotics: two antibiotics that inhibit dissimilar targets in a bacterial cell covalently linked into one mol.  The possible benefits include: (i) activity against drug-resistant bacteria, (ii) expanded spectrum of activity and (iii) reduced potential for generating bacterial resistance.Areas covered in this review: In this article, we detail the recent activity in the design and development of dual-action hybrid drugs with a non-cleavable linker.  We explore newly developed synergistic and antagonistic hybrid compds. with emphases on their potential to reduce resistance development.What the reader will gain: Recently developed synergistic and antagonistic antibacterial drug-drug interactions and the impact of such interactions on the evolution of antibiotic drug resistance are described.  Addnl., we discuss the implications of the latter observations on the development of hybrid antibiotics with the emphases on whether their synergistic or antagonistic effect will be more efficient at forestalling/reducing the development of new resistances.Take home message: The approach of dual-acting hybrid antibiotics holds significant current promise in overcoming existing resistance mechanisms, as three of such compds. are entering clin. trials.  However, the key challenge in this area should be a broader exptl. demonstration of whether the "synergistic effect" or the "antagonistic effect" of the developed hybrid drug is better at preventing/reducing the evolution of resistance.  This fundamental challenge must be overcome before yielding a successful drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx_MW95x-xTbVg90H21EOLACvtfcHk0ljPElu4zvpv8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCntrfL&md5=9f693a57f8b49d61c1ede4f2eaeeccb6</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2010.508069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2010.508069%26sid%3Dliteratum%253Aachs%26aulast%3DPokrovskaya%26aufirst%3DV.%26aulast%3DBaasov%26aufirst%3DT.%26atitle%3DDual-acting%2520hybrid%2520antibiotics%253A%2520a%2520promising%2520strategy%2520to%2520combat%2520bacterial%2520resistance%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2010%26volume%3D5%26issue%3D9%26spage%3D883%26epage%3D902%26doi%3D10.1517%2F17460441.2010.508069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tevyashova, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsufyeva, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preobrazhenskaya, M. N.</span><span> </span><span class="NLM_article-title">Design of dual action antibiotics as an approach to search for new promising drugs</span> <span class="citation_source-journal">Russ. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">97</span><span class="refDoi">Â DOI: 10.1070/RCR4448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1070%2FRCR4448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVOmurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2015&pages=61-97&issue=1&author=A.+N.+Tevyashovaauthor=E.+N.+Olsufyevaauthor=M.+N.+Preobrazhenskaya&title=Design+of+dual+action+antibiotics+as+an+approach+to+search+for+new+promising+drugs&doi=10.1070%2FRCR4448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Design of dual action antibiotics as an approach to search for new promising drugs</span></div><div class="casAuthors">Tevyashova, A. N.; Olsufyeva, E. N.; Preobrazhenskaya, M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Chemical Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-97</span>CODEN:
                <span class="NLM_cas:coden">RCRVAB</span>;
        ISSN:<span class="NLM_cas:issn">0036-021X</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The review is devoted to the latest achievements in the design of dual action antibiotics-heterodimeric (chimeric) structures based on antibacterial agents of different classes (fluoroquinolones, anthracyclines, oxazolidines, macrolides and so on).  Covalent binding can make the pharmacokinetic characteristics of these mols. more predictable and improve the penetration of each component into the cell.  Consequently, not only does the drug efficacy increase owing to inhibition of two targets but also the resistance to one or both antibiotics can be overcome.  The theor. grounds of elaboration, design principles and methods for the synthesis of dual action antibiotics are considered.  The structures are classified according to the type of covalent spacer (cleavable or not) connecting the moieties of two agents.  Dual action antibiotics with a spacer that can be cleaved in a living cell are considered as dual action prodrugs.  Data on the biol. action of heterodimeric compds. are presented and structure - activity relationships are analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKGGyMhEEC7Vg90H21EOLACvtfcHk0ljPElu4zvpv8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVOmurk%253D&md5=c77b2fac7caa86151e238606f156a819</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1070%2FRCR4448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRCR4448%26sid%3Dliteratum%253Aachs%26aulast%3DTevyashova%26aufirst%3DA.%2BN.%26aulast%3DOlsufyeva%26aufirst%3DE.%2BN.%26aulast%3DPreobrazhenskaya%26aufirst%3DM.%2BN.%26atitle%3DDesign%2520of%2520dual%2520action%2520antibiotics%2520as%2520an%2520approach%2520to%2520search%2520for%2520new%2520promising%2520drugs%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D2015%26volume%3D84%26issue%3D1%26spage%3D61%26epage%3D97%26doi%3D10.1070%2FRCR4448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Barbachyn, M. R.</span>, <span> </span><span class="NLM_article-title">Recent advances in the discovery of hybrid antibacterial agents</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_contrib-group">John, E. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">43</span>, Chapter 17, pp  <span class="NLM_fpage">281</span><span class="NLM_x">â</span> <span class="NLM_lpage">290</span>, DOI: <span class="refDoi">Â DOI: 10.1016/S0065-7743(08)00017-1</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2FS0065-7743%2808%2900017-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=281-290&author=M.+R.+Barbachynauthor=E.+M.+John&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2900017-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252900017-1%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520hybrid%2520antibacterial%2520agents%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DJohn%26aufirst%3DE.%2BM.%26pub%3DAcademic%2520Press%26date%3D2008%26volume%3D43%26spage%3D281%26epage%3D290%26doi%3D10.1016%2FS0065-7743%2808%2900017-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Georgopapadakou, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertasso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleeland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, D. D.</span><span> </span><span class="NLM_article-title">Mode of action of the dual-action cephalosporin Ro 23-9424</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1067</span><span class="NLM_x">â</span> <span class="NLM_lpage">1071</span><span class="refDoi">Â DOI: 10.1128/AAC.33.7.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.33.7.1067" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=1067-1071&issue=7&author=N.+H.+Georgopapadakouauthor=A.+Bertassoauthor=K.+K.+Chanauthor=J.+S.+Chapmanauthor=R.+Cleelandauthor=L.+M.+Cummingsauthor=B.+A.+Dixauthor=D.+D.+Keith&title=Mode+of+action+of+the+dual-action+cephalosporin+Ro+23-9424&doi=10.1128%2FAAC.33.7.1067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1128%2FAAC.33.7.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.33.7.1067%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgopapadakou%26aufirst%3DN.%2BH.%26aulast%3DBertasso%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DChapman%26aufirst%3DJ.%2BS.%26aulast%3DCleeland%26aufirst%3DR.%26aulast%3DCummings%26aufirst%3DL.%2BM.%26aulast%3DDix%26aufirst%3DB.%2BA.%26aulast%3DKeith%26aufirst%3DD.%2BD.%26atitle%3DMode%2520of%2520action%2520of%2520the%2520dual-action%2520cephalosporin%2520Ro%252023-9424%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1989%26volume%3D33%26issue%3D7%26spage%3D1067%26epage%3D1071%26doi%3D10.1128%2FAAC.33.7.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christenson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleeland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix-Holzknecht, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrish, H. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specian, A.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1895</span><span class="NLM_x">â</span> <span class="NLM_lpage">1900</span><span class="refDoi">Â DOI: 10.1128/AAC.34.10.1895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.34.10.1895" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=1895-1900&issue=10&author=J.+G.+Christensonauthor=K.+K.+Chanauthor=R.+Cleelandauthor=B.+Dix-Holzknechtauthor=H.+H.+Farrishauthor=I.+H.+Patelauthor=A.+Specian&title=Pharmacokinetics+of+Ro+23-9424%2C+a+dual-action+cephalosporin%2C+in+animals&doi=10.1128%2FAAC.34.10.1895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.10.1895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.10.1895%26sid%3Dliteratum%253Aachs%26aulast%3DChristenson%26aufirst%3DJ.%2BG.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DCleeland%26aufirst%3DR.%26aulast%3DDix-Holzknecht%26aufirst%3DB.%26aulast%3DFarrish%26aufirst%3DH.%2BH.%26aulast%3DPatel%26aufirst%3DI.%2BH.%26aulast%3DSpecian%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520of%2520Ro%252023-9424%252C%2520a%2520dual-action%2520cephalosporin%252C%2520in%2520animals%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26issue%3D10%26spage%3D1895%26epage%3D1900%26doi%3D10.1128%2FAAC.34.10.1895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gu, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">189</span><span class="NLM_x">â</span> <span class="NLM_lpage">195</span><span class="refDoi">Â DOI: 10.1128/AAC.34.2.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.34.2.189" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=189-195&issue=2&author=J.+W.+Guauthor=H.+C.+Neu&title=In+vitro+activity+of+Ro+23-9424%2C+a+dual-action+cephalosporin%2C+compared+with+activities+of+other+antibiotics&doi=10.1128%2FAAC.34.2.189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.2.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.2.189%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DJ.%2BW.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Ro%252023-9424%252C%2520a%2520dual-action%2520cephalosporin%252C%2520compared%2520with%2520activities%2520of%2520other%2520antibiotics%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26issue%3D2%26spage%3D189%26epage%3D195%26doi%3D10.1128%2FAAC.34.2.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Locher, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruyere, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritz, D.</span><span> </span><span class="NLM_article-title">Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">â</span> <span class="NLM_lpage">908</span><span class="refDoi">Â DOI: 10.1128/AAC.01831-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01831-13" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=901-908&issue=2&author=H.+H.+Locherauthor=P.+Caspersauthor=T.+Bruyereauthor=S.+Schroederauthor=P.+Pfaffauthor=A.+Knezevicauthor=W.+Keckauthor=D.+Ritz&title=Investigations+of+the+mode+of+action+and+resistance+development+of+cadazolid%2C+a+new+antibiotic+for+treatment+of+Clostridium+difficile+infections&doi=10.1128%2FAAC.01831-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FAAC.01831-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01831-13%26sid%3Dliteratum%253Aachs%26aulast%3DLocher%26aufirst%3DH.%2BH.%26aulast%3DCaspers%26aufirst%3DP.%26aulast%3DBruyere%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DPfaff%26aufirst%3DP.%26aulast%3DKnezevic%26aufirst%3DA.%26aulast%3DKeck%26aufirst%3DW.%26aulast%3DRitz%26aufirst%3DD.%26atitle%3DInvestigations%2520of%2520the%2520mode%2520of%2520action%2520and%2520resistance%2520development%2520of%2520cadazolid%252C%2520a%2520new%2520antibiotic%2520for%2520treatment%2520of%2520Clostridium%2520difficile%2520infections%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D2%26spage%3D901%26epage%3D908%26doi%3D10.1128%2FAAC.01831-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ding, C. Z.; Ma, Z.; Li, J.; Harran, S.; He, Y.; Minor, K. P.; Kim, I. H.; Longgood, J. C.; Jin, Y.; Combrink, K. D.</span>, <span> </span><span class="NLM_article-title">(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions</span>. U.S. Patent 7,226,931,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Z.+Ding&author=Z.+Ma&author=J.+Li&author=S.+Harran&author=Y.+He&author=K.+P.+Minor&author=I.+H.+Kim&author=J.+C.+Longgood&author=Y.+Jin&author=K.+D.+Combrink&title=%28R%2FS%29+rifamycin+derivatives%2C+their+preparations+and+pharmaceutical+compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3D%2528R%252FS%2529%2520rifamycin%2520derivatives%252C%2520their%2520preparations%2520and%2520pharmaceutical%2520compositions%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simecka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1181</span><span class="NLM_x">â</span> <span class="NLM_lpage">1184</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2006.12.026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1181-1184&issue=5&author=I.+H.+Kimauthor=K.+D.+Combrinkauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=P.+Renickauthor=T.+W.+Morrisauthor=M.+Pulseauthor=J.+W.+Simeckaauthor=C.+Z.+Ding&title=Synthesis+and+antibacterial+evaluation+of+a+novel+series+of+rifabutin-like+spirorifamycins&doi=10.1016%2Fj.bmcl.2006.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DRenick%26aufirst%3DP.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DPulse%26aufirst%3DM.%26aulast%3DSimecka%26aufirst%3DJ.%2BW.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520a%2520novel%2520series%2520of%2520rifabutin-like%2520spirorifamycins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D5%26spage%3D1181%26epage%3D1184%26doi%3D10.1016%2Fj.bmcl.2006.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ma, Z.; Kim, I. H.; Li, J.</span><span> </span><span class="NLM_article-title">Spiro-rifamycin derivatives targeting RNA polymerase</span>. U.S. Patent 7,202,246,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Z.+Ma&author=I.+H.+Kim&author=J.+Li&title=Spiro-rifamycin+derivatives+targeting+RNA+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DSpiro-rifamycin%2520derivatives%2520targeting%2520RNA%2520polymerase%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ding, C. Z.; Kim, I. H.; Wang, J.; Ma, Z.; Jin, Y.; Combrink, K. D.; Lu, G.; Lynch, A. S.</span><span> </span><span class="NLM_article-title">Nitroheteroaryl-containing rifamycin derivatives</span>. U.S. Patent 7,678,791,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Z.+Ding&author=I.+H.+Kim&author=J.+Wang&author=Z.+Ma&author=Y.+Jin&author=K.+D.+Combrink&author=G.+Lu&author=A.+S.+Lynch&title=Nitroheteroaryl-containing+rifamycin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DNitroheteroaryl-containing%2520rifamycin%2520derivatives%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span> </span><span class="NLM_article-title">Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5510</span><span class="NLM_x">â</span> <span class="NLM_lpage">5513</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2007.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2007.08.048" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5510-5513&issue=20&author=J.+Liauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=A.+S.+Lynchauthor=C.+Z.+Ding&title=Preparation+and+in+vitro+anti-staphylococcal+activity+of+novel+11-deoxy-11-hydroxyiminorifamycins&doi=10.1016%2Fj.bmcl.2007.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DPreparation%2520and%2520in%2520vitro%2520anti-staphylococcal%2520activity%2520of%2520novel%252011-deoxy-11-hydroxyiminorifamycins%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D20%26spage%3D5510%26epage%3D5513%26doi%3D10.1016%2Fj.bmcl.2007.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Li, J.; Ding, C. Z.; Ma, Z.</span><span> </span><span class="NLM_article-title">Rifamycin C-11 oxime derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,265,107,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Li&author=C.+Z.+Ding&author=Z.+Ma&title=Rifamycin+C-11+oxime+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRifamycin%2520C-11%2520oxime%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, J.; Ma, Z.</span>, <span> </span><span class="NLM_article-title">Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,256,187,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Li&author=Z.+Ma&title=Rifamycin+C-11+oxime+cyclo+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRifamycin%2520C-11%2520oxime%2520cyclo%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denton, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">522</span><span class="NLM_x">â</span> <span class="NLM_lpage">526</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1016%2Fj.bmcl.2006.10.016" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=522-526&issue=2&author=K.+D.+Combrinkauthor=D.+A.+Dentonauthor=S.+Harranauthor=Z.+Maauthor=K.+Chapoauthor=D.+Yanauthor=E.+Bonventreauthor=E.+D.+Rocheauthor=T.+B.+Doyleauthor=G.+T.+Robertsonauthor=A.+S.+Lynch&title=New+C25+carbamate+rifamycin+derivatives+are+resistant+to+inactivation+by+ADP-ribosyl+transferases&doi=10.1016%2Fj.bmcl.2006.10.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DDenton%26aufirst%3DD.%2BA.%26aulast%3DHarran%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DChapo%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DBonventre%26aufirst%3DE.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DNew%2520C25%2520carbamate%2520rifamycin%2520derivatives%2520are%2520resistant%2520to%2520inactivation%2520by%2520ADP-ribosyl%2520transferases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D2%26spage%3D522%26epage%3D526%26doi%3D10.1016%2Fj.bmcl.2006.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Combrink, K.; Harran, S.; Denton, D.; Ma, Z.</span><span> </span><span class="NLM_article-title">C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes</span>. U.S. Patent 7,250,413,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Combrink&author=S.+Harran&author=D.+Denton&author=Z.+Ma&title=C-25+carbamate+rifamycin+derivatives+with+activity+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%26atitle%3DC-25%2520carbamate%2520rifamycin%2520derivatives%2520with%2520activity%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Ding, C. Z.; Jin, Y.; Combrink, K.; Kim, I. H.</span><span> </span><span class="NLM_article-title">Quinolone carboxylic acid-substituted rifamycin derivatives</span>. U.S. Patent 7,884,099,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+Z.+Ding&author=Y.+Jin&author=K.+Combrink&author=I.+H.+Kim&title=Quinolone+carboxylic+acid-substituted+rifamycin+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%2BZ.%26atitle%3DQuinolone%2520carboxylic%2520acid-substituted%2520rifamycin%2520derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ma, Z.; Jin, Y.; Li, J.; Ding, C. Z.; Minor, K. P.; Longgood, J. C.; Kim, I. H.; Harran, S.; Combrink, K.; Morris, T. W.</span><span> </span><span class="NLM_article-title">Rifamycin derivatives effective against drug-resistant microbes</span>. U.S. Patent 7,247,634,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Z.+Ma&author=Y.+Jin&author=J.+Li&author=C.+Z.+Ding&author=K.+P.+Minor&author=J.+C.+Longgood&author=I.+H.+Kim&author=S.+Harran&author=K.+Combrink&author=T.+W.+Morris&title=Rifamycin+derivatives+effective+against+drug-resistant+microbes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DRifamycin%2520derivatives%2520effective%2520against%2520drug-resistant%2520microbes%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitscher, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L. L.</span><span> </span><span class="NLM_article-title">The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">231</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span><span class="refDoi">Â DOI: 10.1002/1098-1128(200007)20:4<231::AID-MED1>3.0.CO;2-N</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10861727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFSksLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=231-293&issue=4&author=Q.+Liauthor=L.+A.+Mitscherauthor=L.+L.+Shen&title=The+2-pyridone+antibacterial+agents%3A+bacterial+topoisomerase+inhibitors&doi=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The 2-pyridone antibacterial agents: Bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Li, Qun; Mitscher, Lester A.; Shen, Linus L.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-293</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 132 refs.  Many attempts have been made to prep. analogs of 4-quinolone antibacterial agents bearing novel ring systems, which might retain the favorable properties of these widely used antibacterial agents and at the same time increase activity against multidrug-resistant bacteria, streptococci, and anaerobic microorganisms.  One such attempt involved bioisosteric exchange of the 1-N atom and 4a-C atom of naphthyridones, quinolones, and benzoxazines to produce a family of highly active pyridopyrimidines, quinolizines, and ofloxacin bioisosteres.  These new antibacterial agents have been named collectively as the 2-pyridones.  Many hundreds of 2-pyridones have been synthesized and evaluated in vitro and in vivo, and selected members are advancing toward human clin. trials.  Prepn. of these bioisosteres required the development of enabling chem., as previous methods were unsuccessful in producing the needed core structures.  This review compares the structure-activity relationships of these agents with known trends among 4-quinolones, from which it is seen that there are many parallels, but also some significant departures as well.  Generally, 2-pyridones are more highly active in vitro and in vivo and more water sol. than comparable 4-quinolones.  These properties are posited to arise from electronic and conformational alternations in these new substances.  Selected members show excellent pharmacodynamic properties, justifying the view that this is a very promising new class of totally synthetic antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPUqaRhDddcLVg90H21EOLACvtfcHk0ljKqOcJNfh8kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFSksLc%253D&md5=df6229ea2277351f35331c970cfa9eec</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-1128%2528200007%252920%253A4%253C231%253A%253AAID-MED1%253E3.0.CO%253B2-N%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMitscher%26aufirst%3DL.%2BA.%26aulast%3DShen%26aufirst%3DL.%2BL.%26atitle%3DThe%25202-pyridone%2520antibacterial%2520agents%253A%2520bacterial%2520topoisomerase%2520inhibitors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26issue%3D4%26spage%3D231%26epage%3D293%26doi%3D10.1002%2F1098-1128%28200007%2920%3A4%3C231%3A%3AAID-MED1%3E3.0.CO%3B2-N" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saiki, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, C. G.</span><span> </span><span class="NLM_article-title">DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1574</span><span class="NLM_x">â</span> <span class="NLM_lpage">1577</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=1574-1577&issue=7&author=A.+Y.+Saikiauthor=L.+L.+Shenauthor=C.+M.+Chenauthor=J.+Baranowskiauthor=C.+G.+Lerner&title=DNA+cleavage+activities+of+Staphylococcus+aureus+gyrase+and+topoisomerase+IV+stimulated+by+quinolones+and+2-pyridones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DShen%26aufirst%3DL.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BM.%26aulast%3DBaranowski%26aufirst%3DJ.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26atitle%3DDNA%2520cleavage%2520activities%2520of%2520Staphylococcus%2520aureus%2520gyrase%2520and%2520topoisomerase%2520IV%2520stimulated%2520by%2520quinolones%2520and%25202-pyridones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1999%26volume%3D43%26issue%3D7%26spage%3D1574%26epage%3D1577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oleksijew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alder, J. D.</span><span> </span><span class="NLM_article-title">Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">653</span><span class="refDoi">Â DOI: 10.1093/jac/38.4.641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1093%2Fjac%2F38.4.641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=8937959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=1%3ACAS%3A528%3ADyaK28XntFWiu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1996&pages=641-653&issue=4&author=J.+A.+Meulbroekauthor=A.+Oleksijewauthor=S.+K.+Tanakaauthor=J.+D.+Alder&title=Efficacy+of+ABT-719%2C+a+2-pyridone+antimicrobial%2C+against+enterococci%2C+Escherichia+coli%2C+and+Pseudomonas+aeruginosa+in+experimental+murine+pyelonephritis&doi=10.1093%2Fjac%2F38.4.641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis</span></div><div class="casAuthors">Meulbroek, Jonathan a.; Oleksijew, Anatol; Tanaka, S. Ken; Alder, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-653</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">ABT-719 is a 2-pyridone antimicrobial which inhibits DNA gyrase activity.  It has considerable s.c. and oral efficacy in the treatment of exptl. pyelonephritis induced in carrageenan-treated mice by clin. isolates of Enterococcus faecalis, Enterococcus faecium, Escherichia coli, and Pseudomonas aeruginosa.  Therapeutic ED50s, defined here as producing a 2 log10 redn. in kidney bacterial burden, provide a reliable end point for comparison of drug efficacy in this exptl. infection.  Therapeutic ED50s for ABT-719 against these infections were equal to or up to 10-fold lower than those for ciprofloxacin, used as a ref. because of similarity in mode of action.  Against E. faecalis, the therapeutic ED50s for ABT-719 were 4.5-13.6 mg/kg/day for s.c. administration and 6.8-8.9 mg/kg/day for oral administration.  ABT-719 was more potent than ciprofloxacin and vancomycin against the E. faecalis strains, which showed ciprofloxacin and vancomycin resistance covering a range of MICs.  Against E. faecium, the therapeutic ED50s for ABT-719 were 8.8 mg/kg/day (s.c.) and 9.4 mg/kg/day (oral).  Against an isolate of E. faecium showing ciprofloxacin and vancomycin resistance the ED50 for ABT-719 to achieve a 1 log10 redn. in kidney bacterial burden was 17.9 mg/kg/day by s.c. administration.  While ABT-719 had lower efficacy against this isolate than against orders, ciprofloxacin and vancomycin failed to show efficacy.  Against E. coli, the therapeutic ED50 for ABT-719 was 1.1 mg/kg/day (oral), and against P. aeruginosa, this value was 2.7 mg/kg/day (oral) with values against both of these pathogens similar to those for ciprofloxacin ABT-719, which represents the new 2-pyridone compd. class, has promise for the treatment of urinary tract infections, as suggested by the significant efficacy seen against exptl. pyelonephritis caused by E. coli, P. aeruginosa and susceptible and resistant enterococci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMxc3B0a2hrVg90H21EOLACvtfcHk0ljKqOcJNfh8kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFWiu7g%253D&md5=bc19cbba6698ca81905aaf682b28333d</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F38.4.641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F38.4.641%26sid%3Dliteratum%253Aachs%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DS.%2BK.%26aulast%3DAlder%26aufirst%3DJ.%2BD.%26atitle%3DEfficacy%2520of%2520ABT-719%252C%2520a%25202-pyridone%2520antimicrobial%252C%2520against%2520enterococci%252C%2520Escherichia%2520coli%252C%2520and%2520Pseudomonas%2520aeruginosa%2520in%2520experimental%2520murine%2520pyelonephritis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1996%26volume%3D38%26issue%3D4%26spage%3D641%26epage%3D653%26doi%3D10.1093%2Fjac%2F38.4.641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2313</span><span class="NLM_x">â</span> <span class="NLM_lpage">2323</span><span class="refDoi">Â DOI: 10.1128/AAC.01649-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01649-07" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2313-2323&issue=7&author=G.+T.+Robertsonauthor=E.+J.+Bonventreauthor=T.+B.+Doyleauthor=Q.+Duauthor=L.+Duncanauthor=T.+W.+Morrisauthor=E.+D.+Rocheauthor=D.+Yanauthor=A.+S.+Lynch&title=In+vitro+evaluation+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%3A+studies+of+the+mode+of+action+in+Staphylococcus+aureus&doi=10.1128%2FAAC.01649-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1128%2FAAC.01649-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01649-07%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DBonventre%26aufirst%3DE.%2BJ.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520evaluation%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%253A%2520studies%2520of%2520the%2520mode%2520of%2520action%2520in%2520Staphylococcus%2520aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D7%26spage%3D2313%26epage%3D2323%26doi%3D10.1128%2FAAC.01649-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robertson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonventre, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. S.</span><span> </span><span class="NLM_article-title">In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2324</span><span class="NLM_x">â</span> <span class="NLM_lpage">2334</span><span class="refDoi">Â DOI: 10.1128/AAC.01651-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;key=10.1128%2FAAC.01651-07" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2324-2334&issue=7&author=G.+T.+Robertsonauthor=E.+J.+Bonventreauthor=T.+B.+Doyleauthor=Q.+Duauthor=L.+Duncanauthor=T.+W.+Morrisauthor=E.+D.+Rocheauthor=D.+Yanauthor=A.+S.+Lynch&title=In+vitro+evaluation+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%3A+microbiology+profiling+studies+with+staphylococci+and+streptococci&doi=10.1128%2FAAC.01651-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01651-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01651-07%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DBonventre%26aufirst%3DE.%2BJ.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DMorris%26aufirst%3DT.%2BW.%26aulast%3DRoche%26aufirst%3DE.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520evaluation%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%253A%2520microbiology%2520profiling%2520studies%2520with%2520staphylococci%2520and%2520streptococci%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D7%26spage%3D2324%26epage%3D2334%26doi%3D10.1128%2FAAC.01651-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lynch, A. S.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Robertson, G. T.; Roche, E. D.</span><span> </span><span class="NLM_article-title">In vitro mode-of-action studies of CBR-2092: a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2101.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=A.+S.+Lynch&author=E.+J.+Bonventre&author=T.+B.+Doyle&author=Q.+Du&author=L.+Duncan&author=G.+T.+Robertson&author=E.+D.+Roche&title=In+vitro+mode-of-action+studies+of+CBR-2092%3A+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BS.%26atitle%3DIn%2520vitro%2520mode-of-action%2520studies%2520of%2520CBR-2092%253A%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robertson, G. T.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Roche, E. D.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">Comparative in vitro activity of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and rifampin+quinolone combinations</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2102.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=G.+T.+Robertson&author=E.+J.+Bonventre&author=T.+B.+Doyle&author=Q.+Du&author=L.+Duncan&author=E.+D.+Roche&author=A.+S.+Lynch&title=Comparative+in+vitro+activity+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+and+rifampin%2Bquinolone+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26atitle%3DComparative%2520in%2520vitro%2520activity%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520and%2520rifampin%252Bquinolone%2520combinations%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Du, Q.; Doyle, T. B.; Duncan, L.; Robertson, G. T.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">In vitro microbiology profiling of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Q.+Du&author=T.+B.+Doyle&author=L.+Duncan&author=G.+T.+Robertson&author=A.+S.+Lynch&title=In+vitro+microbiology+profiling+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DQ.%26atitle%3DIn%2520vitro%2520microbiology%2520profiling%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Doyle, T. B.; Bonventre, E. J.; Du, Q.; Robertson, G. T.; Roche, E. D.; Lynch, A. S.</span>, <span> </span><span class="NLM_article-title">In vitro studies of the efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in killing staphylococcal cells in biofilms</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2104.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+B.+Doyle&author=E.+J.+Bonventre&author=Q.+Du&author=G.+T.+Robertson&author=E.+D.+Roche&author=A.+S.+Lynch&title=In+vitro+studies+of+the+efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+in+killing+staphylococcal+cells+in+biofilms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26atitle%3DIn%2520vitro%2520studies%2520of%2520the%2520efficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520in%2520killing%2520staphylococcal%2520cells%2520in%2520biofilms%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Renick, P. J.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Weiss, W. J.</span><span> </span><span class="NLM_article-title">Efficacy of CBR-2092, a novel rifamycin-quinolone yybrid antibiotic, in rodent models of bacterial infection</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2105.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+J.+Renick&author=T.+W.+Morris&author=P.+M.+Nguyen&author=M.+E.+Pulse&author=W.+J.+Weiss&title=Efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+yybrid+antibiotic%2C+in+rodent+models+of+bacterial+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRenick%26aufirst%3DP.%2BJ.%26atitle%3DEfficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520yybrid%2520antibiotic%252C%2520in%2520rodent%2520models%2520of%2520bacterial%2520infection%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Weiss, W. J.; Bao, D.; Miller, G. A.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Renick, P. J.; Truong, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic studies with CBR-2092, a novel rifamycin-quinolone hybrid antibiotic</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2106.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=W.+J.+Weiss&author=D.+Bao&author=G.+A.+Miller&author=T.+W.+Morris&author=P.+M.+Nguyen&author=M.+E.+Pulse&author=P.+J.+Renick&author=T.+Truong&title=Pharmacokinetic+and+pharmacodynamic+studies+with+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DW.%2BJ.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520studies%2520with%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.</span><span> </span><span class="NLM_article-title">Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and vancomycin in experimental methicillin-resistant Staphylococcus aureus infective endocarditis</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2107.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Q.+Xiong&author=W.+J.+Weiss&author=T.+B.+Doyle&author=G.+A.+Abdelsayed&author=A.+S.+Bayer&title=Efficacy+of+CBR-2092%2C+a+novel+rifamycin-quinolone+hybrid+antibiotic%2C+and+vancomycin+in+experimental+methicillin-resistant+Staphylococcus+aureus+infective+endocarditis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BQ.%26atitle%3DEfficacy%2520of%2520CBR-2092%252C%2520a%2520novel%2520rifamycin-quinolone%2520hybrid%2520antibiotic%252C%2520and%2520vancomycin%2520in%2520experimental%2520methicillin-resistant%2520Staphylococcus%2520aureus%2520infective%2520endocarditis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.</span><span> </span><span class="NLM_article-title">Comparative efficacy of CBR-2092 and conventional rifampin+quinolone combinations in experimental infective endocarditis caused by a quinolone-resistant MRSA</span>. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>ICAAC Poster F1-2108.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Q.+Xiong&author=W.+J.+Weiss&author=T.+B.+Doyle&author=G.+A.+Abdelsayed&author=A.+S.+Bayer&title=Comparative+efficacy+of+CBR-2092+and+conventional+rifampin%2Bquinolone+combinations+in+experimental+infective+endocarditis+caused+by+a+quinolone-resistant+MRSA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BQ.%26atitle%3DComparative%2520efficacy%2520of%2520CBR-2092%2520and%2520conventional%2520rifampin%252Bquinolone%2520combinations%2520in%2520experimental%2520infective%2520endocarditis%2520caused%2520by%2520a%2520quinolone-resistant%2520MRSA%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i20"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00485">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_10343"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00485">10.1021/acs.jmedchem.6b00485</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and biochemical activity data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00485/suppl_file/jm6b00485_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00485/suppl_file/jm6b00485_si_001.csv">jm6b00485_si_001.csv (0.66 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00485&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00485%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-14%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00485" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995ef699112290","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
